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1 Introduction 
Liquid biopsies are emerging as an important scientific development in cancer medicine 
to provide prognostic information and to help guide patient treatment and management. 
‘Liquid biopsies’ is a more comprehensive term that refers to any liquid samples from 
patients (blood, cerebrospinal fluid, and urine predominantly), due to the vast quantity 
of biologic information that can be gleaned from them. They are an attractive source for 
biopsies because they can be easily repeated for individual patients to track disease 
progress, are reproducible, and can provide biological information or even diagnostic 
information on occasion. Liquid biopsies also take advantage of the current revolution 
in genomic medicine technologies that make once highly technical and difficult tests 
cheaper, more routine, and more commonplace. Nevertheless, much work needs to be 
done before liquid biopsy methodologies can be considered standard of care in the 
clinic. This thesis focusses on the application of liquid biopsies to patients with brain 
cancer, and in particular, the discovery and development of novel methodologies that 
have not previously been described. Our overarching hypothesis was that liquid biopsies 
would yield novel insights that could be translated as biomarkers for patients with 
glioblastoma multiforme in the future. 
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1.1 Literature review 
1.1.1 Clinical features of glioblastoma multiforme 
Glioblastoma multiforme (GBM), a World Health Organisation (WHO) classified stage 
4 astrocytic cancer, is the most common form of primary brain cancer. The incidence is 
3-4 cases per 100 000 of the population occurring worldwide, with a total of 2197 cases 
diagnosed between 2000 and 2008 in NSW and the ACT1. GBM also has one of the 
worst outcomes of all cancers, with less than 5% of patients surviving for more than 5 
years2. 
Astrocytomas are graded based upon their histological features. Grade II represents a 
diffuse glioma (that is, cancer cells are starting to invade the areas of the brain around 
the tumour)3; grade III represents an anaplastic glioma (that is, the cells have reverted 
largely to being undifferentiated cells); and grade IV, GBM, demonstrates features of 
tumour aggressiveness and necrosis4,5. 
 
Clinically, GBM presents with a variety of symptoms that vary depending upon the 
locale of the tumour mass. Symptoms can include headaches, nausea, confusion, mood 
swings and other neurological disorders. GBM is differentiated from other brain 
cancers, microscopically, through the presence of diffuse, invasive cells which display 
glial fibrillary acidic protein (GFAP)5,6 staining on immunohistochemistry. 
The current first-line treatment for GBM is surgery, followed by chemoradiation, and 
adjuvant chemotherapy7,8. Temozolomide (TMZ) chemotherapy is the standard of care, 
which is an agent that causes DNA damage via alkylation and methylation of bases in 
the DNA, which ultimately can cause apoptotic cell death9. However, treatment never 
results in a cure and prognosis is dismal. GBM invariably recurs despite best current 
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care, and patients survive a median of around 15 months with the current standard of 
care10. Follow up of patients after diagnosis involves clinical review and regular 
magnetic resonance imaging (MRI) scans of the brain, usually every 3 months, to try to 
detect recurrence or in many cases where there has been suboptimal resection of the 
tumour mass, disease progression. However, post completion of chemoradiation, 
efficacy of treatment is difficult to determine because tissue inflammation often 
resembles the effects of disease progression on MRI. This effect is termed 
pseudoprogression11. Pseudoprogression can be suspected clinically when a patient 
presents with an apparent tumour size increase on MRI, but cannot be proven until 
repeat MRI scans confirm tumour shrinkage later without specific treatment or with the 
use of steroids alone, suggesting that the apparent tumour size increase previously noted 
may have been due to inflammation12. The question of whether a patient is developing 
pseudoprogression or true disease progression presents real difficulties in management, 
as a decision whether to re-resect an apparently growing tumour mass needs to be made, 
preferably without delay. Depending on performance status of the patient, symptoms at 
the time, disease control interval, and prospects of improving outcomes with surgery, 
re-resection is sometimes offered. At present, there is no gold standard method to 
confirm pseudoprogression at the time it occurs, and in most instances, a watch and wait 
policy is deemed clinically appropriate. Similarly, there is no gold standard to confirm 
true tumour progression at the time the prospect is raised on MRI imaging, and as long 
as the patient remains asymptomatic, many oncologists opt to watch and wait, with the 
knowledge that a repeat MRI confirming increasing tumour size four to six weeks later 
would suggest true disease progression. The watch and wait strategy, in either case is 
not necessarily optimal. There is an urgent need to find biomarkers that reliably predict 
and distinguish between pseudoprogression and true disease progression, as re-resection 
  4 
is ideally undertaken when cancers are smaller, offering the best chance of better 
outcomes. The decision for repeated brain surgery for biopsy of tumour tissue or re-
resection is not undertaken lightly, so liquid biopsies represent an excellent potential 
alternative to follow disease progress and to answer biological questions that predict for 
tumour response, pseudoprogression, or disease progression. In some cases, depending 
on the location of the tumour, or such as in diffuse intrinsic pontine glioma (DIPG) in 
children, a poor prognosis brain tumour, biopsy or resection may not be technically 
feasible. In this scenario, a robust methodology utilising liquid biospies may be 
invaluable in making a diagnosis. 
 
 
1.1.2 Biomarkers in glioblastoma multiforme 
A biomarker that can indicate prognosis and response to treatment in GBM is, of course, 
of great clinical interest, as this will guide the best possible course of clinical 
management, and allow the disease to be monitored. However, there are no biomarkers 
with universal applicability for use in GBM. Several that have been proposed are of 
varying utility.  
 
Clinical factors that are either prognostic or predictive of outcome include: 
• The age of the patient: In general, older patients will respond less well to 
surgery13; be less able to recover from surgery13; and be more likely to suffer 
from primary GBM (which is more aggressive with a lower survival time), 
rather than secondary, GBM14. 
• Primary or secondary GBM: A primary GBM tumour is one that develops 
rapidly without any prior symptoms or clinical indication. A secondary GBM 
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usually develops from a lower grade astrocytoma. Generally, a patient with 
secondary GBM will have a longer overall survival time, likely due to its higher 
likelihood of having an isocitrate dehydrogenase 1 (IDH1) mutation15, or O6-
methylguanine-DNA methyltransferase (MGMT) promoter methylation16, and 
secondary GBM affects usually younger patients. In addition, the two types of 
GBM have different genetic pathways, such as expression of tumour protein 53 
(TP53) markers in secondary GBM, or epidermal growth factor (EGFR) 
overexpression in primary GBM (reviewed in 17). 
• Tumour location: Patients with a tumour located in the frontal lobe have, on 
average, a slightly higher survival time18. 
• Eastern Cooperative Oncology Group (ECOG) Performance status: This is a 
measure of a patient’s ability to function and ability to look after themselves. 
The ECOG score ranges from 0 (no physical impairment) to 5 (the patient is 
deceased). It is used to stratify patients during treatment. It has been found that 
patients who start treatment with a better ECOG score (that is, a lower one), 
have better treatment outcomes19,20. 
In addition to these purely physical markers of patient outcomes, there are a variety of 
biomarkers that are measured using immunohistochemistry and molecular techniques 
from tissue samples. 
 
 
1.1.3 Molecular biomarkers in GBM 
There have been many proposed molecular biomarkers, but almost all have arisen from 
specific genomic, metabolic, or proteomic changes noted in brain cancer cell lines from 
in vitro experiments. As a result, not many have been validated in the clinic. Of these, 
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the most commonly described are: Isocitrate dehydrogenase 1 (IDH1) mutations, 
MGMT promoter methylation, and EGFR alteration (usually, in GBM, through the 
mutation EGFR variant III, (EGFRvIII)). Important GBM biomarkers are listed in Table 
1.1. 
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Table 1.1 List of GBM biomarkers  
Biomarker name Occurrence rate in GBM Other notable features 
IDH1 mutations Primary GBM: <5%21 
Secondary GBM: >80%21 
Used to indicate patient 
outcomes and differentiate 
between primary and 
secondary GBM21. 
MGMT promoter 
methylation 
39%22,23-40%24 Indicates response to 
TMZ25. Cutoff for 
methylation significance 
set at 30% methylation23. 
GFAP N/A Found in all astrocytomas, 
but not in all astrocytoma 
cells26.  
EGFRvIII 21%27- 31%28,29  
IDH2 3.3%30 Negative correlation with 
IDH1 mutations31.  
Loss of PTEN 53%32. Prior to TMZ, prognostic 
for outcomes in GBM33. 
p53 22%34  
Loss of Heterozygosity 
1p/19q loci 
<10%35  
TERT promoter Primary GBM: 83%36. 
Secondary GBM: 5%37. 
 
GLAST 51% high level expression. 
49% low-level 
expression38. 
GLAST is internalised in 
GBM39. 
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1.1.3.1  IDH1 
IDH1 is an enzyme responsible for the conversion of isocitrate to α-ketoglutarate, part 
of the metabolism of sugars, lipids and amino acids. IDH1 serves in the reduction of 
nicotinamide adenine dinucleotide phosphate (NAD) from NAD(P)+ to NAD(P)H. 
NAD(P)H is involved in cellular defences against oxidation caused by other metabolic 
reactions40. IDH1 mutations in GBM, the commonest being IDH1-R132H, are a 
predictor of patients’ increased overall survival (OS) and progression free survival 
(PFS)41. In general, IDH1 mutations are found most frequently in secondary cases of 
GBM- that is, cases where the cancer has been detected at WHO stage II or III and 
dedifferentiates into WHO stage IV. IDH1 mutations in secondary GBM are found in at 
least 80% of cases31,41. Primary GBM, where there is no antecedent history of a brain 
tumour, is usually more lethal than secondary GBM41,  and generally has a wild-type 
IDH1, with IDH1 mutations being demonstrated in less than 5% of cases31. 
 
 
1.1.3.2 MGMT promoter methylation 
MGMT is an enzyme that is responsible for the repair of damage from alkylation in 
DNA25. MGMT expression is repressed via promoter methylation. This means that 
methyl groups are conjugated to specific CpG islands (DNA sequences where a cytosine 
(C) is directly followed by a guanine (G), concentrated in groups where methylation can 
occur that affects gene expression, generally in the promoter region where methyl 
groups on the DNA can inhibit the function of RNA polymerase) in the promoter region 
of the gene42. When the MGMT promoter region is methylated in GBM tissue, the 
cancer cells are more susceptible to TMZ treatment, the primary chemotherapeutic 
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agent that is used to treat GBM. This is because normally MGMT effectively reverses 
TMZ-induced DNA alkylation thus preventing DNA damage and ultimately apoptotic 
cancer cell death, whereas with methylation dependent silencing of MGMT expression, 
TMZ-induced DNA damage will proceed unhindered, and promote tumour cell 
death25,43. The detection of MGMT promoter methylation has, therefore, become one of 
the best predictors of OS and PFS for GBM patients, owing to its direct relevance to the 
efficacy of one of the main forms of treatment25. 
 
 
1.1.3.3 GFAP 
GFAP is a protein that forms one of the primary structural filaments in astrocytes, and 
hence is usually associated with brain tissue (its history and importance in brain tissue 
are reviewed in 44), although it is also found in liver cells45. GFAP was initially reported 
to be primarily expressed in cells that were less invasive and malignant46, however later 
work suggested that there was no statistically significant difference in GFAP expression 
in GBMs of different grades47, leaving the significance of GFAP expression 
controversial at best. GFAP concentration as a free protein in the blood has, however, 
been shown to be indicative of tumour volume in GBM patients48. GFAP has been 
shown to have intratumoral heterogeneous expression- while it was found to be 
expressed in all GBM tumours, it may not be expressed in every cancer cell of that 
tumour49. While GFAP is one of the primary markers used to identify GBM cells, it has 
sufficient limits that in circumstances with a limited number of cells, supplementary 
markers would be of some utility. 
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1.1.3.4 EGFRvIII 
EGFR is a receptor found on cells that is linked to the cell signalling for growth and 
replication (reviewed in 50). EGFR expression is linked to worse outcomes in other 
cancers, for example gastric cancer51 and is frequently amplified in GBM33. While there 
is some ambiguity regarding the effect of EGFR amplification on patient outcomes in 
GBM52, the most frequent mutation of EGFR in GBM, EGFRvIII, is found in up to 33% 
of GBM, and has been associated with decreased survival, particularly in 
adolescents27,53,54. EGFRvIII is caused by various DNA deletions that all affect splicing 
of the messenger RNA (mRNA) to exclude exons 2-753. 
It is of such prominence in GBM that is has frequently been targeted for immune 
therapies, such as with the use of EGFRvIII vaccinations like rindopepimut. However, it 
has thus far been shown that there is little effect on patient outcomes if EGFRvIII is 
targeted by these new therapies55, which suggests that EGFRvIII may not be as 
significant to patient outcome as initially thought, or that immunotherapy for EGFRvIII 
on its own is insufficient treatment. 
 
 
1.1.3.5 IDH2 
Isocitrate dehydrogenase 2 (IDH2) is closely linked to IDH1. IDH2 is an enzyme that 
serves the same purpose as IDH1, but uses NADP+ as an electron acceptor56. While 
mutations of IDH2 are similarly associated with improved outcomes, they are 
significantly less frequent than mutations in IDH1, although they are usually found 
exclusively in tumours that do not have an IDH1 mutation31. 
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1.1.3.6 Phosphatase and tensin homolog 
The phosphatase and tensin homolog (PTEN) gene is associated with tumour 
suppression and is frequently mutated in cancer, with its loss leading to increased 
translation of mRNA to proteins (reviewed in 57). PTEN loss in grade III anaplastic 
astrocytomas is associated with worse outcomes33. However, in GBM, with current 
treatments, its loss does not imply worse survival outcomes32. 
 
 
1.1.3.7 Tumour protein 53 
TP53, a gene that encodes the protein p53, is a tumour suppressor responsible for the 
suppression of the proliferation of cells following damage that impairs their function. It 
modulates the expression of genes that cause a cell to undergo apoptosis, or senescence, 
or temporary cessation of the cell cycle, suggesting that it is arguably the most 
important tumour suppressor (reviewed in 58). Despite its importance in the regulation 
of other cancer types, p53 mutations have been found to have no association with 
survival outcomes in GBM. However, there is an apparent association with outcomes in 
anaplastic astrocytomas58, (reviewed in 34). 
 
 
1.1.3.8 Loss of heterozygosity 1p/19q 
Loss of heterozygostiy (LOH) 1p/19q refers to the loss of one allele of the 
chromosomes 1, on the short arm ‘p’, and 19, on the long arm ‘q’. The deletion of one 
or both of 1p or 19 has been associated with improved survival outcomes in brain 
cancers overall59. However, while one meta-analysis concluded that there was an 
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association between LOH 1p/19q and improved survival in GBM, a different study 
(though not a meta-analysis) found that there is no association between the two60. 
 
1.1.3.9  Telomerase reverse transcriptase promoter 
Telomerase reverse transcriptase (TERT) is an enzyme responsible for extending the 
telomeres of DNA following the replication of chromosomes61. Usually, it is inactivated 
in mature cells, but in cancers it can be reactivated via promoter mutation and 
contributes to the immortalisation and transformation of normal cells into cancer cells, 
and these mutations can be detected via PCR-based assays in cancer-positive patients, 
for example in the urine of bladder cancer patients (serving as a form of liquid 
biopsy)62. In GBM, TERT mutations have been found to be frequently present, with 2 
specific mutations being the most frequent, specifically C to T mutations at nucleotide 
numbers 1295228 (in regards to start ATG codon: C228T), and at 1295250 (in regards 
to start ATG codon: C250T). Furthermore, their presence is indicative of a decreased 
survival time63. They have recently been found in the cerebrospinal fluid (CSF) of brain 
cancer patients64. TERT mutations have been detected in the plasma of prostate cancer 
patients, and suggested as a possible supplement to the prostate specific antigen test65. 
TERT mutations have also been detected in malignant pleural effusions, and suggested 
as a diagnostic tool66. This suggests that the detection of TERT mutations could be a 
possible avenue for the prognosis of GBM. 
 
1.1.3.10 Glutamate Aspartate Transporter 
The glutamate-aspartate transporter (GLAST) is a surface protein found on astrocytes 
that is responsible for transporting glutamate (a neurotransmitter) through the cell 
membrane. This will take glutamate back into the cell after it has been exported during 
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signalling processes. This is important, as in high concentrations in the extracellular 
space, glutamate has neurotoxic properties67. 
In GBM, GLAST has been observed to be internalised into the cell, meaning that it no 
longer serves as a transporter39. It has also been found that GLAST causes the release of 
glutamate in GBM, rather than its uptake. This means that higher GLAST expression in 
GBM has been associated with worse patient outcomes38. 
 
1.1.3.11 Other biomarkers 
Melanoma cell adhesion molecule (MCAM) is a biomarker frequently associated with 
poor outcomes in cancer, and has been reported to be present in GBM, likewise 
correlating with higher grade brain cancers68. 
Chondroitin sulphate proteoglycan (NG2) is a transmembrane protein associated with 
tumour progression, and has been detected in GBM tumour cells69. 
N-cadherin is a cadherin (a transmembrane glycoprotein) associated with the brain. It 
has been detected in GBM, in some cases at levels elevated above normal tissue70. 
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1.1.4 Novel biomarkers 
Programmed cell death ligand 1 (PD-L1) is a cell surface antigen and a ligand that binds 
to programmed cell death 1 (PD-1) on T cells. PD-L1 interaction with PD-1 and the 
immune cells prevents T cell mediated killing of the target cell71. This is a normal 
process to limit autoimmune reactions in the body, but is hijacked by cancer cells to 
evade anti-tumour immune responses. Recently, targeting this interaction using 
antibodies that bind to either PD-1 or PD-L1 and thereby blocking the interaction and 
resulting immunosuppression has led to remarkable success with reinstatement of 
immune reactivity against cancer tissue. This type of antibody therapy is referred to as 
immune checkpoint inhibitor therapy72. In GBM, PD-L1 expression on tumour tissue 
has been found to be suggestive of a decreased OS independent of treatment. However, 
if expressed at a high level on neurons proximal to the main tumour mass, OS is 
increased73. 
Since PD-L1 expression reduces the effectiveness of the immune response to the 
tumour, checkpoint inhibitor therapy may be successful if inhibitors are able to pass the 
blood brain barrier. In metastatic melanoma, this appears to be the case, with response 
to immunotherapy being obsesrved in intracranial metastases74. 
However, in GBM, thus far checkpoint inhibitor therapy has not been shown to be 
effective. A retrospective case study found that there was no survival benefit to the use 
of nivolumab (a PD-1 immune checkpoint inhibitor) in GBM following disease 
progression75. Another large-scale study, Checkmate 143, likewise presented results 
recently that indicated that nivolumab has a very limited effect on patient outcome in 
GBM in comparison to bevacizumab, with only 2 patients having a complete response, 
10 having a partial response, and 107 having progressive disease76. Other immune 
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checkpoint inhibitors targeting PD-1 (such as pembrolizumab, durvalumab) have also 
been trialed, or are currently undergoing clinical trials. Neither of the above mentioned 
drugs have shown good responses in patients77,78. 
While the utility of both IDH1 mutations and MGMT promoter methylation has been 
established in GBM, and PD-L1 expression may be a reasonable biomarker in other 
cancers, the traditional method of detecting these biomarkers relies on access to tumour 
tissue. The difficulty in obtaining tissue in a timely and repeated manner is the crux of 
the issue for GBM research. As in other cancers, a liquid biopsy may provide the 
solution. 
 
 
1.1.5 Liquid biopsies and advantages 
Liquid biopsy refers to the idea of capturing all the same relevant biological information 
that would be available from a traditional core or surgical biopsy through a liquid 
sample, usually by a simple blood draw. The blood will contain tumour materials such 
as circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), and exosomes 
(see Figure 1.1). This material, being sourced from the original cancer cells, is of great 
interest to many researchers as it contains information identical to that which could be 
obtained from the tumour mass79,80 thus having the potential to inform clinical 
decisions. While in other cancers, CTCs can include cells from metastases81 as well as 
from the primary source, in GBM the primary tumour mass is likely to be the sole 
source of these cells, since GBM has very low rates of metastasis82. 
  16 
 
Figure 1.1 Circulating tumour material release and distribution 
 
Figure 1.1: The above figure (adapted from Po, Lynch et al.83) shows the release of CTCs and 
ctDNA from the Primary Tumour, and the subsequent involvement of CTCs in the formation of 
metastases. 
 
Thus far, liquid biopsies have been shown to be of clinical utility in several other cancer 
types, for example prostate, breast, colon and lung cancers84-87.  
The advantages of liquid biopsies are that, firstly, access to tumour material is much less 
restricted than through purely surgical means. A patient can only have resection or a 
surgical biopsy carried out infrequently at best. A liquid biopsy, by contrast, can be 
carried out frequently, as it is minimally invasive to the patient. There are multiple uses 
for longitudinal testing of cancer patients, permitting the detection of the recurrence of 
the cancer and the response to treatment88,89. 
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Secondly, in a minority of patients with inaccessible tumours or a state wherein they are 
unable to endure surgery, tissue may be difficult to procure for analysis. This means that 
a liquid biopsy, fully realised to provide the same information as standard 
histopathology, would make the standard prognostic and treatment-determining tests 
available to all cancer patients, rather than just the portion who can undergo surgery. 
Finally, there is an economic consideration. In the Australian medical benefits scheme, 
the reimbursement for glioma debulking surgery is $1586.7590, which ignores the 
additional fees a neurosurgeon is likely to charge, in addition to costs pertaining to 
pathology and anaesthesia, and the direct and indirect costs from down time recovery 
from surgery. This represents a significant monetary investment for all parties. For a 
liquid biopsy, the cost ranges from $100-$500 AUD per sample, with the bulk of the 
cost due to technician time and modern genomic analysis. In addition, a biopsy for 
GBM requires a trained surgeon, compared to a blood draw.  
The advantages of a liquid biopsy, provided that it can be clinically validated, would 
certainly permit at the very least the supplementation of traditional tissue samples. 
 
Another advantage of liquid biopsies is that the biological information present is likely a 
summary of multiple tumour sites, unlike tumour sampling, which is subject to 
geographical sampling errors, and therefore provides a more 
comprehensive/representative picture than a single site biopsy91. A liquid biopsy may 
also give an insight into the intratumoural heterogeneity of that specific patient, which 
can display features from multiple different subtypes of GBM92. This heterogeneity may 
be missed due to sampling bias during a biopsy. 
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The data available from liquid biopsies may change over time in each patient, usually 
dependent on therapy response or disease progression. For instance, it has been 
demonstrated in lung cancer that the levels of ctDNA fall as treatment successfully 
proceeds, and rise again as the cancer reemerges88. Further, CTC levels can rise 
immediately following surgery, such as in liver cancer (where it has been shown to be 
linked to worse outcomes)93, or in pancreatic cancer (where it has been shown to have 
no effect on patient outcomes)94. In any event, it must be kept in mind that the patient’s 
treatment and disease status may affect ctDNA and CTC concentrations and the 
interpretation of this data. 
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1.1.6 Circulating tumour cells 
CTCs are released into the bloodstream as cancer cells break off from the main tumour 
mass95. They can be used for biomarker testing as a surrogate tissue source of the 
primary or metastatic tumour 84,95,96.  
Currently, there are several methods used for CTC enrichment and isolation. The most 
notable of these is the CellSearch platform, which is approved by the USA’s Food and 
Drug Administration (FDA) for clinical use. The CellSearch system uses automated 
epithelial cell adhesion molecule (EpCAM)-based immunomagnetic isolation in order to 
enrich samples for CTCs, whose identities are then confirmed using positive 
identification with cytokeratins 8, 18 and 19, and negative identification with CD4597. 
Other methods used in the research environment include separation based upon the 
differences between blood cells and CTCs in size; electric properties; plasticity; 
invasive capacity; and cell-surface antigens (reviewed by Gabriel et al.98 and Alix-
Panabières et al95). 
CTC counts after isolation with the CellSearch CTC isolation platform are a prognostic 
marker in breast, prostate and colorectal cancer (reviewed in 99) and the CellSearch CTC 
isolation platform FDA approval is specifically to undertake CTC enumeration in these 
three malignancies (reviewed in 100). 
In brain cancer, until recently, it was believed that CTCs did not exist, due to the blood-
brain-barrier, which is the filter formed by the tight junctions of capillaries. The blood-
brain-barrier is highly selective in what it allows to traverse between the brain and the 
rest of the body101. However, recently Macarthur et al. found GBM CTCs in the blood 
using a green fluorescent protein (GFP) gene transduced via adenovirus under the 
control of the promoter for telomerase. Since telomerase in adults is only actively 
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expressed in cancer or germline cells, any cells expressing GFP following the virus 
transduction were assumed to be cancer cells, as the GFP is expressed in a cell that is 
simultaneously expressing telomerase102.  
This method can detect an average of 8.8 CTCs/mL of blood in 72% of patients, but 
false positives in healthy controls were also found, which meant the authors had to set a 
minimum threshold of 1.3 GFP positive cells to qualify as CTCs. This study included a 
very limited number of patients- 11 pre-radiotherapy and 8 post-radiotherapy patients in 
total. In addition, the methods used by Macarthur et al. are complicated, as it involved 
the adenoviral genetic modification of cells prior to analysis102. However, this report 
was the first to show a decrease in the number of CTCs in patients who responded to 
treatment, in contrast to an increase in the number of CTCs for patients who 
experienced disease progression; both trends were apparent before MRI imaging 
changes, and before clinicaly observed symptoms indicating disease progression. A 
level of 8.8 CTCs/mL could be considered the upper limit for CTC detection in GBM 
patients, at least with current methods, with the caveat that there is a background level 
of false positives found in 30 healthy control subjects. 
 
In a much larger patient cohort of 147 patients, Müller et al. found that only 20.6% of 
patients had detectable CTCs, using anti-GFAP antibody staining as the identification 
method. In addition, the numbers (per mL) of CTCs were much lower, ranging from 0.1 
to 2.2, as compared to the maximum of approximately 60 cells/mL noted by Macarthur 
et al. In addition, Müller et al. concluded that there was no relationship between CTC 
numbers and patient outcome103.  
GFAP is not expressed in all GBM cells104, and it has also been found to be a diagnostic 
marker as a free protein in plasma105. Therefore, by relying solely on GFAP 
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identification of CTCs, Müller et al. may have missed GFAP null cancer cells. In 
addition, there is some (though controversial) evidence that GFAP is expressed at a 
lower level in some types of GBM that have worse outcomes106,107. As a result, the sole 
use of GFAP to identify GBM CTCs may be suboptimal.  
Sullivan et al.108 also developed an assay that involved the use of immunocytostaining 
to identify GBM CTCs, albeit in a study of a smaller scope than Müller or Macarthur. In 
that study, a combination of 5 antibodies in a single microscope fluorescence channel 
(SOX-2; Tubulin beta-3; EGFR; A2B5; and c-met, combined given the acronym 
STEAM in the report) was used. GBM CTCs were found in 39% of 33 patients, or a 
total of 30% of the overall samples to allow for the fact that they took repeat samples 
from some patients. Also, unlike both Müller et al. and Macarthur et al., a relatively 
high threshold of ≥7 positive cells /mL of blood was required before they would call a 
patient CTC positive, due to the comparatively high number of false positives they 
found in their healthy controls (ranging from 0 to 6.4 cells/mL of blood). In patients 
with progressive disease, a median of 11.4 STEAM positive cells/mL was found (please 
note that it is impossible given the methodology to distinguish which markers were 
positive in each individual CTC), with a range of 0 to 32.7 cells/mL, while in those with 
stable disease a median of 2.1 cells/mL, (range 0 to 30.3 cells/mL), was found. Given 
the high rate of false positives, compared to the very low numbers of CTCs, it is 
difficult to say what conclusions can be drawn from these data. However, Sullivan et al. 
did conclude that there was a tendency for brain cancer cells to be mesenchymal (that is, 
they begin to show stem-cell like features109, which are indicative of worse outcomes). 
This was due to an RNA in-situ hybridisation (RNA-ISH) performed on xenograft mice 
models, along with subsequent comparisons of the primary tumours of the mice with 
primary tumour tissue taken from formalin-fixed paraffin embedded tissue blocks. They 
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also stated that these mesenchymal cells were primarily located along the invasive edge 
of the tumour in the models they used108. 
The only other published study, by Gao et al. investigating brain cancer CTCs (n=31 
used) used the presence of aneuploidy in chromosome eight, a common feature of 
cancer cells, as a marker for CTCs. Aneuploidy is the state in cells whereby there is an 
excess number of chromosomes in the cell. The referenced study stated that aneuploidy 
is generally only found in cells in the blood stream in cancer patients110, based upon a 
method previously characterised that stained for aneuploidy in the cerebrospinal fluid 
(CSF)111. While they state that they successfully found cells with aneuploidy in 77% of 
patients (similar numbers to Macarthur et al.)102, and there is no mention of false 
positive CTCs detected in the blood of their 10 healthy controls, there has been prior 
work by a different team of investigators that indicates that there are aneuploidy cells in 
the blood of healthy controls (e.g. in cell division)112. However, this may be explained 
by the high number of copies of chromosome eight (greater than or equal to five) that 
were detected in individual cells marked as CTCs by Gao et al, as a cell undergoing cell 
division would only have a maximum of 4 copies of a chromosome, ergo 5 or more 
could be concluded to be aberrant. Much like Macarthur et al. this study concluded that 
there is an increase in CTC numbers prior to recurrence. Table 1.2 summarises the data 
reviewing studies of CTCs in GBM. 
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Table 1.2 Summary of studies demonstrating the existence of GBM CTCs 
Study	 Patient	Numbers	 Percentage	 CTC	
positive	
CTC	numbers	per	mL	 Maximum	
number	 of	
CTCs	per	mL	
1102.	 Pre-RT:		11.		
Post-RT:	8.	
Pre-RT:	 72%		
Post-RT:	12.5%	.	
Pre-RT:	8.8*	
Post-RT:	not	provided.	
Pre-RT:	 60.	
Post-RT:	5-20.	
2103	 Total:	147.		
Primary:	117.	
Recurrence	
(1st/2nd):	30.		
20.6%	 0.1	to	2.2*		 2.2.	
3108	 33	
	
39%	 11.8#	 (progressive	
disease);		
2.1#	(stable	disease)	
32.7.	
4110.	 31	 77%	 0.13#	 1.33.	
RT: Radiation therapy; * mean; # median 
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1.1.7 Circulating tumour DNA 
In the case of ctDNA, DNA molecules are released by cancer cells undergoing cell 
death and from there are released into the bloodstream79. As the cells are broken down 
via apoptosis, the average base pair (bp) length of the cell-free DNA (cfDNA) tends to 
be consistent (approximately 170 bp) as the DNA is cut into equal-sized fragments by 
the restriction enzymes involved in apoptosis (reviewed by Heitzer et al113). Much like 
CTCs, they can be extracted from the blood via a liquid biopsy. However, circulating 
free DNA (cfDNA) is a normal physiological by product of normal tissue homeostasis. 
ctDNA represents a variable proportion of the total cfDNA derived from normal cell 
turnover and cancer cell death (ranging from 0.01% to over 90%)114,115. Unlike CTCs, 
ctDNA has no identifying features beyond the presence of tumour specific DNA 
alterations such as mutations or methylations. This suggests that, while mutations and 
methylation can be detected116,117, a negative result (the lack of a tumour marker) is 
harder to prove using a purely ctDNA-based result.  This is because cfDNA can be 
derived from either cancer cells or healthy cells. If the DNA from both sources is 
identical in specific regions containing the target markers, there is no way to 
differentiate between ctDNA and background DNA that would be found in normal 
controls. Due to this observation, there are inherent limitations to the analysis of 
cf/ctDNA as a substitute for a tissue biopsy. While there is evidence that cfDNA 
concentration is higher in cancer patients than in the cfDNA of those without cancer, 
cfDNA concentration is so variable that, by itself, it is a less than ideal biomarker, for 
example in colorectal cancer (reviewed by meta-analysis in 118). 
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Despite this drawback, some authors suggest that circulating tumour nucleic acid 
(ctNA) analysis is superior to CTC-based biomarker analysis. For instance, in 
pancreatic cancer, ctNAs offer a more effective method of determining the genotype of 
the tumour, as ctDNA csn be detected much more consistently than CTCs. In one case, 
KRAS mutation detection derived from CTC analysis was shown to give a false 
negative, in contrast to the result from the ctDNA, based on subsequent tissue 
analysis119. Other authors suggest that CTC and ctNA analyses are complementary, with 
increasing reliability when both are used for analysis of biomarkers, at least in small cell 
lung cancer120. A study comparing the presence of ctDNA between different cancer 
types in a large patient population found only low levels of ctNAs in 10% (based upon 
the detection in the blood of mutations known to be found in the different cancers) of 
patients with early and late stage glioma. However, other investigators specifically 
looking for IDH1 mutations or MGMT promoter methylation found a much higher 
proportion of patients with ctDNA (35% to 60% of patients had detectable cancer 
biomarkers verifying ctDNA)121-123. This indicates that disease stage will highly 
influence the utility of ctDNA analysis in brain cancer. By comparison, ctNAs in other 
types of cancer are detectable in 50 to >75% of patients122. 
In GBM, as mentioned above, IDH1 mutations are of particular clinical interest. In 
liquid biopsies IDH1 mutations have also been observed in leukaemia, albeit as an 
indicator of a poorer prognosis, although there is some contention regarding this 
conclusion124. While IDH1 mutations have been found in other cancer types such as 
thyroid cancer125, and prostate cancer126 there is limited data in these cancers on whether 
the mutations have predictive or prognostic capabilities. However, the detection of the 
mutations in the cell-free DNA of leukaemia indicates feasibilty of detecting the 
mutation in GBM ctDNA. 
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The feasibility of IDH1 detection in ctDNA in GBM is supported by one study that 
examined a cohort of 80 glioma patients, and found IDH1 mutations in the cfDNA with 
100% specificity and 60% sensitivity as compared to matching tumour samples that had 
tested positive for the IDH1-R132H mutation. The study also found that the detection of 
IDH1 mutant DNA, and its amount, was dependent upon the size of the tumour (i.e. 
correlated with tumour burden)117. While the amount of ctDNA found is low, the 100% 
specificity suggests that, if the mutation is found in patient plasma samples, confidence 
can be placed in the results. 
 
Another genetic region of interest as a biomarker is, as mentioned above, the promoter 
region of the MGMT gene. In a study of colorectal cancer, ctDNA MGMT promoter 
methylation status was found to reflect that in patient tissue, and MGMT promoter 
methylation correlated with longer PFS and OS127. However, in other studies where 
ctDNA from GBM was analysed, it was found that GBM ctDNA was detected in only 
10%-60% of brain cancer patients, dependent on the study cohort116,117,122. The lower 
bound of 10% was provided by the only study that compared ctDNA detection in GBM 
to other cancers, discussed above. 
 
Detection of MGMT promoter methylation in GBM CTCs would, due to the very 
limited CTC counts, require more sensitive single cell approaches. As discussed below, 
MGMT promoter methylation is measured in a clinical setting by bisulphite conversion, 
which is known to damage DNA128. Given the limited amount of DNA available from a 
single cell, a bisulphite conversion method risks the loss of all of the DNA from the 
single cell. For this reason, the detection of MGMT promoter methylation is better 
performed from ctDNA. 
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Indeed, MGMT promoter methylation in ctDNA has been detected in patients with 
metastatic colorectal cancer. This study found concordance of MGMT promoter 
methylation between tissue and ctDNA samples to be 86.1% of the patient samples 
analysed127 with a number of both false negative and false positive results. It cannot be 
excluded, of course, that the tissue testing resulted in incorrect data due to, for example, 
contamination with normal tissue or test inconsistencies. Regardless of the cause, it 
would have affected the best prediction of the patients’ TMZ response. Thus, a test with 
higher specificity and sensitivity would be desirable, certainly for cfDNA, but possibly 
also for MGMT promoter methylation testing in tissue samples. 
 
EGFR is a potential biomarker for treatment in GBM. As mentioned above, it is 
associated with oncogenic changes (mutations, overexpression, expression of transcript 
variants) which often confer ligand independent activity129. DNA deletions causing 
EGFRvIII expression have been detected in ctDNA from three of thirteen GBM 
patients53. In this particular study, the exact deletions in genomic DNA from matching 
tumour tissue were first determined by long range polymerase chain reaction (PCR), 
then primers adjacent to the deletions were generated to confirm presence in ctDNA. 
However, long range PCR assay is not useful for ctDNA which has a short average 
length of only 170 bases53. 
 
 
1.1.8 Circulating tumour RNA 
Circulating tumour RNA (ctRNA) is, similarly to ctDNA, a nucleic acid that is released 
from both normal and cancer cells and may be distributed through the bloodstream130. 
As the RNA is indicative of genes that are actively being expressed, an RNA profile 
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may help to characterise a cancer. For example, one study found a significant difference 
in expression of specific ctRNAs in non-small-cell lung cancer. In this study, the 
expression of four different microRNAs (miRNAs) in the serum were found to be 
indicative of different survival rates; high expression of miR-486 and miR-30d were 
indicative of a reduced survival rates, while high expression of miR-1 and miR-499 
were associated with improved survival131. This suggests that the variable expression of 
RNA in the blood can be indicative of the activity of the individual cancer that may 
ultimately be helpful in determining clinical benefit. 
In GBM, a meta-analysis of various studies has suggested that some miRNAs are also 
of interest. Specific miRNAs, such as miR-21, indicate tumourigenesis132, and so could 
be developed as a test for the detection or confirmation of disease progression in 
GBM133. This review did not find any reports of the examination of ctRNA in GBM; 
however, the techniques established in other cancers suggest that it is a potential avenue 
for the development of a novel liquid biopsy assay. 
 
 
1.1.9 Cerebrospinal fluid 
The collection and analysis of CSF is also attracting interest as a potential source of 
tumour material for GBM diagnostic analysis. CSF contains GBM specific DNA, with 
at least two studies finding that there are detectable levels of mutated DNA in the CSF 
of patients with various types of brain tumour. One examined the detection of mutated 
DNA in the CSF of patients with paediatric diffuse midline gliomas, wherein they 
detected a disease associated histone H3 mutation, with a sensitivity of 87.5%, and a 
specificity of 100%134.  
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Indeed, there is evidence that a greater amount of tumour derived DNA can be obtained 
from the CSF than from ctDNA. A study that compared the detection of known 
mutations in both the CSF and ctDNA of patients found that there was a much greater 
sensitivity (58% vs 0%) across 12 patients (though only 4 were GBM patients) for the 
DNA detected in the CSF than in the ctDNA135. However, there were very few specific 
mutations examined. While the TERT mutation was investigated across all the GBM 
samples, there were no other consistent mutations examined in the assays. Nevertheless, 
the results do suggest that there is an increased amount of tumour derived DNA 
available in the CSF compared to ctDNA. 
On the other hand, CSF is less attractive as the source of a liquid biopsy than blood as 
the CSF is acquired via lumbar puncture. Lumbar punctures can have significantly more 
severe side effects than blood draws, including but not limited to back pain; severe 
headaches; infections; and subdural cerebral haematoma. These complications can lead 
to hospitalisation136. 
 
 
1.1.10 Exosomes 
Exosomes are vesicles approximately 50-90 nm in size which are actively released from 
cells through the process of fusing with the cell’s membrane and then ‘budding’ off 
from the plasma membrane. These exosomes can contain proteins, RNA, DNA, and 
other cellular components, and can be found in the blood137-140. Exosomes can be 
isolated from cancer patient blood as a source of biomarker information that include not 
only DNA and RNA, but also proteins and lipid based biomarkers that may be 
indicative of the state of the disease89,140,141. The DNA in exosomes makes up more than 
90% of the cfDNA in the blood142. The DNA and RNA molecules in the exosomes are 
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usually extracted as part of the standard method for isolating ctDNA or ctRNA, which 
suggests that current methods for the extraction of ctDNA and ctRNA will already 
suffice for these. 
 
Proteins isolated from exosomes have also been linked to the disease state in GBM 
patients. It was found that certain proteins (specifically a combination of elevated levels 
of EGFR; EGFRvIII; podoplanin; and IDH1-R132H) could be identified from 
exosomes of cancer patients using micro-nuclear magnetic resonance imaging and 
protein typing. The number of exosomes in mouse cells that responded to TMZ was 
found to decrease in that study, suggesting that, exosomes may be used to indicate 
treatment response. 
 
Interestingly, exosomes have been shown to be released from GBM cells, and to 
modulate the tumour microenvironment, including disruption of the blood-brain-barrier 
143. Although these findings have only been demonstrated in mouse models to date, 
exosomes from liquid biopsies represent another potentially useful source of 
biomarkers. 
 
 
1.1.11 Proteins 
Currently, there is also interest in the implications of specific circulating proteins as an 
indicator of disease state in various cancers. One of the most well-known, clinically, is 
the prostate-specific antigen (PSA), which has been associated with an advanced 
prostate cancer disease state144. Likewise, there are some proteins that are elevated in 
the blood of patients with GBM, such as GFAP, insulin-like growth factor-binding 
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protein 2 (IGFBP-2), and chitinase-3-like protein (YKL-40). Elevated levels of these 
proteins above the standard level in the blood was a strong independent indicator of a 
brain tumour. In addition, differentiation between GBM and non-GBM tumours may be 
possible based upon the serum levels of GFAP and then YKL-4048. This study suggests 
that there is a potential circulating proteins to be used for both diagnostic and prognostic 
purposes.  
 
 
1.1.12 Optimum target for liquid biopsies in GBM 
There is much on-going research examining the comparative utility of the different 
components of the liquid biopsy, or alternatives that may prove equally viable. 
With regards to GBM, there is limited evidence of the utility of any form of liquid 
biopsy, given that this area of study is in its infancy. 
 
There are numerous challenges that are inherent to liquid biopsy and CTC analysis in 
GBM or generally. One study has found that there is a significantly lower amount of 
ctDNA in the blood of brain cancer patients compared to blood of patients with other 
cancer types122, likely due to the blood-brain-barrier preventing the egress of the tumour 
material from the brain. This observation also appears to be true of CTCs, where only 
an average of 2.9 CTCs/mL of blood was found in GBM patients103, for example, in 
ovarian cancer (Po et al found up to 144 CTCs/mL of blood)145, lung cancer (greater 
than 5000 CTCs/mL of blood146), or breast cancer (up to 620 CTCs/mL147).  
In regards to circulating protein markers in GBM, the range of concentrations is large. 
For example, the study cited above (Gállego et al.) found an average amount of 435.0 
pg/mL of IGFBP-2 in the blood of GBM patients, with a standard deviation of 387.2 
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pg/mL. By comparison, the healthy controls had an average 184.0 pg/mL, with a 
standard deviation of 154.6 pg/mL48. The large range of protein concentrations in 
patients, as well as controls suggests their utility for prediction or prognostication may 
be limited.  
It must be acknowledged that CTCs have yet to be shown to have clinical utility for 
GBM patients, and there is less data than for ctDNA and circulating proteins48,117. 
However, CTCs are viable, intact cells, which means that, despite the difficulty in 
detecting them, it can be argued that they are the best possible choice for future further 
investigation as they contain examples of tumour DNA, RNA, and protein expression 
that are representative of the tumour in GBM. More recently, short-term CTC cultures 
have also been used to test responses to drug libraries148. 
 
 
1.1.13 Methylation and methylation detection methods 
Methylation, discussed briefly above (MGMT promoter methylation, page 7), is a means 
whereby the expression of particular genes can be controlled. A methyl group is bound 
to a cytosine and guanine pair in the promoter region of the gene. Methylation allows 
specific transcriptional inhibitors to bind and inhibit gene transcription42. This has been 
reviewed thoroughly by Moore et al149. The CG groups are usually clustered in regions 
called CpG islands that are generally found in promoter regions (72% of all promoter 
regions) in the human genome, providing a means to control gene expression150. 
Methylation is most commonly studied in human samples via the bisulphite-conversion 
method, which involves the conversion of unmethylated cytosine bases to uracil; DNA 
amplification is then performed by PCR (this process is called pyro sequencing) on both 
the unconverted and converted DNA in order to confirm the location in the DNA 
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sequence that possesses methylation by comparing the sequences of the two151. The use 
of methylation sensitive restriction enzymes is rarer152. These enzymes only digest 
unmethylated DNA, and PCR can then be used to confirm whether the targeted DNA is 
still present153. The effects of bisulphite conversion have, as a side-effect, the tendency 
to lead to the destruction of DNA, up to 99.9% after a 16 hour (h) incubation, or at a 
rate of 4.1x10-6 bases per second128. As a result of this, bisulphite conversion may be 
inappropriate for the analysis of ctDNA, especially GBM ctDNA, due to the very 
limited amounts of ctDNA available from a sample122. The use of methylation-sensitive 
enzymes should permit the detection of methylation in MGMT without a concern for 
whether the target DNA sequence will survive the enzymatic digestion or not. However, 
this method may lead to false positives due to incomplete restriction digest for reasons 
other than methylation; as a result, appropriate controls are necessary154-156. 
 
 
1.1.14 Novel testing methods 
As analysis technology has progressed, so too have the most reliable methods for the 
analysis of samples. Currently, one of the most reliable methods for determining if a 
specific nucleic acid is present in a sample and determine its concentration is droplet 
digital polymerase chain reaction (ddPCR). This process involves segregating a sample 
with multiple DNA templates into single molecules in, oil-based droplets of similar 
size, each of which contains the reagents necessary for PCR157. The advantage of this 
method is that it permits the accurate quantification of the amount of DNA in the 
original sample, even in heterogeneous samples, as the sequences with a lower 
concentration in the solution will be segregated from the others, and can be amplified 
and detected much more easily than as part of a single solution. This is possible because 
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each droplet that contains a successfully amplified PCR template is detected 
individually which allows high sensitivity and specificity (see Figure 1.2). This is 
particularly useful in the case of liquid biopsies, as nucleic acids from the normal 
somatic cells can mask the existence of variants of the DNA that are less common in a 
particular sample if all the DNA fragments are processed simultaneously. 
Figure 1.2 Droplet digital PCR 
 
Figure 1.2: Taken from Hindson et al157. An example of how ddPCR works; DNA fragments are 
segregated into individual droplets (see 1.), then as PCR is performed, fluorescent droplets will 
indicate where the target sequence is present (see green droplets in 2). As demonstrated in 3 
this permits the use of droplet readers to give an accurate quantification of the DNA sequences 
that are present. 
 
 
1.2 Hypothesis and Aims 
1.2.1 Hypothesis 
CTCs and ctDNA can be isolated from the blood of brain cancer patients, and that they 
have clinical relevance for the detection of biomarkers relevant to the patient’s disease. 
 
1.2.2 Aim 1 GBM CTC isolation and identification 
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This project aims to establish a method of directed immunomagnetic isolation of 
CTCs from the blood of brain cancer patients and improve on current GBM CTC 
identification. 
 
1.2.3 Aim 2 Cryopreservation for CTC isolation and characterisation of PD-L1 
expression 
This study aims to determine the utility of cryopreservation of PBMCs for delayed 
GBM CTC isolation and to screen GBM CTCs for PD-L1 expression. 
 
1.2.4 Aim 3 MGMT methylation testing from liquid biopsies  
This project aims to establish a novel highly sensitive assay to determine MGMT 
promoter methylation, validate it using patient derived tumour tissue and cfDNA 
and correlate the resulting data with patient disease outcome. 
 
1.2.5 Aim 4 IDH1 mutation testing from liquid biopsies 
This study aims to screen GBM CTCs and patient cfDNA for IDH1-R132H using a 
ddPCR assay. 
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2 Materials and methods 
2.1 Cell lines and tissue culture 
All cell lines were cultured at 37° C with 5% atmospheric CO2. The GBM cell lines 
A172, LN-229, T98G, U251 and U87 (kindly provided by A/Prof Kieran Scott, Ingham 
Institute for Applied Medical Research, Liverpool, Australia) were cultured in DMEM 
media [Lonza, Basel, Switzerland], containing 10% foetal bovine serum (FBS) 
[Interpath, Melbourne, Australia] and 4 nM hepes [Lonza]. 
The leukocyte cell line WME-099 (kindly provided by Prof Graham Mann, Westmead 
Institute for Medical Research, Australia) was cultured in RPMI-1640 [Lonza] 
containing 10% FBS and 4 nM hepes. 
The GBM cell line BT-142 (American Type Culture Collection, through Invitro 
diagnostics [Noble Park North, Australia]) were cultured in Neurocult media [Stemcell, 
Tullamarine, Australia] 37° C with 5% atmospheric CO2 with 20 ng/mL human 
Epidermal Growth Factor [Stemcell]; 100 ng/mL platelet-derived growth factor [Sigma-
Aldrich, Castle Hill, Australia]; 20 ng/mL Fibroblast growth factor [Stemcell]; and 2 
µg/mL heparin sulphate [Sigma-Aldrich]. Cells were harvested mechanically washing 
semi-attached cells off by pipetting with 0.5 mM ethylene diamine tetra-acetic acid 
(disodium) (EDTA) [Sigma Aldrich] solution.  
All cell lines were short tandem repeat (STR) authenticated [AGRF, Melbourne, 
Australia] and proven free of mycoplasma, Mycoalert kit [Lonza] through an Ingham 
Institute service. 
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2.2 Coupling of isolation antibodies to magnetic beads  
Immunomagnetic beads from the Rare Cell Isolation Kit [Fluxion, San Francisco, USA] 
are pre-coupled with anti-mouse antibodies to immobilise IgG antibodies chosen for cell 
isolation. Beads were removed from suspension using a strong handheld magnet. 
Supernatant was discarded and the beads were washed in 5 times the original 
suspension volume of binding buffer [Fluxion]. They were resuspended in the original 
volume of binding buffer, along with the appropriate amount of antibody (see Table 
2.1). The beads were incubated for 90 minutes (min) at room temperature on a rotating 
platform. Beads were then washed with binding buffer before resuspension in the 
original volume of binding buffer. The antibody conjugated beads were stored at 4°C 
for use within 4 weeks. 
Table 2.1 Antibody dilutions for immunomagnetic bead binding 
Antibody Clone Ig Subtype Company Dilution for binding 
to Immunomagnetic 
Isolation beads  
 
Anti-human 
MCAM 
antibody 
P1H12 IgG1 Millipore, 
Temecula, 
USA 
1:40 
Anti-NG2 
antibody 
9.2.27 IgG2a Millipore, 
Temecula, 
USA 
1:90 
Anti-EGFR 
antibody 
LA1 IgG1 Millipore, 
Temecula, 
USA 
1:35 
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2.3 Immunomagnetic isolation of GBM cells  
LN-229 cells were cultured for 72 h then harvested by repeated pipetting using 0.5 mM 
EDTA. Cells were counted using a haemocytometer to determine concentration. One 
hundred cells were pipetted into a 1.5 mL non-protein binding microcentrifuge tube to 
serve as the sample. Input controls were made by pipetting an equal volume of cell 
suspension independently onto a microscope glass slide and allowing it to dry, after 
which the dried cells were stained with Hoechst-containing mounting media [Fluxion] 
and covered with a glass coverslip. The cells in each drop were counted on a BX53 
microscope [Olympus, Notting Hill, Australia] to verify the number of cells pipetted. 
 
Thirty µL of Fc blocker [Fluxion] for each type of antibody-conjugated 
immunomagnetic bead to be used with the sample was added to the sample. Thirty µL 
of antibody-conjugated immunomagnetic beads (see Coupling of isolation antibodies to 
immunomagnetic beads, page 35) for each type of antibody used was added to the 
sample to block the cells. The total volume was made up to 800 µl using binding buffer. 
The sample was placed on a rotating platform at 4° C for 90 min. The beads were then 
removed from suspension using a magnet held against the tube for 30 seconds (s). The 
supernatant was drawn off and discarded without disturbing the beads. The beads were 
washed twice with 1 mL of binding buffer, using the magnet to draw down the beads 
each time. The remaining cells attached to the beads were fixed in 4% fixative [Fluxion] 
solution for 10 min. The cells were washed with binding buffer following fixation. Fifty 
µL of 0.1% Triton-X100 [Sigma-Aldrich] was used to permeabilise the cells after 
washing, and were left for 10 min at room temperature. Cells were washed twice with 
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binding buffer and resuspended in 8 µL of Hoechst-containing mounting media. Cells 
were finally transferred to a glass slide and covered with a coverslip. 
GBM cells were counted using a BX53 microscope.  
 
 
2.4 PBMC enrichment 
Blood was taken from patients in 3 x 9 mL EDTA tubes [Greiner, Frickenhausen, 
Germany]. 15 mL of Lymphoprep [Stemcell] was transferred into two 50 mL SepMate 
tubes [Stemcell] through the insert. The total blood volume was divided into two equal 
parts between the two SepMate tubes, pipetting slowly on the side of the tube so as not 
to prevent the blood from forming a separate layer from the lymphoprep. An equal 
volume of phosphate-buffered saline (PBS) [Lonza] to the blood was used to wash the 
EDTA tubes twice, with the PBS used being split between the two SepMate tubes. The 
samples were centrifuged at 1200 x g for 10 min. After centrifugation the plasma and 
peripheral blood mononuclear cell (PBMC) layer were then poured quickly into two 
new 50 mL Falcon tubes [Greiner], without removing the lymphoprep or red blood cell 
layers. The samples were centrifuged at 280 x g for 10 min, and the supernatant was 
removed without disturbing the cell layer. Six mL of PBS was added to each of the 50 
mL tubes and the cells were resuspended by tapping the bottom of the 50 mL tubes on 
the bench top. The samples were centrifuged again at 280 g for 10 min. Following 
removal of the PBS, cells were ready for use in experiments. 
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2.5 CTC isolation from GBM patients 
Patient or healthy control derived PBMCs, which is the cell population containing CTCs 
in cancer patient blood samples, suspended in a volume of 800 µl of binding buffer, 
were incubated with 30 µl of magnetic beads coupled to individual antibodies. In 
experiments requiring the combination of antibodies, for each additive amount of 30 µl 
of beads each coupled to a specific antibody, 30 µl Fc blocker was added and the 
sample incubated for 1.5 h, gently agitated by rotation, before CTC enrichment was 
performed using the IsoFlux CTC isolation platform [Fluxion]. 
Cells were fixed as described in Immunomagnetic isolation of GBM cells, page 36. Cells 
were blocked in 10% FBS in PBS. Cells were incubated for 30 min with anti-CD45 
antibody (see Table 2.2 for dilutions) in 1% FBS in PBS. The cells were washed with 
binding buffer and permeabilised with 0.1% Triton-X100 for 10 min. 0.05% Triton-
X100 was used to dilute the antibody required for staining (see Table 2.2 for antibody 
dilutions). Cells were incubated with anti-GFAP solution for 1 h, washed with binding 
buffer, incubated with anti-rabbit alexafluor 555 (AF555) antibody for 30 min in the 
dark, washed with binding buffer again, then incubated with anti-glutamate-aspartate 
transporter (GLAST) antibody solution. 
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Table 2.2 Dilution of antibodies for immunostaining 
Antibody 
Name 
Cloneality 
[specific 
clone] or 
<catalogue 
number> 
Ig Subtype Company Immunocytostaining 
Dilutions 
Anti-GLAST 
antibody 
Rabbit 
Polyclonal, 
<NB100-
1869AF488> 
IgG Novus Bio, 
Centennial, 
USA 
1/100 
Anti-GFAP 
antibody 
Rabbit 
Polyclonal, 
<AB5804> 
IgG Merck, St. 
Louis, USA 
1/300 
Anti-
cytokeratin 
antibody 
Unknown* Unknown* Fluxion, San 
Francisco, 
USA 
1/10 
Anti-CD45 
antibody 
Unknown* Unknown* Fluxion, San 
Francisco, 
USA 
1/200 
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Antibody 
Name 
Cloneality 
[specific 
clone] or 
<catalogue 
number> 
Ig Subtype Company Immunocytostaining 
Dilutions 
Anti-CD45-
Cy5 
Fluorophore 
Conjugated 
antibody 
Mouse 
monoclonal 
[HI30] 
IgG1 Novus Bio, 
Centennial, 
USA 
1/200 
Goat anti-
rabbit AF555  
fluorophore 
conjugated 
antibody 
Goat 
Polyclonal 
<A-21428> 
IgG Thermo 
Fisher, 
Waltham, 
USA 
1/2000 
* Fluxion does not provide this information on their proprietary antibodies.
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2.6 cfDNA extraction 
Blood was taken in 9 mL EDTA tubes [Greiner] from either patients or healthy controls. 
These tubes were centrifuged within 1 h of blood draw for 30 min at 280 x g with the 
brake off. Then, the upper layer of the plasma was carefully pipetted into 1.5 mL tubes 
without disturbing the red blood cell layer. Samples were spun at 13 000 rotations per 
minute (rpm) on a Heraeus Pico 21 centrifuge [Thermo-Fisher, Waltham, USA]. 
Following centrifugation the supernatant was transferred to either new 1.5 mL tubes for 
immediate use (for which they were stored on ice) or to 2.0 mL cryotubes [Greiner] to 
be frozen at -80° C. 
cfDNA from the supernatant was then extracted using the QIAmp Circulating Nucleic 
Acid kit [Qiagen, Chadstone, Australia]. 
To prepare the buffers (ACB [Qiagen], ACW1 [Qiagen], and ACW2 [Qiagen]) the 
appropriate amount of isopropanol [Sigma-Aldrich] or 96-100% ethanol [Sigma-
Aldrich] was added. 1550 µL of buffer AVE [Qiagen] was used to resuspend 310 µg of 
lyophilised carrier RNA in order to dissolve it. Based upon the volume of samples being 
processed, carrier RNA solution (to improve binding to silica membrane) was then 
added to buffer ACL [Qiagen], with approximately 5.6 µL of carrier RNA solution 
being used per sample, and approximately 2.6 mL of buffer ACL being used per 
sample. 
 
For each individual patient sample, 300 µL of proteinase K [Qiagen] was pipetted into a 
50 mL tube. Three mL of plasma was pipetted into each tube, 2.4 mL of the previously 
prepared buffer ACL with carrier RNA was then pipetted into the sample. The sample 
was vortexed for 30 s and incubated at 60° C in a water bath for 30 min. After this, 5.4 
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mL of buffer ACB was added to the lysate, vortexed for 30 s and incubated for 5 min on 
ice. 
The QIAmp mini column [Qiagen] was inserted into the VacConnector [Qiagen] on the 
QIAvac 24 plus [Qiagen]. A 20 mL tube extender [Qiagen] was inserted into the open 
mini column. The lysate mixture was carefully pipetted into the tube extender, through 
which the lysate was drawn through the column by vacuum pump. 600 µL of buffer 
ACW1, 750 µL of buffer ACW, and 750 µL of ethanol (96-100%) were added to the 
column and drawn through by vacuum pump individually. After the final wash the mini 
column was removed and placed in a clean 2 mL collection tube [Qiagen] and 
centrifuged at 20 000 x g for 3 min. The mini column was then transferred to a new two 
mL collection tube and incubated at 56° C for 10 min. Following incubation the mini 
column was transferred to a clean 1.5 mL elution tube [Qiagen] and 60 µL of buffer 
AVE was added to the sample and incubated at room temperature for 3 min. The sample 
was then centrifuged for 3 min at 20 000 x g. The elute was pipetted onto the same 
membrane again and incubated as before for three min before being centrifuged again at 
20 000 x g for 3 min and then frozen at -20° C. 
 
 
2.7 Immunocytostaining of patient GBM CTCs 
The isolated cells were fixed using 4% formaldehyde for 10 min, washed once and 
resuspended in binding buffer. Anti-CD45-AlexaFluor647 (AF647) conjugate [Novus 
Bio, Centennial, USA] (refer to Table 2.2) was used to stain residual PBMCs, and cells 
were permeabilised and incubated with anti-GFAP antibody (refer to Table 2.2) diluted 
in Triton-X100 0.05% in binding buffer for 1 h. The cells were washed and incubated 
with AlexaFluor-555 (AF-555) conjugated anti-rabbit secondary antibody (refer to 
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Table 2.2) diluted in Triton-X100 0.05%for 30 min. Cells were washed with binding 
buffer again and incubated with anti-GLAST (refer to Table 2.2) antibodies diluted in 
0.05% Triton-X100 for 1 h. After washing, cells were resuspended in binding buffer 
containing a 1/2000 dilution of Hoechst dye [Fluxion] for 3 min, followed by washing 
with binding buffer and resuspension in 100 µL of binding buffer. 
 
 
2.8 GBM CTC counts 
Samples were analysed using the CellCelector [ALS, Jena, Germany] in order to locate 
and pick individual CTCs. The CellCelector is an instrument that has fluoresecent 
microscope detecting colours from DAPI, FITC, TRITC, and Cy5 channels; an 
automatic stage for scanning and software to analyse images; a robotic arm to pick 
individual cells located digitally into individual tubes to allow for later molecular 
analysis. Samples were transferred to a glass slide and placed on the microscope. The 
samples were scanned in all four channels to detect Hoechst (nucleated cells) (DAPI 
channel), GLAST expressing CTCs (FITC), GFAP expressing CTCs (TRITC) and 
CD45 expressing PBMCs (Cy5) to distinguish residual blood cells from true CTCs. 
Accordingly, CTCs were defined as nucleated (Hoechst positive) events probing 
positive for GFAP and/or GLAST in the absence of CD45 staining (see table 2.3 for 
ALS CellCelector analysis conditions) in the automatically scanned images. Final 
confirmation of CTC identity was done by a visual checking of each event in all 
available channels of the microscope including bright field.  
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Table 2.3 CTC definition criteria as used with the ALS CellCelector software 
Channel Particle Area 
Minimum 
Particle Area 
Maximum 
Particle 
Diameter 
Minimum 
Particle 
Diameter 
Maximum 
DAPI 25µm2 500µm2 2.5µm 50µm 
FITC 15µm2 500µm2 1.5µm 50µm 
TRITC 15µm2 500µm2 1.5µm 50µm 
Cy5 15µm2 500µm2 1.5µm 50µm 
 
 
2.9 ddPCR 
All reagents were thawed and warmed to room temperature. The solution of primers and 
probes was made up at 20 times the final concentration required (900 nM and 250 nM 
for primers and probes respectively). 1.5 mL tubes were labelled for each sample being 
run. Eleven µL of ddPCR supermix [BioRad, Hercules, USA] was then added to each 
1.5 mL tube, followed by 1.1 µL of primer/probe. 9.9 µL of DNA solution was added to 
the 1.5 mL tubes. The samples were vortexed for 15 s and then incubated at room 
temperature in the dark for 3 min. A droplet generator cartridge [BioRad] was placed 
into a droplet generator cartridge holder [BioRad]. Twenty µL of each sample was 
loaded into an individual sample well in a droplet generator cartridge. Any wells in the 
cartridge not loaded with sample were instead loaded with ddPCR water [BioRad]. 
Seventy µL of droplet generation oil was loaded into each droplet generation oil well in 
the cartridge. The cartridge was covered with a rubber gasket [BioRad], and loaded into 
the droplet generator [BioRad]. After droplet generation, the droplets were carefully 
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loaded into a column of the 96-well ddPCR plate [BioRad]. The ddPCR plate was 
covered with a plate foil seal [BioRad] and placed into a plate sealer [BioRad]. After the 
plate had been sealed, the samples were transferred to a ddPCR thermocycler [BioRad] 
and the appropriate protocol for amplification was run (see relevant chapters for 
amplification conditions). After amplification, the plate was transferred to a QX200 or 
QX150 plate reader [BioRad]. The amplified products were analysed using the plate 
reader and the QuantaSoft program [BioRad]. 
 
 
2.10 Patients 
Patients with astrocytoma grade 3 or 4 (with grade 4 astrocytoma patients classified as 
primary or secondary GBM) were recruited from Liverpool Hospital. The study was 
undertaken with written patient consent and approval of the South Western Sydney 
Local Health District Ethics Committee (HREC/13/LPOOL/158). Blood was drawn into 
three nine mL tubes [Greiner], and processed immediately for use in the procedures 
cfDNA extraction (page 40) or for CTC isolation from GBM patients (page 38), as 
described above.  
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3  Development of a targeted enrichment method 
for GBM-CTCs 
3.1 Introduction 
As discussed in chapter 1, Circulating tumour cells, page 14, CTCs in GBM patients 
(“GBM CTCs”) have so far been reported in five studies102,103,108,110,111. Due to different 
methods used for CTC detection in different patient cohorts, these studies show that 
GBM CTCs can be found in the blood of various proportions of patients, ranging 
between 20.6-77%. All studies note that the detected number of CTCs is small, varying 
between 0.1 to 60 CTCs per mL of blood, possibly due to restricted CTC release into 
circulation secondary to the blood brain barrier. Although the presence of GBM CTCs is 
now accepted, whether their detection has clinical value is yet to be shown, and their 
biology is still not understood.  
As discussed earlier, CTCs are predictive for OS and PFS158 in other cancers, as well a 
source of molecular biomarker information159,160.It is tempting to hypothesise that the 
presence of GBM CTCs, despite being rare, are similarly clinically and prognostically 
useful. The current evidence for a clinically informative link between CTCs and GBM 
patient outcome is controversial102,103,108,110 but research on the utility of brain cancer 
CTCs for molecular biomarker detection is only in its infancy (see Chapter 1, 
Circulating Tumour Cells, page 14). 
Current methods for GBM CTC extraction are complex and yield a low detection rate of 
GBM CTCs, likely indicating GBM CTC numbers are indeed relatively low but 
detection inefficiencies may contribute to this finding. CTC enrichment methods for 
  49 
GBM CTCs have not yet been reported. Detection and identification methods by 
specific immunostaining are usually based on either GFAP probing, a combination of 
SOX-2, tubulin beta-3, EGFR, A2B5 and c-MET immunostaining or rely on genetic 
manipulation with ectopic GFP expression or fluorescent in-situ hybridisation (FISH) 
for aneuploidy of chromosome 8102,103,108,110, as discussed in chapter 1, Circulating 
Tumour Cells, page 14.  
While the use of immunomagnetic CTC enrichment is well established for other 
cancers161, the lack of suitable cell surface markers for GBM cells makes 
immunomagnetic methods for detection of GBM CTCs challenging. However, if better 
markers can be found, CTC detection efficiencies from brain cancer patients might be 
considerably improved.  
Usually even targeted immunomagnetic capture of CTCs still requires positive 
identification by immunocytostaining to distinguish tumour cells from residual blood 
cells. One of the primary methods used in other GBM CTC studies has been to 
immunoprobe CTCs for GFAP expression. However, GFAP, while being relatively 
unique to brain cells, and critically, absent in blood cells103, is not equally expressed on 
all brain tumour cells104.  
The aim of the study presented in this chapter was to develop a novel immunomagnetic 
enrichment method for GBM CTCs and additionally improve identification of these 
cells. Specifically, we wished to find markers for both cell isolation (which requires the 
targeted antigens to be expressed on the cell surface, to be absent on the surface of 
blood cells, and for the selected antibodies to be able to bind to our immunomagnetic 
beads and to GBM CTCs), and for cell identification (which requires antigens that are 
also not present in blood cells, but may be expressed intracellularly).
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3.2 Methods 
3.2.1 Immunocytostaining to evaluate GBM cell surface proteins as candidates 
for GBM CTC isolation 
For cell surface protein detection experiments, GBM cell lines A172, LN-229, T98G, 
U251 and U87 were seeded at 2.5 x 104 on glass coverslips and grown for 72 h. Cells on 
coverslips were fixed using 4% formaldehyde [VWR, Radnor, USA], washed with 1 x 
PBS, blocked in 10% FBS for 10 min, and incubated with primary antibody for 1 h 
(please refer to Table 3.1 for antibodies and concentrations). The cells were washed 
with PBS and incubated for 30 min with AlexaFluor488 conjugated secondary goat 
anti-mouse IgG antibodies [Thermo Fisher], then washed twice with PBS and once with 
distilled H2O. The coverslips were mounted on slides containing mounting media with 
Hoechst-dye and were visualised on a BX53 microscope. 
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Table 3.1 List of antibodies for use in isolation 
Antibody Clone Ig Subtype Company Flow Cytometry/ 
Immuno-
cytostaining 
Dilutions 
Dilution for 
binding to 
Immunomagnetic 
Isolation beads  
 
Anti-human 
MCAM 
antibody 
P1H12 IgG1 Millipore, 
Temecula, 
USA 
1:250 1:40 
Anti-NG2 
antibody 
9.2.27 IgG2a Millipore, 
Temecula, 
USA 
1:500 1:90 
Anti-EGFR 
antibody 
LA1 IgG1 Millipore, 
Temecula, 
USA 
1:200 1:35 
Anti-Nestin 
antibody 
Polyclonal 
Catalogue 
number: 
AB5922 
IgG Merck, St. 
Louis, USA 
1:1000 N/A 
Anti-CD271 
antibody 
C40-1457 IgG1k BD 
Biosciences, 
Franklin 
Lakes, USA 
1:200 N/A 
 
Anti-CD339 
antibody 
HMJ1-29 IgG Lonza, 
Gordon, NSW 
1:200 N/A 
Anti-CD253 
antibody 
RIK-2 IgG1 Biogems, 
Westlake 
Village, USA 
1:250 N/A 
Anti-N-
Cadherin 
antibody 
GC4 IgG1 Merck, St. 
Louis, USA 
1:100 N/A 
 
Anti-Her2 
antibody 
24D2 IgG1k Biolegend, 
San Diego, 
USA 
1:200 N/A 
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Antibody Clone Ig Subtype Company Flow Cytometry/ 
Immuno-
cytostaining 
Dilutions 
Dilution for 
binding to 
Immunomagnetic 
Isolation beads  
 
Anti-Her3 
antibody 
H3.105.5 IgG1 Millipore, 
Temecula, 
USA 
1:100 N/A 
 
 
 
3.2.2 FACS analysis to evaluate GBM cell surface proteins as candidates for 
GBM CTC isolation 
A172, LN-229, T98G, U251 and U87 GBM cells were seeded at 1 x106 in 2 separate 
T75 tissue culture flasks [Corning, Corning, USA] and cultured for 72h and then to 
avoid loss of cell surface proteins harvested with 0.5 mM EDTA in PBS at 37°C. Cells 
not detaching within 10 min were loosened with cell scrapers. Approximately 106 cells, 
as counted by haemocytometer, were aliquoted into separate 1.5 mL tubes. The cells 
were spun down at 300 x g for 5 min, the supernatant removed, and blocked with 10% 
FBS in PBS for 15 minutes.  
For all antibodies, an IgG matched control was prepared, isotype matched IgG1 or 
IgG2a to an amount equal to the highest concentration of evaluated antibody of the 
same type was used for probing of parallel cell samples. Specific antibody probing and 
isotype matched control probing was performed for each cell line. 
The samples were incubated at room temperature for 30 min in primary antibody diluted 
in 10% FBS/90% PBS solution, prepared according to Table 3.1. After 2 washes with 
PBS cells were probed with secondary antibodies (see Table 3.2 for dilutions), for 20 
min in the dark. After another wash with PBS, cells were resuspended in 300 µL of PBS 
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and transferred to fluorescence activated cell sorting (FACS) tubes and analysed using 
the flow cytometer, FACS Canto II [BD Biosciences, Franklin Lakes, USA] according 
to the manufacturer’s instructions. Analysis was subsequently performed using the 
program Flowing Software 2 [Perttu Terho, Terku, Finland]. For analysis, the main 
viable cell population was gated according to their forward scatter (FSC) and side 
scatter (SSC) appearance while the relevant cell surface protein expression was gated on 
the FL-1 channel for each cell line in comparison to the isotype IgG probed control of 
the same cell line. 
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Table 3.2 Names and dilutions for antibodies for identification 
Antibody 
Name 
Cloneality 
[specific 
clone] or 
<catalogue 
number> 
Ig Subtype Company Flow Cytometry/ 
Immunocytostaining 
Dilutions 
Anti-GFAP 
antibody 
Rabbit 
Polyclonal, 
<AB5804> 
IgG Merck, St. 
Louis, USA 
1/300 
Anti-GLAST 
antibody 
Rabbit 
Polyclonal, 
<NB100-
1869AF488> 
IgG Novus Bio, 
Centennial, 
USA 
1/100 
Anti-O4 
antibody 
Mouse 
monoclonal 
[O4]  
IgM Miltenyi 
Biotec, 
Bergisch 
Gladbach, 
Germany 
1/11 
 
Anti-OLIG2 
antibody 
Rabbit 
Polyclonal, 
<AV31464-
100UL> 
IgG Sigma-Aldrich, 
St. Louis, USA 
1:250 
Anti-A2B5 
antibody 
Mouse 
monoclonal 
[105-HB29] 
IgM Miltenyi 
Biotec, 
Bergisch 
Gladbach, 
Germany 
1/11 
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Antibody 
Name 
Cloneality 
[specific 
clone] or 
<catalogue 
number> 
Ig Subtype Company Flow Cytometry/ 
Immunocytostaining 
Dilutions 
Anti-CD45-
Cy5 
Fluorophore 
Conjugated 
antibody 
Mouse 
monoclonal 
[HI30] 
IgG1 Novus Bio, 
Centennial, 
USA 
1/200 
Goat anti-
rabbit AF555  
fluorophore 
conjugated 
antibody 
Goat 
Polyclonal 
<A-21428> 
IgG Thermo Fisher, 
Waltham, USA 
1/2000 
Goat anti-
rabbit AF488 
fluorophore-
conjugated 
anti-rabbit 
antibody 
Goat 
Polyclonal 
<A-11008> 
IgG Thermo Fisher, 
Waltham, USA 
1/2000 
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3.2.3 Cytoplasmic immunocytostaining to evaluate GBM markers for CTC 
identification  
Cells were grown on glass coverslips as described in Immunocytostaining to evaluate 
GBM markers for CTC identification, page 47. 
For cytoplasmic protein detection of the evaluated identification markers, after fixing 
cells were permeabilised using 0.1% Triton-X100 for 10 min. The cells were then 
incubated for 1 h with primary antibody (see Table 3.2 for antibody concentrations). 
Following incubation the cells were washed using PBS, and if required (i.e. bound to a 
not already fluorescently conjugated primary antibody), incubated with secondary 
antibody for 30 min, and washed with PBS again. The coverslips were mounted in 
Hoechst-dye containing mounting media, and were visualised on a BX53 microscope. 
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3.3 Results 
In this work we wanted to find markers for both GBM cell isolation (which requires the 
antigens for the antibodies used to be expressed on the cell surface; to not be expressed 
on the surface of blood cells; and for the antibodies to be able to bind to our 
immunomagnetic beads and still be able to bind to GBM CTCs) and for GBM cell 
identification (which requires for us that the antibodies not be sourced from mice, as 
that would cause cross-reactiity with our immunomagnetic beads).  
 
 
3.3.1 Choice of candidate cell surface targets for CTC isolation 
First, we conducted a thorough literature search to produce a list of cell surface proteins 
with potential as immunomagnetic cell isolation targets. The search included markers 
previously indicated as brain cancer markers or predicted to be neural cell – specific, yet 
excluded any antigens also known to be expressed on blood cells. This information was 
not always readily available in the literature, or resources such as the Human Protein 
Atlas (https://www.proteinatlas.org)162. Table 3.3 lists all cell surface proteins evaluated 
as isolation target candidates. 
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Table 3.3 List of candidate isolation markers 
Cell Protein Also known 
as 
Presence on 
GBM Cells 
Presence in 
Blood Cells 
Results from 
this study 
MCAM CD146; 
MUC18; 
P1H12; 
Gicerin 
Yes162 Yes162 Shown in GBM 
cell lines. 
NG2 Chondroitin 
sulphate 
proteoglycan;  
Yes162 No162 Shown in GBM 
cell lines. 
N-Cadherin Cadherin 2; 
CD325; 
NCAD; 
CDHN 
Yes162 145 Yes162 Stained both 
GBM and blood 
cells. 
EGFR ERBB; 
HER1; PIG61 
Yes54 No162 Shown in GBM; 
not in blood cells 
CD339 Jagged 1; Jag-
1; Serrate-1 
Yes162 163 Yes162 Not shown in 
GBM cells 
O4 N/A No162 N/A Not shown in 
GBM cells 
CD253 TRAIL; N2B2 Yes162 Yes162 Not shown in 
GBM cells 
CD271 NGFR  Yes162 164 Yes162 Not shown in 
GBM cells 
 
 
3.3.2 Evaluation of candidate antibodies for CTC isolation- flow cytometry  
The five GBM cell lines A172, LN-229, T98G, U251 and U87, were analysed by flow 
cytometry for expression of the range of candidate cell surface proteins as identified in 
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Table 3.1. The five cell lines (listed in Table 3.4 with detailed information) were also 
chosen to try to represent tumour heterogeneity. The expression of these candidate 
proteins on healthy donor PBMCs was also evaluated, as their presence on PBMCs 
would make them unsuitable targets for CTC isolation due to incidental co-isolation of 
blood cells (false positives). Figure 3.1 shows representative flow cytometry 
histograms. The proportion of cells expressing the chosen cell surface proteins ranged 
between 0.6 and 96.6% (see Table 3.5). A number of antibodies against candidate cell 
surface targets (anti-human O4, A2B5 and CD271) consistently recognised only small 
proportions (10% or less) of cells (see Table 3.5) in these GBM cell lines. These 
antibodies were therefore disregarded as unsuitable isolation antibodies early during the 
testing process. As a result, 4 antibodies remained candidates as possible tools for 
GBM-CTC isolation: MCAM, NG2, N-cadherin and EGFR. Flow cytometry revealed 
that MCAM was expressed on all cell lines, with 3 out of 5 cell lines (LN-229; T98G; 
and U87) having detectable MCAM on at least half of the cell populations, while just 
below 20% of A172 cells and 41% of U251 cells expressed this cell surface marker. Of 
the other three remaining candidate antigens, NG2 and EGFR were expressed well by at 
least two cell lines, being detectable in nearly 80% or more of the cells. However, for 
three cell lines (A172; T98G; and U251) NG2 expression was minimal (e.g, only 6% of 
A172 cells expressed NG2, as seen in Table 3.5), while EGFR expression in comparison 
was marginal (2.7% of cells expressing EGFR, with minimal expression on individual 
EGFR cells) for one cell line (U87), whereas about a third of cells of the remaining cell 
line (T98G) expressed EGFR. EGFR was not tested on U251, as it had already been 
excluded from the list of possible target antigens by the time that U251 cells were 
available for this study. N-cadherin was expressed to some extent on cells of all cell 
lines but the proportions of cells expressing the marker did not reach more than 60% of 
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cells for the highest expressing A172 and LN-229 cell lines, and reached between 13 
and 30% for the other two cell lines. Further, N-Cadherin had been excluded as a 
potential target antigen by the time U251 cells began to be evaluated due to expression 
on PBMCs as shown in an independent study from our lab145. 
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Table 3.4 Cell line feature summary 
Cell Line Mutations Origin Notable Features 
A172 EGFR (Substitution, 
position 3159 T->C) 
Primary glioma, 
53-year old 
male. 
Not tumourigenic in 
immunosuppressed 
mice 
LN-229 TP53 (Substitution, 
position 293, C->T) 
Glioblastoma  /  
Tissue: 
brain/right 
frontal parieto-
occipital cortex 
Forms tumours in nude 
mice 
T98G RASEF (Substitution, 
position 605, T->C); 
TP53 (Substitution, 
position 711, G->A) 
Primary glioma, 
61-year old 
male 
This is a human cell line 
with hyperpentaploid 
chromosome count. It is 
able to grow anchorage 
independent. 
U87 RASL11B (Substitution, 
position 548, T->C); 
NF1 (Deletion) 
Primary glioma; 
44-year old 
female 
This is a hypodiploid 
human cell line with the 
modal chromosome 
number of 44 occurring 
in 48% of cells. 
U251 RASA1 (Substitution, 
position 2461, A->C); 
RASA1 (Substitution, 
position 1930, A   ->C); 
TP53 (Substitution, 
position 818, G->A); 
NF1 (Insertion) 
Primary glioma, 
unknown 
patient 
Known for genetic 
instability (genetic drift 
of U251 cells cultured 
long term in different 
labs165) 
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All data was taken from the COSMIC somatic cancer cell database166 or the information from 
the  American Tissue Culture Collection (ATCC). 
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Table 3.5 Cell surface antigen expression of GBM cell lines by flow cytometry 
Antigen 
 
A172  * 
 
LN-229  
* 
 
T98G  *  U87  U251  * PBMC  * 
MCAM 17.3-
31.1% / 
11.7 (n=2) 
83.2-
83.5% / 
53.2 
(n=2) 
45.4-
46.8% 
/26.1 
(n=2) 
56.1-
61.9% 
/13.5 
(n=2) 
41.0%/742.7 
(n=1) 
1.8% / 
10.5 
(n=1) 
NG2 0.0-0.1% / 
n/a 
(n=2) 
87.9-
98.3% 
/50.2 
(n=2) 
0.5-0.6% 
/n/a 
(n=2) 
73.2-
78.9% 
/15.5 
(n=2) 
2.7%/ 785.1 
(n=1) 
 
18.4%/ 
7.1 (n=1) 
CD271 5.8-5.9% / 
52.6 
(n=2) 
57.0-
57.5% 
/28.8 
(n=2) 
1.2-1.6% 
/n/a 
(n=2) 
1.0-1.9% 
/n/a 
(n=2) 
- - 
N-
Cadherin 
60.4-
79.9% / 
13.6 
(n=2) 
54.9-
55.7% 
/12.1 
(n=2) 
16.5-
17.5% 
/8.2 
(n=2) 
0.8-2.7% 
/n/a 
(n=2) 
- - 
EGFR 96.6-
97.0% / 
20.3 
(n=2) 
77.2-
79.0% 
/11.9 
(n=2) 
28.9-
29.4% 
/15.0 
(n=2) 
8.9-
13.4% 
/8.8 
(n=2) 
- - 
A2B5 1.7% /n/a 
(n=1) 
0.8% / n/a 
(n=1) 
1.9% 
/n/a 
(n=1) 
1.7% 
/n/a 
(n=1) 
- - 
O4 3.2% / n/a 
(n=1) 
0.6% / n/a 
(n=1) 
0.8% 
/n/a 
(n=1) 
0.9% 
/n/a 
(n=1) 
- - 
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* % of cells positive / mean fluorescence (indicator of mean expression levels per positive cell). 
The percentages represent the range of results from a number of experiments equal to n. The 
mean fluorescence is equal to the average result of n experiments. Mean fluorescence is only 
provided if positive populations are >5%, otherwise it is marked with an n/a. Healthy donor 
PBMCs and the later obtained cell line U251 were only tested for the promising isolation 
candidates MCAM and NG2. 
When FACS was run for MCAM and NG2 in U251 and PBMCs, N-cadherin, having stained cells 
under immunocytochemistry, was not analysed by FACS. 
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Figure 3.1 Representative flow cytometry histograms  
 
Figure 3.1: This image shows representative histograms for flow cytometry analysis of cell 
surface protein expression for both LN-229 cells and PBMCs, demonstrating both the 
fluorescence detected for isotype matched IgG controls (dark grey peak) and the antigens 
indicated (light grey peak). Isotype matched control on its own is shown to the left of specific 
antigen detection. The percentage of cells expressing fluorescence above the gated 
background is shown in the top right hand corner of the graph. 
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3.3.3 Evaluation of candidate antibodies for CTC Isolation - immunocytostaining 
Immunocytostaining confirmed the above FACS data. Representative data is shown for 
LN-229 cells probed for MCAM and NG2 (see Figure 3.2).  
 
With N-cadherin excluded as an isolation antibody due to data indicating false positive 
CTC isolation in our lab145, our data suggest that targeting EGFR together with MCAM 
would be optimal, as the combination could cover the range of GBM cells best for 
isolation, since the cell line with poor MCAM expression (A172), has highly expressed 
EGFR. NG2, on the other hand, was predicted to be a useful isolation marker for GBM-
CTCs if they proved to have similar target antigen expression patterns as shown for our 
cell lines. We therefore decided to only evaluate MCAM, EGFR and NG2 further as 
candidates for GBM-CTC isolation. 
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Figure 3.2 Immunocytostaining of LN-229 cells for NG2 and MCAM 
 
Figure 3.2: Immunocytostaining of NG2 and MCAM on LN-229 cells. LN-229 cells were probed 
with Hoechst dye for detection of nuclei and anti-NG2 antibody (3.2a, blue and 3.2c, green, 
respectively) and Hoechst dye and anti-MCAM antibody (3.2b, blue, and 3.2d, green, 
respectively). 
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3.3.4 Confirmation of antibody utility for immunomagnetic cell capture 
To validate whether anti- MCAM, NG2 and EGFR had utility for immunomagnetic cell 
isolation, defined numbers of cells from cultured cell lines, initially resuspended in 
PBS, were recovered using immunomagnetic beads coupled to each of the respective 
antibodies. These antibody-coupled beads were used either alone, or in various 
combinations. While anti-NG2 and anti-MCAM recovered approximately 20% and 40% 
of LN-229 cells, respectively, the anti-EGFR antibody only captured about 12% of the 
LN-229 cells. Nevertheless, in combination with the anti-MCAM antibody, the anti-
EGFR antibody produced the most efficient LN-229 recovery, even in comparison to 
the other antibody combinations (71%) (see Figure 3.3). However, taking into account 
the unreliability of the anti-EGFR antibody on its own for cell isolation, and since our 
laboratory had established that targeting MCAM together with NG2 has proven utility 
for immunomagnetic melanoma CTC isolation (melanocytes, the cells that give rise to 
melanoma, are of neural crest origin and thus have a similar phenotype to brain cancer 
cells)167, we decided to prioritise MCAM in combination with NG2 as isolation 
markers. 
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Figure 3.3 Immunomagnetic capture of GBM cells 
 
 
Figure 3.3: 100 LN-229 cells were resuspended in PBS and captured using immunomagnetic 
beads conjugated to the indicated antibodies, for a total of n=3 experiments. The recovered 
proportion of cells are depicted in the graph. The columns show the mean proportion of 
recovered cells from the various independent experiments, with the error bars showing the 
standard deviation. 
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3.3.5 Evaluation of antibodies for CTC identification by immunocytostaining 
A list of proteins tested for their suitability as candidate markers for GBM CTC 
identification is listed in Table 3.6. Most possible candidates were ruled out as a result 
of either lack of expression in any of the 5 GBM cell lines, or expression on blood cells. 
The exception was the glutamate-aspartate transporter, GLAST, also identified through 
a literature search as a potential identification marker for GBM CTCs, in addition to 
GFAP (see Table 3.6).  
 
GLAST is a transport protein almost exclusively expressed on brain cells, and upon 
malignant transformation, GLAST is internalised39,suggesting it might be a potentially 
useful marker for GBM-CTC identification. When cultured the cell line US51 was 
probed for GFAP, or GLAST, or both together, GFAP probing was found to be inferior 
as it was not detected in any of the U251 cells, even though the literature had suggested 
a proportion of these cells expressed GFAP103,162. GLAST, on the other hand, was 
detected consistently in U251 cells. Staining was homogeneous with predominantly 
nuclear localisation. As shown in a representative figure for U251 cells (see Figure 3.4), 
GLAST was detected while GFAP was not. Importantly however, probing with both 
antibodies does not interfere with the detection of GLAST positivity. While GFAP has 
been used as an identifier of GBM CTCs previously owing to its ubiquity in GBM103, 
GLAST would appear to be superior to GFAP in terms of  immunocytostaining of 
cultured cells. Based upon our cell line results, we hypothesized that using antibodies to 
both GFAP and GLAST in combination might yield a superior return of CTCs in 
patients, compared to GFAP alone. 
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Table 3.6 Cell markers for identification 
Cell Protein Also known as Presence 
in GBM 
Cells 
Presence in 
Blood Cells 
Results from our Experiments 
GFAP N/A Yes103,104,1
62 
No162 Shown in GBM cells from the 
literature103; not in blood cells 
GLAST EAAT1; GluT-
1; EA6. 
Yes39,162 No162 Shown in GBM; not in blood 
cells 
OLIG2 bHLHb1; 
RACK17 
No162 N/A Not expressed in GBM cell 
lines. 
A2B5 N/A Yes168 No162 Not expressed in GBM cell 
lines. 
Her2 ErbB2; CD340; 
MLN 19 
No169 N/A Not expressed in GBM cell 
lines. 
Her3 ErbB3  Yes162,170 Yes162 Not expressed in GBM cell lines 
Nestin FLJ21841; 
Intermediate 
filament 
protein; NES 
Yes162 Yes162 Shown in GBM and blood cells. 
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Figure 3.4 GFAP and GLAST detection via immunocytostaining 
 
Figure 3.4: This image shows U251 cells immunostained with combined Hoechst (blue) (3.4a); 
anti-GLAST (green) (3.4b) and anti-GFAP (3.4c). 
 
 
3.3.6 Validation of isolation antibodies for GBM-CTC enrichment from patient 
blood 
The strategy of immunomagnetic targeting of NG2 and MCAM for GBM CTC isolation 
was then validated on patient blood samples. Immunomagnetic beads conjugated to 
anti-NG2 or anti-MCAM antibodies were incubated alone or in combination with 
PBMCs, the cell population comprised of nucleated cells including CTCs, if present, 
and isolated using the IsoFlux CTC isolation platform. Antibodies for GFAP and 
GLAST were then used to detect CTCs using immunocytostaining. CTCs, i.e. cells that 
were positive for GFAP and/or GLAST, were detected in 60% (9/15) of CTC enriched 
samples (27 mL blood each) (see Figure 3.5a). CTCs were found in low concentrations 
(counts ranged between one to eight per sample, equivalent to 0.04-0.3/mL blood). 
However, specificity of GBM CTC identification is very high, as no false positive cells 
were detected in blood draws from healthy donors (see Figure 3.5b). Importantly, 
although most CTCs stained positive for both GFAP and GLAST, confirming their 
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GBM nature, some (10/30) were purely GLAST positive, while fewer (3/30) were only 
GFAP positive, highlighting the value of using both identification markers (see Figure 
3.6 for a comparison between GLAST and GFAP positive CTC numbers). Notably, 
there was a statistically significant difference between the number of GFAP alone 
positive and both GLAST and GFAP positive CTCs (p=0.041). In contrast, there was no 
significant difference between the number of GLAST – alone positive CTCs detected 
compared to both GLAST and GFAP positive CTCs (p=0.361) (see Figure 3.6), 
confirming GLAST as the more prominent marker. Critically, both GFAP and GLAST 
could be detected in GBM CTCs (see Figure 3.7), there was no GLAST detected in any 
blood cells, and CTCs that stained poorly for GFAP tended to stain more strongly 
positive for GLAST (see Figure 3.8). 
Figure 3.5 GBM CTC counts 
 
 
Figure 3.5: (3.5a) CTC counts, defined as: cells isolated by MCAM and NG2 targeted 
immunomagnetic isolation using the IsoFlux and positive for GFAP and/or GLAST by 
immunocytostaining are depicted for patient samples P1-P13. Repeat samples for the 
same patients are indicated by superscript. (3.5b) Specificity of this GBM CTC 
isolation approach was confirmed as no cells matching the GBM CTC definition were 
recovered from healthy donor bloods HC1-HC5. 
  74 
 
Figure 3.6 Comparison of CTC numbers identified by GFAP and GLAST 
 
Figure 3.6: This figure compares the number of CTCs identified by specific antibodies in CTC 
positive patients. As can be seen, the number of GFAP positive alone CTCs is less than the 
number of GLAST positive alone CTCs (P=0.041), or the number of GLAST and GFAP positive 
CTCs (P=0.041). n=9, (CTC negative patient samples were excluded for analysis). Error bars 
represent the standard deviation. 
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Figure 3.7 GFAP and GLAST detection in patient CTC samples 
 
Figure 3.7: A series of images in different fluorescent channels was taken of the same cells 
using the ALS Cellcelector. Two cells are visble; the top left cell, identified through Hoechst 
(blue, 3.7a) and CD45 (purple, 3.7d) positivity, as a blood cell. The bottom right cell (indicated 
by the arrows), confirmed through Hoechst, GLAST (green, 3.7b), and GFAP (red, 3.7c) 
positivity, is a CTC. Note: the immunomagnetic beads did have a varying level of 
autofluorescence in different channels; notable, in the image with GFAP staining (red) but also 
in the green and purple, the level of bead autofluorescence is similar (though not quite equal to) 
the fluorescence of the cell, making the contrast between the beads and the cell in the GLAST 
channel more obvious. 
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Figure 3.8 Cell images of GLAST positive GFAP negative CTC 
 
Figure 3.8: A series of images taken with the ALS CellCelector of a CTC (indicated by the 
arrows) of the nucleus of the cell through a Hoechst stain (Figure 3.8a, blue); identified as a 
CTC through the absence of CD45 positivity (Figure 3.8d, red) and GLAST positivity (Figure 
3.8b, green). Notably, there is a lack of GFAP positivity (Figure 3.8c, red). 
 
In our patient cohort, recruited mainly for validation of the CTC isolation method, no 
observable trend could be seen in terms of relationship between CTC presence and 
progression free survival (PFS) (see Figure 3.9), although there was a trend for longer 
  77 
overall survival (OS) for patients without CTC detection (see Figure 3.10) (see Table 
3.7).  
Figure 3.9 Progression-free survival of patient cohort based upon CTC presence or 
absence 
 
Figure 3.9: This figure compares the progression-free survival (PFS) of patients with detectable 
CTCs to patients without detectable CTCs. There is no significant difference between the two 
curves (p=0.80) under the log-rank test, although PFS in the population of patients without 
CTCs is slightly higher than those without. 
 
  78 
Figure 3.10 Comparison of overall survival of patient cohort based upon CTC 
presence 
 
 
Figure 3.10: This figure compares the overall survival (OS) of patients with detecable CTCs and 
without detectable CTCs. There is no significant difference between the two curves (p=0.40) 
using the log-rank test, although OS in the population of patients without CTCs is slightly higher 
than those without. 
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Table 3.7 CTC counts from 27ml blood by identification method 
Patient 
Number 
GFAP 
Positive/GLAST 
Negative 
GFAP 
Negative/GLAST 
Positive 
GFAP 
Positive/GLAST 
Positive 
Pt 11 1 0 3 
Pt 12 0 0 0 
Pt 21 0 0 0 
Pt 31 0 1 1 
Pt 41 0 0 0 
Pt 42 0 0 0 
Pt 51 0 1 1 
Pt 61 0 0 0 
Pt 71 0 0 1 
Pt 81 0 0 0 
Pt 91 0 1 0 
Pt 101 0 1 0 
Pt 111 0 0 1 
Pt 121 0 2 1 
Pt 131 1 2 5 
Superscript numbers are used to number samples from patients who contributed blood to this 
study more than once. 
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3.3.7 Alternative Identification Antibody 
Given its use in other GBM related studies, blood cells from healthy controls were 
stained using a polyclonal nestin antibody. As can be seen in Figure 3.11b, there is clear 
staining in many blood cells using the nestin antibody, indicating that this was not a 
viable option for identification or isolation in our study. 
Figure 3.11 Immunocytostaining of blood cells with nestin antibody 
 
Figure 3.11: The above figure shows the staining of the same healthy control PBMCs in two 
separate channels with a Hoechst DNA stain (Figure 3.11a), and with an anti-nestin and 
secondary antibody comination (Figure 3.11b). As can be seen, there is clear evidence that the 
nestin antibody binds to the PBMCs based upon the green cells seen in Figure 3.11b. 
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3.4 Discussion 
3.4.1 CTC isolation 
For the purpose of isolating GBM CTCs, a range of cell surface proteins were 
nominated as targets for immunomagnetic isolation. Similarly, in order to identify the 
CTCs and appropriately distinguish them from any residual blood cells, once they had 
been isolated, a range of putative GBM specific proteins were tested as potential 
identification markers for GBM-CTCs. Initially eight antibodies against specific cell 
surface candidate markers were evaluated for their potential use in the isolation of GBM 
CTCs. A major difficulty was finding antibodies against candidate GBM proteins that 
would not interact with blood cells, since cross reactivity would diminish the ability to 
separate GBM CTCs from blood cells immunomagnetically. The many co-expressed 
cell surface markers identified from the literature search attests to the difficulty in 
finding unique markers, perhaps not surprisingly, since blood cells and neural cells are 
closely related embryologically. Blood stem cells can in fact, differentiate into cells 
with neural characterstics171.  
 
Three remaining isolation target candidates (MCAM, NG2, EGFR) were further studied 
for their ability to capture GBM cells when conjugated to immunomagnetic beads. It 
must be noted that, while initial literature searches for the presence of these markers 
included immunohistochemistry studies in tumour and healthy tissue, for a variety of 
reasons we decided to only use GBM cell lines to test the usefulness of these markers 
for immunomagnetic isolation, despite the fact that cell lines may not be ideal due to the 
occasional loss of biomarkers in tissue culture172. Firstly, we did not have access to 
tissue microarrays (an arrangement of human tumour and healthy control tissues) at the 
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time, which would have allowed us to confirm the suitability of our chosen antibodies to 
detect biomarkers. Secondly, using paraffin-embedded tissue would also be difficult, 
due to the known alterations to proteins from paraffin-derived tissues as formalin causes 
cross-linking between proteins that alters antigen binding sites173, and we had no access 
to fresh tissue. Thirdly, while tissue staining may confirm the membraneous location of 
antigens, the utility of an antibody for cell isolation cannot be determined by probing 
tissue, it must be done with individual cells. When tested for cell retrieval of cultured 
cells, EGFR targeting alone produced the poorest recovery rate of all tests. However, 
the combination of MCAM with EGFR targeting produced the highest recovery of cells. 
Due to the poor performance of anti-EGFR alone for cell isolation, and because any 
GBM cells lacking MCAM expression would thus be poorly isolated with the 
combination, we decided against using EGFR as a marker. The use of all three 
antibodies was dismissed as there was prior evidence within our lab that too many 
antibodies for isolation interfere with each other145. Further, EGFR can be present on 
endothelial cells that can be found in circulation174, which could have confounded CTC 
counts. In a previous study, Sullivan et al. (2014) included EGFR probing in the 
immunofluorescence cocktail that was used to identify potential GBM CTCs108. 
Through FISH, they found that EGFR expression in the CTCs isolated from their 
patient blood samples mimicked that of the original tumour, and in a lung metastasis. 
However, in other samples analysed via RNA- ISH, there was evidence that EGFR was 
down-regulated in CTCs compared to the primary tumour cells. The CTCs appeared, 
based upon the gene expression, to have lower expression of markers of neural cell 
lineage. This was linked to what are, in other cancers, markers of epithelial-
mesenchymal transition (EMT)108, which are believed to be an indicator of metastasis 
and decreased survival. EMT has been suggested as a mechanism whereby GBM cells 
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invade surrounding tissues (reviewed by Iser et al175). Owing to the paucity of patient 
blood samples that could be obtained, we decided to focus on the more reliable MCAM 
and NG2 antibody bead combination for experiments, which had also been successfully 
used in detection of melanoma CTCs167,176.   
Ultimately, the broader utility of MCAM and NG2, as seen in Figure 3.3, was the 
deciding factor in their selection for CTC isolation. Although NG2 was found to be 
expressed on some cells within the PBMC population, a considerably lower level of 
expression per cell (mean fluourescence of 7.1 versus 34.9 for LN-229 cells for 
example) compared to GBM cells was noted. Given the small, expected loss of recovery 
of cells due to experimental methods, we reasoned that it was unlikely that any cells 
with a fluorescence level of <10 would be sufficiently bound by the antibody beads to 
be extracted by our methods and the rare blood cells extracted would be excluded by 
our GBM CTC identification. 
 
 
3.4.2 CTC identification 
Seven candidate antibodies for the purpose of identifying CTCs, as opposed to isolating 
CTCs discussed earlier in this chapter, were considered (see Table 3.6 for the antibodies 
examined). One, anti-Her3, was ruled out due to the reported expression of Her3 on 
blood cells177. 
Of the remaining candidate antibodies, three (anti-OLIG2, anti-A2B5, and anti-Her2) 
were ruled out because they did not react with antigens on any of our cell lines.  
Nestin, another antigen which we evaluated, is a stem-cell marker that usually 
diminishes in expression as the astrocytes form178, and has been identified as a marker 
of GBM severity in high-grade gliomas; a higher level of nestin expression has been 
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associated with a decreased OS179. Nestin has also been detected in CTCs in other 
publications (MacArthur et al developed a method to detect it alongside telomerase 
expression and used it to identify U251 cells implanted in nude mice102). Currently, no 
study has used nestin as a detection method for human GBM CTCs. In our hands, we 
found that nestin was also detected with our antibody in blood cells (see Figure 3.11), 
and not in our negative controls (no-primary antibody), which led us to discard it as an 
identification marker. It is possible that the choice of anti-nestin antibody could account 
for differences between our study (a polyclonal anti nestin antibody from Sigma-
Aldrich) and others (Abcam 10C2 anti nestin antibody102). We chose to use a rabbit 
polyclonal anti nestin antibody as using the mouse monoclonal anti nestin antibody used 
by MacArthur et al would have caused cross-reactivity with the mouse antibodies used 
on the immunomagnetic isolation beads. 
 
 
In terms of identifying the GBM CTCs, therefore, we chose one of the major markers 
for astrocytes that has been used successfully in previous studies, GFAP (see Müller et 
al. (2014)), and therefore was an obvious candidate for use in identifying CTCs103. Of 
note, we were not able to detect GFAP in any cultured GBM cell lines but that may not 
be surprising as GFAP has been reported to be commonly lost under culture 
conditions180,181. However, GFAP is not found in all GBM cells26 and furthermore, 
GFAP can be found to a greater degree in some cases of GBM with worse outcomes107. 
There is a need to identify an alternative marker to GFAP to detect GBM CTCs. As 
discussed in Chapter 1, Circulating tumour cells, page 17, Sullivan et al (2014) used a 
cocktail of antibodies for: SOX2, Tubulin beta-3, EGFR, A2B5, and c-MET, dubbing 
this combination STEAM108. They combined detection for all of the antibodies into one 
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fluorescent microscopy channel, and proposed that any cells positive for any of these 
markers were CTCs. However, as discussed above, we could not find a reason to use 
EGFR for CTC isolation. We also could not find expression of A2B5 within our own 
cell line models (please see Table 3.6). For this reason, we turned to other markers for 
brain cells, specifically GLAST.  
 
GLAST has been detected in neural cells, usually on the cell surface182, suggesting that 
GLAST may be a good candidate for immunomagnetic isolation of normal brain cells. 
Because GLAST has been shown to be internalised into the cytoplasm39 in brain cancer 
cells, we reasoned that it could also be useful as an identifier of brain cancer CTCs post-
immunomagnetic isolation.  
 
 
3.4.3 CTC isolation and identification from patient samples 
The data presented here confirm that patient derived GBM CTCs tend to express 
GLAST, either together with GFAP, or by itself (see Figures 3.7 and 3.8). Using GFAP 
and GLAST co-staining, CTCs were found in a higher proportion of patients (60%) 
compared to 20.6% found in the study of Müller et al.103. However, 27 ml of blood was 
used for CTC detection for each sample analysed in this study, while only 10 mL was 
used by Müller et al.103. Although slightly higher CTC counts were found by Müller et 
(approximately four CTCs per sample versus three in our study), sampling occurred 
before, during and immediately after surgery103, which could have artefactually inflated 
tumour material, including CTCs, released into the blood stream183. Given our own 
small sample size, it is difficult to compare our study with Müller et al’s, but it is 
possible that the lower proportion of patients that they found GBM CTCs in is a result 
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of heterogeneous GFAP expression, or that the number of patients with detectable GBM 
CTCs was indeed inflated, but not to the extent to equal the number in our study. The 
majority of our samples were taken well after treatment had begun, in most cases 
beyond 6 weeks after surgery. Müller et al. suggested that there was no difference in 
CTC counts based upon timing of blood sampling, but Macarthur et al. suggested that 
blood taken prior to treatment could contain larger counts of GBM CTCs than blood 
taken afterwards102. However, despite a slightly lower average CTC count, we found 
CTCs in a considerably higher proportion of patients than Müller et al., which might 
also be linked to the tumour heterogeneity of GBM (discussed further below). In neither 
study were false positives found. This suggests we have discovered a very sensitive 
assay for CTCs in GBM patients, without losing specificity, or that an increase in the 
volume of blood is required to detect GBM-CTCs, due to rarity. Regardless, our cell 
line and GBM patient data suggest that GLAST, in addition to GFAP, can improve CTC 
detectability (see Figure 3.6). Another possible explanation for the differing CTC 
prevalence could be the heterogeneous expression of GFAP in astrocytomas104, which 
was the primary identifying marker used in the Müller study103. To complicate the issue, 
there is some (though controversial) evidence to suggest that GFAP expression is lost in 
some GBMs that have more severe outcomes106,107. This may have influenced the 
conclusion of Müller et al., who found the presence of GBM CTCs was unrelated to 
disease state or treatment, but they may have only obtained CTCs from patients who 
were already going to have improved outcomes, which would have skewed the results if 
GFAP expression is not, in fact independent of patient prognosis. As, in our own study, 
we observed that there were cells where GLAST would be quite evident while only very 
weak GFAP staining (as in Figure 3.8) was observed, this would seem to be supported 
by our results. In addition, in opposition to Müller et al.’s findings, MacArthur et al. 
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found that lower CTC counts reflected patients who had a reduced disease burden102. In 
our study, we found a trend (statistically insignificant, likely due to low patient 
numbers) towards improved OS in patients without CTCs compared to those with 
CTCs; this is worthy of further study in a larger patient cohort. Nevertheless, we 
demonstrated that GBM CTCs can be detected in approximately 60% of GBM patient 
blood samples, disavowing the notion that the blood-brain barrier is generally 
impermeable. 
 
Our assay, based upon comparison to healthy controls (see Figure 3.5), is highly 
specific for the detection of CTCs, as no false positives were found. Sensitivity is 
difficult to calculate, as there is no gold standard to determine the true number of CTCs 
that were missed in a blood sample and spiking experiments of cultured cells poorly 
mimic heterogeneous CTCs. Based upon the extraction of cultured cells from PBS (see 
Figure 3.3), however, and our patient data, a recovery of approximately 50%-60% can 
be estimated, despite evidence to suggest that in patient samples, there is lower 
sensitivity for immunomagnetic bead cell extraction than in spiking experiments176. 
 
 
3.5 Conclusion 
The work presented in this chapter demonstrates the successful development of an 
improved immunomagnetic isolation method for GBM-CTCs. We also show that 
probing for GLAST as an additional GBM-CTC identification marker is a useful 
strategy to detect more GBM-CTCs than with GFAP probing alone. One of the 
advantages of enriching CTCs immunomagnetically is that it allows for easier 
workflows, compared to full PBMC screening for GBM-CTCs. The implications of this 
  88 
enhanced liquid biopsy are significant since, as detailed in Chapter 1 (Clinical Features 
of Glioblastoma, page 2) it is sometimes difficult to obtain brain cancer biopsies either 
for diagnosis or discovery of therapeutic biomarkers, and characterisation of the 
biomarkers in the CTCs might permit the biomarker characterisation of the tumour. Any 
advance in liquid biopsy technologies may ultimately help to improve patient survival, 
since other diagnostic and molecular interrogation methods, for example whole genome 
amplification (see Chapter 6), can be employed. 
  
.
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4 Use of cryopreserved GBM CTCs to identify 
biomarkers 
4.1 Introduction 
As discussed in chapter 1, Novel Biomarkers, page 11 the presence of PD-L1 on GBM 
CTCs is a potential marker for use in immunotherapy (reviewed by Xue et al184). 
However, PD-L1 expression is not an ideal marker of treatment utility, since some 
patients who do not express PD-L1 respond to treatment, and vice versa.  
In other cancers, such as melanoma and non-small cell lung cancer, PD-L1-targeted 
immunotherapy has already proven an effective means of treatment72,185. The evidence 
of PD-L1 expression as a predictor for treatment outcomes has been mixed. PD-L1 
expression may be linked to the success of PD-L1 inhibitor treatment outcomes in non-
small cell lung cancer186, but this has been contradicted by other studies that have not 
found this link, even in studies that have examined the same drug and type of cancer187 
(see review for non-small cell lung cancer188).  
Histopathologically, PD-L1 has been found to be expressed in many cases of GBM189, 
and that has raised the question of whether checkpoint inhibitor therapy can bypass the 
blood brain barrier and aid in the treatment of brain cancer. Despite initial suggestions 
that the therapeutic benefits are limited in brain cancer190 clinical trials for PD-L1 
inhibition in brain cancer are still ongoing191. There is a varied amount of PD-L1 
present in the tumour tissue in cases of brain cancer192. Therefore, the ability to stratify 
patients based upon their expression of PD-L1 into those likely to respond to treatment, 
and those not likely to, may be clinically beneficial. For the work presented in this 
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chapter we accessed blood samples from brain cancer patients who had been enrolled in 
a clinical trial of checkpoint inhibitors. 
Thus, the aims of this study were firstly to determine a method for the preservation of 
PBMCs such that CTCs could be extracted successfully from them at a later time using 
the methods for isolating and identifying CTCs outlined in the previous chapter, 
because patient samples were available prior to having established the GBM CTC 
isolation method (chapter 3), and secondly, to develop a method for co-staining PD-L1 
expression on GBM CTCs. 
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4.2 Methods 
4.2.1 Cell culture 
MDA-MB-231 cells, a breast cancer cell line, were cultured in RPMI-1640 [Lonza] 
media with 10% FBS for 72 h before being harvested for use in experiments. Breast 
cancer cells were used because they are more easily detectable in samples than GBM 
cells as they are cytokeratin-positive and finding the optimal GBM identification 
markers (see chapter 3) was still ongoing at the time. See Table 4.1 for details on the 
cell line. 
Table 4.1 Details of MDA-MB-231 cell line  
Mutations Origin Notable Features 
BRAF (Substitution, Position 
1391, G->T).  
KRAS (Substitution, position 
38, G->A).  
TP53 (Substitution, position 
839, G->A).  
NF1 (Insertion, position 
1398/1399). 
Breast 
Carcinoma, 51-
year old female 
Chromosome count in 
the near-triploid range; 
normal chromosomes 
N8 and N15 are absent. 
All information on the cell line was taken from the COSMIC cell line database166 and the 
ATCC193.
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4.2.2 Cell freezing and thawing 
PBMCs were extracted from 9ml EDTA blood samples as described in chapter 2, 
PBMC Enrichment, page 36, with the following adjustments:  
• After the initial centrifugation in a SepMate tube, 4.5 mL of plasma was pipetted 
from the plasma in the SepMate into separate 1.5mL tubes. To remove any 
remaining cellular debris, the plasma was centrifuged at 13000 RPM on a 
Heraeus Pico 21 centrifuge [Thermo-Fisher], and transferred to a new 15 mL 
tube, being careful not to disturb the sediment, and stored on ice.  
• For spiked samples used to optimise the freezing/thawing process, 100 MDA-
MB-231 cells were spiked into the PBMCs. Cells were counted using a 
haemocytometer to determine the concentration of MDA-MB-231 cells. The 
required volume of cell suspension containing 100 cells was calculated from this 
concentration. Care was taken to ensure that the cells were re-suspended in as 
uniform a manner as possible to limit any concentration gradients that might 
occur as cells settled out of the solution. 
When the cells were to be frozen, 500 µL of dimethyl sulfoxide (DMSO) [Sigma-
Aldrich] was added to, depending on the freezing media being used, 4.5 mL of the 
plasma previously extracted, to produce a 10% DMSO in plasma solution, or 4.5 mL of 
PBS, to produce a 10% DMSO in PBS solution. One mL of this solution was used to 
resuspend the PBMCs, which were then immediately frozen at -80° C in a 2 mL 
cryovial [Greiner]. In addition, several additives besides complete RPMI-1640 (RPMI-
1640 with additives as described in chapter 2, Cell lines and tissue culture, page 33) 
were trialled in order to determine the optimum thawing media (henceforth, any 
reference to ‘thawing media’ will refer to any of these variants in addition to RPMI-
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1640 media). Bovine Serum Albumin (BSA) [Bovogen, Melbourne, Australia] and 
dextran [Alfa Aesar, Ward Hill, USA] additives were, individually, added to PBS in the 
volumes described in Table 4.2 as a substitute for RPMI-1640 in the freezing/thawing 
process. All variants of the thawing media contained 1.5 mM magnesium chloride 
[Sigma-Aldrich], to serve as a co-factor for the benzonase enzyme [Sigma-Aldrich]. 
To thaw the samples, 15 mL of 37°C thawing media was aliquoted per sample. The 
samples were placed in a water bath at 37° C. Thawing was completed by adding 
dropwise 1 mL of thawing media with 25 units/mL benzonase and the cell solution was 
then transferred to a new 15 mL tube. Another 1 mL of thawing media was added to the 
cryovial, which was transferred to the same 15 mL tube. Six mL of RPMI media was 
slowly added to the sample. The sample was incubated, with occasional shaking, at 
room temperature for 3 min. The sample was centrifuged at 280 xg for 5 min, and 
thawing media was discarded without disturbing the cell pellet. Seven mL of fresh 
thawing media was added to the cell pellet and incubated for 3 min at room temperature. 
The sample was then centrifuged for 5 min at 280 x g, and the thawing media was 
discarded again. The cells were washed with 1 mL PBS, and centrifuged for 5 min at 
280 x g, and the PBS was discarded.  
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Table 4.2 List of additives to freezing/thawing media 
Additive to media Concentration in 
Freezing/Thawing Media 
Manufacturer 
Dextran 0.075 mg/mL Alfa Aesar, Ward Hill, 
USA 
Bovine Serum Albumin 
(BSA) 
50 mg/mL Bovogen, Melbourne, 
Australia 
Benzonase 25 Units/mL Sigma-Aldrich, St 
Louis, USA 
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4.2.3 Cell staining (cytokeratin) 
PBMC’s spiked with MDA-MB-231 cells were treated, after thawing, in the same 
manner as described in chapter 3, Immunocytostaining of patient GBM CTCs, page 40, 
with the following adaptation: Instead of GLAST and GFAP, after permeabilisation, 
cells were only probed for cytokeratin [Fluxion], which was diluted in 0.05% Triton-
X100 solution (see Table 4.3 for concentrations). Cells were incubated at room 
temperature in the dark with the cytokeratin antibody for 1 h, then mounted on slides 
with Hochst-dye containing mounting media [Fluxion].  
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Table 4.3 Names and concentrations for antibodies for identification 
Antibody 
Name 
Clone Ig Subtype Company Immunocytostaining 
Dilutions 
Anti-GLAST 
antibody 
Polyclonal, 
NB100-
1869AF488 
IgG Novus Bio, 
Centennial, 
USA 
1/100 
Anti-PD-L1 
antibody 
E1L3N IgG Cell 
Signalling, 
Danvers, 
USA 
1/50 
Anti-
cytokeratin 
antibody 
Unknown* Unknown* Fluxion, San 
Francisco, 
USA 
1/10 
Anti-CD45 
antibody 
Unknown* Unknown* Fluxion, San 
Francisco, 
USA 
1/200 
* Fluxion does not provide this information on their proprietary antibodies 
 
 
4.2.4 Cell Staining (PD-L1) 
The GBM CTCs were immunocytostained as described in chapter 3, 
Immunocytostaining of patient GBM CTCs, page 40 with the following adaptation: 
Immediately after CD45 staining, instead of GFAP, cells were probed with the rabbit 
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anti-human PD-L1 antibody (Cell Signalling, Danvers, USA) 1:50 followed by AF555 
conjugated anti-rabbit IgG secondary antibody 1:2000. Cells were permeabilised and 
stained for GLAST as previously described (chapter 3, Cytoplasmic 
immunocytostaining to evaluate GBM markers for CTC identification, page 40). GFAP 
co-probing was omitted due to incompatibility of the anti-GFAP antibody with the anti-
PD-L1 probing (antibodies were from the same host). See Table 4.3 for antibody 
concentrations. 
 
 
4.2.5 Comparison of CTC detection from fresh and frozen PBMCs  
Three 9 mL vials of blood were taken from patients with GBM. Blood samples were 
subsequently separated into two equal volumes. PBMCs were extracted as described in 
chapter 2, PBMC Enrichment, page 36 from both volumes of blood. One of the volumes 
of PBMCs was frozen as described above, in Cell Freezing and Thawing, page 84 using 
DMSO and PBS as the freezing media. The other volume of PBMCs was processed for 
CTCs, as described in chapter 2, CTC Isolation from GBM Patients, page 37, and 
subsequently fixed as described in chapter 2, Immunocytostaining of patient GBM 
CTCs, page 36. After approximately seven days, the frozen PBMCs were thawed, as 
described above in Cell Freezing and Thawing, page 84 using complete RPMI-1640 
with benzonase as the thawing media. The cells were fixed as described in chapter 2, 
Immunocytostaining of patient GBM CTCs, page 40. Both samples were stained as 
described above in Cell Staining (PD-L1), page 87. Samples were analysed on the 
CellCelector as described in chapter 2, GBM CTC Counts, page 41 with the addition of 
recording any CTCs that were positive for PD-L1 expression. The counts of CTCs from 
both samples (frozen vs non-frozen PBMC preparations) were compared.
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4.3 Results 
4.3.1 Cell freezing and thawing of spiked cells 
Cells were frozen using a variety of methods to determine the optimal method for 
maintaining CTC viability for extraction and analysis following cell thawing 
(Summarised in Table 4.2). As can be seen from Figure 4.1, the optimum method for 
freezing and thawing samples involved the use of benzonase, an enzyme that digests 
extracellular nucleic acids. Without the addition of benzonase, as can be seen in Figure 
4.2a, nucleic acids from lysed cells cause the cells to form agglutinated clumps that 
made it impossible to distinguish individual cells. In addition, without benzonase, the 
CTC processing method would frequently fail as the mass of cells would prevent the 
cells from passing through the IsoFlux cartridge, which unfortunately made 
comparisons between the different methods in the absence of benzonase impossible. 
The addition of BSA to the freezing/thawing media provided roughly the same 
outcomes as the use of RPMI-1640 media; the use of dextran gave noticeably worse 
recovery of the cells, as seen in Figure 4.1. 
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Figure 4.1 Comparative recovery of cancer cells from frozen PBMCs 
 
Figure 4.1: The above figure compares the recovery of cultured MDA-MB-231 breast cancer 
cells from frozen PBMC samples, the bars indicating the mean and the standard deviation for 
n=4. The main effector of cell recovery is the presence of the nuclease benzonase to the 
thawing media. RPMI-1640 media alone is significantly different from PBS with albumin and 
benzonase (p=0.013). While it is not significantly different from RPMI-1640 with benzonase 
(p=0.137), RPMI-1640 with benzonase is not significantly different from the recovery with PBS 
with albumina and benzonase (p=0.664). 
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Figure 4.2 Comparison of PBMCs thawing method ±benzonase 
 
Figure 4.2: PBMCs were thawed without benzonase (4.2a), or addition of benzonase (4.2b) and 
visualised using Hoechst staining. Note the immunomagnetic beads used to isolate the cells are 
visible in black. As can be seen in 4.2a, without benzonase cells form into large, agglutinated 
clumps (in this case, large enough to take up the entirety of the field of view). The cell clumps 
have a tendency to obfuscate the stains of other cells that are joined together with them, posing 
the risk that CTCs may be missed. With the addition of benzonase, as can be seen in 4.2b, the 
cells are recognisably distinguishable units. 
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4.3.2 Analysis of PD-L1 presence in CTCs detected in frozen patient PBMC 
samples 
Frozen PBMCs from 17 patient samples were thawed as described using RPMI with 
benzonase and GBM CTCs were then isolated as described in chapter 3. The staining 
method for brain cancer CTC detection relied solely on GLAST probing. Positively 
identified CTCs were co-probed for detection of PD-L1 expression. There was a limited 
recovery of CTCs from frozen PBMC samples, but PD-L1 was detectable in (2/3) CTCs 
in total (see Figure 4.3). 
 
Figure 4.3 CTC counts from frozen patient samples by PD-L1 expression 
 
Figure 4.3: The above figure shows the total number of recovered CTCs from the frozen 
samples. As can be seen, while some of the CTCs recovered were PD-L1 positive, there are 
very few total CTCs detected. 
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4.3.3 Comparison of PD-L1 positive CTC numbers from frozen and fresh PBMC 
samples 
To exclude the possibility that low extraction of CTCs from PBMC populations was 
affected by parameters other than the freezing, a direct comparison was performed. 
Patient blood samples were divided into two equal amounts. PBMCs were then 
extracted from both aliquots of blood. One of the PBMC samples was frozen as above, 
while the other was processed for CTCs immediately. The frozen sample was 
subsequently thawed (approximately 7 days later) and CTCs were extracted.  
As expected total GBM CTC counts were low overall, but there is a clear trend that 
CTCs can be detected from fresh samples whereas no CTCs were detected in the 
parallel frozen sample (see Figure 4.4). As spiked cell counts were also reduced by 
approximately 50-60%, the lack of detection of CTCs in frozen samples can be assumed 
to be due to the small numbers of GBM CTCs combined with decreased CTC 
detectability.  
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Figure 4.4 CTC counts from frozen and fresh PBMC samples 
 
Figure 4.4: The above figure shows the total number of CTCs isolated from 4 matched frozen 
and unfrozen patient PBMC samples. As can be seen, CTC isolation was more common from 
the fresh samples, with no CTCs identified from frozen patient samples. 
 
 
4.3.4 PD-L1 positive CTC detection in patient samples 
From a different patient cohort, CTCs were extracted from unfrozen samples, in order to 
determine if PD-L1 positive CTCs could be detected in patient blood, using methods 
carried out as described in the prior section. As can be seen in Figure 4.5, PD-L1 
positive CTCs can indeed be found.  
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Figure 4.5 PD-L1 positive CTC from a patient sample 
 
Figure 4.5: The above figure shows monochromatic images of a PD-L1 positive CTC. Anti-
GLAST antibody was used to confirm that it was a CTC (as shown in 4.5a), and an anti-PD-L1 
antibody was used to confirm that the CTC was PD-L1 positive (as shown in 4.5b). 
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4.4 Discussion 
4.4.1 Detection of the protein biomarker PD-L1 on GBM CTCs  
The work presented in this chapter clearly shows that GBM CTCs can be successfully 
analysed for the presence of protein biomarkers such as PD-L1. Moreover, although the 
freezing method of PBMCs employed here is challenging, we found that PD-L1 can be 
detected, even with delayed CTC isolation after PBMC freezing. Other techniques to 
improve recovery of CTCs from frozen PBMCs, for example using plasma as the 
medium194, could be employed in the future. PD-L1 has been previously detected on 
CTCs in other cancer types by our lab and others167,195, but given the rarity of GBM 
CTCs, our finding of PD-L1 positive CTCs suggests we have developed a very sensitive 
and specific method. The patient samples used in this series of experiments were all 
taken from patients in a clinical trial for nivolumab. However, only a small patient 
cohort was available to us, so no correlation was possible between the finding of PD-L1 
positive CTCs and patient outcome. Unfortunately, PD-L1 data from patient tissue was 
not available. Future studies involving this method will be much improved by access to 
this data. Two patients in this cohort responded to the immune checkpoint inhibitor used 
in this clinical trial, but they did not correspond to the patients from whom we detected 
CTCs. However, given the low response rates reported to nivolumab, this may be due to 
the lack of response overall in the clinical trial76. While stored PBMC samples could be 
a valuable source of information if CTCs could be extracted reliably, this was unable to 
be demonstrated in our work. As discussed above, there is a need for liquid biopsy – 
based biomarkers to stratify patients into likely responders and non-responders to 
checkpoint inhibitor immunotherapy. While evaluation of biomarkers using 
immunohistochemical techniques in tissue samples may be adequate for most patients, 
  106 
they do not permit longitudinal studies as patients are not usually biopsied repeatedly, 
and there are also concerns that historical tissues may not truly represent current cancer 
biology in a given individual who needs treatment decisions. Further, brain tissue is not 
always available, for example in paediatric patients with DIPG. Tissue samples are not 
ideal biomarkers of response196 (reviewed by Kee et al197). Our team has shown for 
melanoma cells that their exposure to blood can increase PD-L1 expression167, 
suggesting that such adaptive PD-L1 expression is detectable in CTCs and that might 
make screening for PD-L1 expression on CTCs a more suitable biomarker for response, 
but this hypothesis needs further testing. 
 
 
4.4.2 Freezing of PBMCs for delayed GBM CTC analysis: pitfalls and future 
directions  
Given the urgency for the development of CTC detection in frozen samples from our 
clinical trial cohort, we only used simple methods for freezing semi-processed blood, 
storing PBMCs for later analysis. This method evidently proved poor for CTC recovery. 
It was subsequently established in our lab that there are better freezing methods for 
CTCs that were later used in a study for the retrieval of gastric cancer cells. In this 
method plasma with 10% DMSO was found to be the best medium for sample 
freezing194. We speculate that this improved method may have been better for detecting 
PD-L1 CTCs in GBM patients. 
Spiked samples of cultured cells in PBMC’s were used in order to imitate the conditions 
of freezing CTCs. This meant that large numbers of cells similar to CTCs could be 
frozen, rather than relying on an unknown number of CTCs from patient samples. This 
allowed the quantification of the recovery of cancer cells after thawing. The limitations 
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are the the exact reproducibility of spiking small cell numbers, and the aforementioned 
differences between cultured cells and tumour cells. 
 
Nevertheless, our data suggest that it is possible to perform delayed CTC isolation and 
analysis from frozen PBMCs. Other studies suggest that total CTC counts would not 
change significantly through cryopreservation, especially in samples with low CTC 
counts, but in samples with higher CTC counts, between 10% to 82% could be 
lost194,198,199. The differences between the detected numbers of CTCs may be due to 
different cancer types being studies (breast cancer versus metastatic castration-resistant 
prostate cancer respectively), or possibly due to the different methods of CTC isolation 
(flow cytometry versus the Epic platform, which involves the detection of CTCs from 
blood via slide-based immunofluorescence and genetic markers). Notably, the cited 
studies were both published after our own investigations into freezing and thawing 
methods. Taken together, these, and our own studies suggest that there is no immediate 
barrier to the use of cryopreservation to permit the long-term storage and transport of 
CTC samples, provided that the correct method is used. This is important because initial 
PBMC processing is a relatively straightforward method that can be performed at most 
clinical trial sites and a simple freezing protocol could preserve the samples for delayed 
CTC isolation. CTC isolation, detection and analysis are more complex, time 
consuming processes that require specialised equipment and expertise. PBMC 
preservation for later CTC analysis could ensure that CTCs could be an outcome 
measurement with standardised analysis in clinical trials that involve several sites at 
different locations. 
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4.5 Conclusion 
This chapter has shown that GBM CTCs isolated with the novel method described in 
chapter 3 can successfully be immunoprobed for PD-L1 expression.  
While we were unable to recover high counts of CTCs from frozen PBMC populations, 
a subsequent optimisation of these cryopreservation methods in our laboratory has 
proven far more successful for gastric cancer patient CTC analysis. Both detection of 
PD-L1 on CTCs as a potential biomarker for brain cancer patients, and the utility of the 
novel improved cryopreservation method need to be tested in larger patient cohorts. 
Future studies should also focus on the improved method detailed earlier in gastric 
cancer cells and use a combination of DMSO and plasma from the patient as a freezing 
medium. 
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5 MGMT promoter methylation detection in 
cfDNA 
The work presented in this chapter was performed in collaboration with Dr Daniel 
Burke from the National Measurement Institute, and experimental work was partly 
conducted at the National Measurement Institute, Lindfield, Australia. While some of 
the data are being currently being prepared for a manuscript, submission for publication 
has been delayed as we are considering intellectual property protection on certain 
aspects of the assays. Due to the latter, some sensitive information is not fully disclosed 
in this thesis. 
 
 
5.1 Introduction 
In brain cancer, particularly adult GBM, there are only a limited number of treatments. 
The primary chemotherapeutic agent used is the drug TMZ7. This drug, as discussed in 
chapter 1, Clinical features of glioblastoma, page 2, is an alkylating agent that 
methylates the DNA of cancer cells at a variety of bases- the N7 position on guanine, the 
O3 position on adenine, and the O6 position on guanine. When the O6 position on 
guanine is methylated, it base pairs with thymine rather than guanine, thereby 
generating a mismatch, which, if not repaired, ultimately causes cell death by 
apoptosis200, as reviewed by Friedman et al.201. However, the effects of this drug can be 
counteracted by the enzyme MGMT, as discussed in chapter 1, MGMT promoter 
methylation, page 7, which demethylates the guanine residue and prevents accumulation 
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of DNA mismatches and drug induced cancer cell death202. Thus, the activity of this 
enzyme is a significant factor in determining how well a patient will respond to 
treatment. One of the major ways that the presence of this enzyme can be determined is 
through establishing whether the MGMT gene’s DNA promoter region is methylated or 
not. Promoter methylation will significantly reduce MGMT expression in the cell, 
improving the TMZ capacity to function optimally25. Current methods for determining 
MGMT methylation involve taking a tissue sample, either following surgical removal of 
the tumour, or a biopsy for that purpose, followed by tissue DNA extraction and 
MGMT promoter methylation analysis. However, this process is time-consuming, 
involves the degradation of DNA as a result of the commonly used MGMT promoter 
analysis method (bisulphite conversion128), and cannot be performed for patients 
without available tissue samples. 
 
If MGMT methylation testing were feasible via liquid biopsies, a faster, cheaper, and 
potentially more sensitive method could be developed that may provide a significant 
improvement in clinical decision making for brain cancer patients. In order for the 
liquid biopsy to be effective, a highly sensitive and novel method of analysing MGMT 
promoter methylation needs to be developed, especially for brain tumours, because the 
blood brain barrier could limit the release of ctDNA isolatable from blood, the 
commonest form of liquid biopsy. 
 
The aim of this chapter was to both establish such a method of MGMT promoter 
methylation analysis, and to validate it using initially traditional tumour tissue samples 
and ultimately ctDNA extracted from patient plasma samples. In order to establish a 
highly sensitive DNA methylation test for the MGMT promoter, we decided to avoid 
  111 
the most commonly used method for methylation analysis involving bisulphite 
conversion, because that is known to result in loss of DNA128. Given the low amounts of 
ctDNA expected in liquid biopsies, we instead opted for methylation-sensitive 
restriction digest - based approach, based on previous work by Dr. Daniel Burke at the 
National Measurement Institute (currently unpublished). One challenge with this 
method is to avoid false-positive results caused by incomplete digestion for reasons 
other than DNA methylation (reviewed by Laird et al)154. This problem usually can 
be controlled for by including standardised control DNAs in the same assay. 
 
 
5.2 Methods 
5.2.1 MGMT promoter- evaluation of possible methylation sites 
Prospective sites for methylation analysis were analysed in the literature, based upon 
CpG island numbers203 (see Figure 5.1), effect of methylation upon MGMT expression 
and patient outcomes204, and the number of restriction enzyme consensus sites in the 
target region, as more than two restriction sites were considered optimal to allow for 
complete digestion of the DNA. 
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Figure 5.1 Diagram of MGMT promoter region 
 
Figure 5.1: This figure shows a schematic presentation of the MGMT promoter region, up to 
954 base pairs (bp) upstream from the transcription start site and a 289 bp region downstream 
from it. The CpG island is marked by the green box. The purple boxes indicate the regions 
which, when methylated, correlate most closely to patient outcomes according to a study by 
Nakagawachi et al205. The regions for target region 1 (TR1) and target region 2 (TR2) are 
marked on the figure. 
 
 
5.2.2 Generation of primers and probes 
Primers targeting three specific sequences in the MGMT promoter region (which cannot 
be disclosed presently as they are currently under a non-disclosure agreement) were 
designed based upon the identified consensus sites using the NIH primer blast online 
program (https://blast.ncbi.nlm.nih.gov/Blast.cgi), and ordered from Sigma-Aldrich. 
Once PCR amplification was confirmed, probes (a Fam-bound probe for target region 1 
(TR1) and a Hex-bound probe for target region 2 (TR2), with a BHQ1 quencher) were 
then designed using the Primer Blast online program, and then ordered from Sigma-
Aldrich. 
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5.2.3 Testing primer combinations for PCR amplification 
Quantitative PCR (qPCR) was used to determine primer function. A 4.5 µM Forward 
and Reverse primer solution was prepared. Four µL of this solution was transferred to 
one of eight wells in a column on a 96-well plate. A stock sample of human genomic 
DNA (hgDNA) [Promega, Madison, USA] was diluted to 4000 cp/µL. 30 µL of hgDNA 
solution was then transferred to a 0.5 mL tube. To this tube, 150 µL of Brilliant II 
SYBR green reagent [Agilent, Santa Clara, USA] and 60 µL of 5M betaine [Sigma-
Aldrich] was added, and vortexed for 15 s. 16 µL of this DNA solution each was 
transferred to eight of the wells in the 96-well plate. To a second column, 16 µL of 
nuclease-free H2O was added to eight wells. The plate underwent DNA amplification 
and a melt curve was run in order to determine the optimal annealing temperature for 
PCR and verify amplification of a single product using a quantitative PCR (qPCR) 
instrument [Stratagene]. The best two primer combinations were chosen for droplet 
digital PCR, as described in Chapter 2, ddPCR page 42. 
 
 
5.2.4 Methylation-sensitive restriction enzyme digestion 
A total volume of 16 µL of each DNA solution to be tested per repeat, along with 16 µL 
of DNAse-free water and 16 µL of control DNA solution (either hgDNA [Promega] 
manufactured amplicons [IDT, Singapore] per repeat, was split between two 1.5 mL 
tubes. To 1 tube of each different sample, 1 µL of DNAse-free water per repeat was 
added, to serve as the undigested control. To the other tube to serve as the digested 
samples, 1 µL per replicate (that is, for each sample well of the final 96 well plate) of 
5M betaine [Sigma-Aldrich] was added. To the non-digested control samples, 1 µL per 
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repeat of Diluent A [New England Biolabs, Ipswich, USA] was added. To the samples 
that were to be digested, 1 µL per repeat of restriction enzyme solution one [New 
England Biolabs] was added. The samples were then incubated on a Thermomixer for 1 
h at 60° C at 600 rpm for mixing. 
The solutions were then cooled to room temperature, and to the undigested samples 1 
µL per repeat of 2-amino-2-hydroxy-(hydroxymethyl)-propane-1, diol (Tris) 
hydrochloric acid buffer (Tris.HCl) was added. To the digested samples, 1 µL per repeat 
of restriction enzyme solution 2 [New England Biolabs] was added. The samples were 
then incubated on a Thermomixer for one h at a temperature of 37° C at 600 rpm for 
mixing.  
In a new 1.5 mL tube, 11 µL of ddPCR master mix per well of the ddPCR plate (with 1 
well per repeat of each sample) was made. The master mix was made using primers for 
each MGMT promoter region being added to the 1.5 mL tube for a final concentration 
of 900 nM (with 0.36 µL per well for each primer); probes for a final concentration of 
250 nM (with 0.1 µL per well for each probe); and 0.18 µL per well of Tris/EDTA0.1 
(TE0.1) buffer was added. Finally, 9 µL of ddPCR supermix [Bio-Rad] per well was 
added to the 1.5 mL tube. 11 µL of MGMT promoter master mix was added to each 
well of the ddPCR plate per repeat of the samples. Following this, 11 µL of each repeat 
of each sample was added to each well of the ddPCR plate that had ddPCR master mix 
added to it. The samples were placed in an auto-droplet generator [Bio-Rad]. The 
ddPCR plate was placed in a ThermoCycler for amplification. Following amplification, 
the plate was analysed in a ddPCR plate reader [Bio-Rad]. 
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5.2.5 Generation of standards 
The sequences of the standards were generated based upon the known target regions. 
Synthetic duplex sequences were ordered from Integrated DNA Technologies [IDT]. 
 
 
5.2.6 Analysis of standards 
The standards were analysed using the BioAnalyser [Agilent], and the High 
Performance Liquid Chromotograph (HPLC) [Shimadzu, Kyoto, Japan]. For the 
BioAnalyser, all materials were produced either in-house at the NMI (the PuC19 DNA 
control, which serves as a pre-made DNA solution with known DNA fragment lengths, 
and an internal standard for the NMI in addition to the DNA ladder provided by 
Agilent) or by Agilent. For all analysis methods, a concentration of DNA of at least 10 
ng/µL was used. The gel dye, gel matrix, DNA ladder, DNA markers, and samples 
(including the PuC19 control) were equilibrated to room temperature for 30 min.  
The dye concentrate was vortexed for 10 s, then centrifuged briefly. Twenty-five µL of 
dye concentrate was added to the gel matrix tube. The gel matrix-dye mixture was then 
vortexed for 15 s and transferred to the top receptacle of a spin filter and centrifuged at 
2240 x g for 15 min. A DNA 1000 assay chip was placed in the chip priming station. 
Nine µL of gel matrix-dye mixture was pipetted into the designated well. The other two 
gel matrix-dye wells were loaded with 9 µL of gel matrix-dye. Each of the other 13 
wells were loaded with 5 µL of DNA marker. The ladder well was loaded with 1 µL of 
DNA ladder. The remaining wells were loaded with either sample, PuC19 control, or 
water. The samples were analysed on the BioAnalyser.  
The Shimadzu HPLC was loaded with the required buffers. A minimum volume of 10 
µL of 10 ng/µL DNA solution was loaded into the machine, based upon the results from 
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the BioAnalyser. The samples were processed over the course of 15 to 20 min to permit 
any DNA fragments of different lengths to be easily observed. 
 
 
5.2.7 ddPCR 
ddPCR was performed as described in Chapter 2, ddPCR, page 42. However, droplet 
generation was carried out in an Auto droplet generator [BioRad], by pipetting the DNA 
solution and primer/probe solution into a 96-well plate, then transferring that into the 
auto droplet generator for droplet generation. In addition, the NMI has an internal 
algorithm used to adjust ddPCR results against uncertainty that gives a more accurate 
measurement of DNA concentration. This was used in all calculations for ddPCR in this 
chapter. 
 
 
5.2.8 Patient tissue sample cohort and processing 
Patient samples were obtained from the Centre for Oncology Education and Research 
Translation (CONCERT) Biobank, based at the Ingham Institute for Applied Medical 
Research, Liverpool, Australia. Twenty samples were requested, with at least four 
patients that were confirmed to be MGMT promoter methylation positive, and at least 
four that were confirmed to be methylation negative, based on standard 
histopathological tissue evaluation. Fresh frozen patient tissue samples were processed 
using TRI Reagent [Sigma-Aldrich]. Tissue was removed from the -80°C freezer, and 
placed in the fume hood. Tissue was placed on sterile, unused Petri dishes. Using a 
scalpel, the required amount of tissue was cut into smaller pieces, with a maximum final 
mass to be used in the extraction of 100 mg. Obvious tumour tissue (harder, discoloured 
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sections) was prioritised for inclusion in the process. The tissue was transferred to a 1.5 
mL tube. 
150-200 µL of TRI Reagent was added to the tissue. A pellet pestle [Sigma-Aldrich] 
was used to break up large pieces of tissue. If necessary, some of the TRI Reagent was 
removed to a separate 1.5 mL tube. The remainder of the TRI Reagent after the tissue 
had been broken up by the homogeniser was added to the 1.5 mL tube (for a total of one 
mL for 100 mg of tissue). If the tissue was dissolved entirely, the lid of the 1.5 mL tube 
was covered with parafilm and the homegenate centrifuged at 12 000 xg for 10 min at 2-
8° C to remove insoluble material. The high fat content of the brain tissue presented 
itself in a layer above the aqueous phase. This was removed with a pipette, leaving the 
clear aqueous phase behind. This clear, aqueous phase was retained for RNA extraction 
for other projects.  
 
To the remaining solution, 0.3 mL of 100% ethanol [ThermoFisher] was added and 
mixed by inversion. The samples were allowed to stand for 2 min at room temperature. 
The samples were then centrifuged at 2000 xg at 2-8° C for 5 min. The supernatant was 
removed. The DNA pellet was washed twice with 0.1M trisodium citrate [BDH 
chemicals, Kilsyth, Australia] solution, and an additional time if non-DNA material was 
present in the sample, based upon the presence of volumes of tissue or fat in the DNA 
layer. After the addition of each wash solution, the samples were allowed to stand, with 
inversion by hand every 10 min, for 30 min. The samples were then centrifuged at 2000 
xg at 2-8° C for 5 min. The DNA pellet was then resuspended in 75% ethanol (2 mL for 
each mL of TRI Reagent used in the process) and allowed to stand for 20 min at room 
temperature. The ethanol was removed carefully and the pellet dried for 5-10 min under 
a vacuum. The pellet was then resuspended in nuclease-free H2O heated to 37° C. The 
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sample was centrifuged at 12 000 xg for 10 min and the supernatant transferred to a new 
1.5 mL tube. 
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5.3 Results 
5.3.1 MGMT promoter target region identification  
The MGMT promoter region, extending approximately 950 bp before the transcription 
start site, to approximately 290 bp after it, has a CpG island, which contains 97 putative 
methylation sites (see Figure 5.1) (reviewed by Weller et al16). Ninety-six of these sites 
(or sites in several regions (see Figure 5.1)) were previously found to be methylated in 
MGMT-negative cancer cell line DNA in comparison to MGMT positive cancer cell 
line DNA using bisulphite conversion for detection of methylated DNA, although 
methylation was present in some cases in the six sites furthest upstream in the promoter 
region in MGMT positive samples (shown by Nakagawachi et al.205, Figure 5.1). 
Importantly, methylations in regions highlighted in purple in the schematic in Figure 5.1 
have previously been linked to decreased transcriptional expression of the MGMT 
gene204. Putative methylation sites with evidence for association with cancer and/or for 
regulation of MGMT expression were therefore considered the best candidates for 
establishment of novel MGMT methylation assays. Genetic regions including these 
candidate sequences were screened for methylation sensitive restriction sites for 
restriction enzymes previously identified to work best for quantitative methylation 
detection (specific enzymes not disclosed). Undisclosed DNA sequences covering 
candidate sequences of between 77 and 90 bp length with at least two restriction sites 
were chosen to establish methylation assays. This strategy resulted in three candidate 
regions for assay development, these regions are referred to as target region (TR) one, 
two and three throughout the thesis. While specifics of the tested TRs remain 
undisclosed, it is important that TR2 includes the MGMT promoter region which is 
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currently analysed for diagnostic MGMT methylation using the Qiagen Therascreen 
MGMT pyro kit. 
 
 
5.3.2 Primer and probe design and confirmation of PCR amplification of TRs 
Initially primers were designed to test whether three regions could be PCR amplified, 
because GC-rich DNA sequences, while a prerequisite for CpG islands that can be 
methylated, are often very difficult to amplify by PCR.  
 
The MGMT promoter target region one (TR1), and target region two (TR2) could be 
successfully amplified by PCR from human genomic DNA (hgDNA), suggesting the 
feasibility of these regions to detect and quantify DNA methylation by this method. 
Target region three (TR3), on the other hand, could neither be amplified by PCR in 
several attempts using the first set of primers nor with alternate primers covering 
adjacent sequences. TR3 was therefore ruled out for MGMT promoter methylation 
measurement. Figure 5.2 shows the successful amplification of the target regions by 
quantitative PCR (qPCR) initially relying on SYBR green incorporation. Once 
amplification of TR1 and TR2 was confirmed specific Taqman probes for TR1 
conjugated to 6-FAM and TR2 conjugated to HEX were designed. 
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Figure 5.2 Real time PCR figure for TR1 and TR2 
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Figure 5.2: Real time PCR amplification using SYBRgreen incorporation for detection of target 
region 1 (TR1) (5.2a) and target region 2 (TR2) (5.2b) amplicons from human genomic DNA 
(hgDNA). The grey horizontal line in both the graphs represents the threshold, above which 
measured fluorescence reflects accumulation of double-stranded DNA (dsDNA) during 
amplification. The earlier (fewer cycles) the threshold is crossed the more efficient is the DNA 
amplification. Eventually, above approximately 30 cycles depending on DNA and primer 
concentrations, real time PCR may be affected by the amplification of artefacts such as 
complexes formed by the combination of the primers (“primer dimers”), rather than the 
amplification of specific DNA. As both TR1 and TR2 reactions produce fluorescence before that 
(at 24 and 26 cycles respectively), it can be concluded that mainly correct amplification is 
measured for both target sequences. This was confirmed by performing melting curves for both 
PCR products (data not shown owing to a non-disclosure agreement). 
 
 
5.3.3 MGMT promoter TR1 and TR2 ddPCR optimisation- duplex assay 
development 
Primer and probe combinations were optimised for use in ddPCR alone and in 
combination to test if they were suitable for multiplexing, i.e. their use simultaneous in 
the same reaction without interference with correct quantification of template DNA. 
As introduced in chapter 1, Novel Testing Methods, page 30, the difference between 
conventional PCR and ddPCR is that ddPCR involves the separation of a PCR reaction 
into approximately 12,000-20,000 droplets of equal size so that DNA templates are 
comparmentalised and as a result, some droplets will not have any molecules of a given 
template. In general, other components of the reaction such as primers, nucleotides and 
polymerase are in excess and equally distributed throughout droplets. During the PCR 
reaction in a thermal cycler only droplets that contain template will amplify the specific 
product and thus produce specific fluorescence of the template specific Taqman probes. 
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This means that the primary method of analysing the ddPCR results relies upon 
detection of fluorescence in positive versus no detection in negative droplets. 
First, the best annealing temperatures for each assay was determined using a thermal 
cycling protocol with a temperature gradient (data not shown as exact PCR conditions 
are under a non-disclosure agreement). Figure 5.3 shows a 2D dot-plot output file of 
TR1 and TR2 from ddPCR of hgDNA, highlighting that both target regions are 
detectable using the designed primers and probes by ddPCR. Blue dots (symbolising 
TR1 amplified droplets) and green dots (symbolising TR2 amplified droplets) are well 
separated from black dots symbolising droplets without template and that clearly 
indicates that the designed primers and probes as well as the established PCR conditions 
are suitable to detect DNA of TR1 and TR2. Importantly, the data show that both assays 
can be combined into the same multiplexed PCR reaction which not only will save 
consumables but also DNA samples, an invaluable practical advantage, once the assay 
is applied to limited patient-derived cfDNA. 
 
Figure 5.3 2D Image of ddPCR amplification of TR1 and TR2 
 
Figure 5.3: 2D droplet digital PCR (ddPCR) output for both TR1 (blue dots) and TR2 (green 
dots). The threshold at which an individual droplet is considered positive for the target sequence 
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(blue or green dots) is indicated by the purple line- below that amplitude, a droplet is considered 
negative (black dots). Ideally, there should be one cluster of each type of dot. In this case, the 
positive droplets in particular for TR2 (green) are spread across a wide area, which indicates a 
variation in the fluorescence of the positive droplets. The presence of a single main body does 
still suggest that the assay is clearly identifying TR2 templates. 
 
 
5.3.4 MGMT promoter region TR1 and TR2 methylation sensitive restriction 
enzyme digestion 
For detection of methylated TR1 and TR2 promoter regions, parallel hgDNA samples 
were either digested using methylation restriction enzymes or mock treated (ie not 
incubated with restriction enzymes but otherwise treated and diluted identically). 
Digested and non-digested samples then underwent multiplexed ddPCR amplification 
for TR1 and TR2. As can be seen in Figure 5.4, the number of TR1 and TR2 positive 
droplets as symbolised by blue or green droplets significantly decreases after digestion. 
Measured as a concentration of copies per microlitre using the NMI’s normalisation 
algorithm, for TR1 and TR2 there is a mean 99.8% decrease (standard deviation 
(SD)=0.2%) and 92.8% (SD=2.1%), respectively. This decrease is sufficient to suggest 
that both assays may have utility in detecting methylation. The data highlight however 
that the samples retain a large amount of remaining DNA of template TR2 following 
digestion as seen by relatively high numbers of positive TR2 droplets after digestion 
while TR1 template DNA appears to have been cleaved far more efficiently by the 
methylation sensitive restriction enzymes and very few droplets contain TR1 template 
after digestion.  
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Figure 5.4 Methylation sensitive digestion of TR1 and TR2 hgDNA- ddPCR output 
 
Figure 5.4: Data from one representative experiment showing human genomic DNA (hgDNA) 
TR1 before methylation sensitive digestion (5.4a) and after methylation-sensitive digestion 
(5.4b); and for TR2 before digestion (5.4c) and after digestion (5.4d). For this experiment there 
is a distinct decrease in the number of droplets between 5.4a and 5.4b (99.5% decrease), and 
5.4c and 5.4d (89.5%).  
 
 
5.3.5 MGMT promoter region TR1 and TR2 limit of detection  
Ultimately, this assay is aimed to be applicable to plasma derived ctDNA samples from 
GBM patients. Since ctDNA concentration is expected to be very low, especially for 
brain cancer patients, and because this small amount of tumour derived DNA will be 
within a comparably high background of normal cfDNA, it is necessary to develop an 
assay sensitive enough to reliably detect very low copy numbers of methylated DNA 
sequences in the presence of normal DNA (i.e. from healthy cells). As an initial test to 
determine sensitivity of the TR1 and TR2 assays methylated DNA was titrated into 
normal hgDNA.  
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Figure 5.5a shows the limit of detection for TR1, which is 5 methylated copies in 1000 
copies of normal hgDNA. The final equation for the graph resulting from 3 independent 
experiments, is: 
 
It suggests both a close relationship between the calculated concentration of methylated 
DNA copies per microlitre and the measured concentration of DNA copies per 
microlitre. This suggests, in turn, the TR1 assay is highly suitable to measure 
methylation of human MGMT promoter DNA and has good potential to work with 
cfDNA. 
 
In regard to TR2, as can be seen from Figure 5.5b, given the high background of non-
digested (potentially methylated) DNA in the healthy normal hgDNA as seen in Fig 5.3, 
detection of the titrated methylated DNA appears less sensitive with 50 copies in 1000 
copies of normal hgDNA. The final equation for the graph resulting from 2 independent 
experiments, is: 
 
. 
This indicates a much less precise relationship between the calculated and measured 
methylated DNA copies per microlitre. This, in turn, suggests that when diluted in 
normal hgDNA, the TR2 assay is less suitable to measure methylation in human DNA 
of the associated region of the MGMT promoter. Digestion of the TR2 region DNA 
occurs, and methylation is still detectable, however the assay is less sensitive than that 
for TR1 and would need the careful determination of a cut-off above which methylation 
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is likely disease associated. For TR1 on the other hand such a cut-off appears to be 
extremely low. 
Figure 5.5 Limit of detection for TR1 and TR2 assay 
 
 
Figure 5.5: Methylated DNA was titrated into a background of 1000 cp/µL of unmethylated 
hgDNA for both TR1 (5.4a) and TR2 (5.4b). For TR1, 5.4a, there is a clear, linear relationship 
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between each point of the graph, which indicates that very low levels of methylated DNA can be 
detected accurately in a large amount of background DNA. For TR2, however, this relationship 
is less precise; combined with the x-intercept being at approximately 15 cp/µL, this suggests, 
that there is a background level of methylation in hgDNA for TR2, or that there is a limitation to 
the digestion of the DNA for TR2 using the specific restriction enzymes that we have. Data 
points show the mean and error bars the range of n=2. 
 
 
5.3.6 Standards for the MGMT promoter region- mass spectrophotometry of 
manufactured amplicons 
As can be seen in the previous section, determining clear sensitivity and specificity of 
the TR1 and TR2 assay is impacted on by the fact that there is likely, at least for TR2, a 
significant proportion of methylation normally occurring on healthy donor hgDNA. 
Additionally, exact determination of methylation requires DNA that is methylated at an 
exactly defined proportion, ideally 100%. 
 
The NMI is equipped to highly accurately measure the concentration of DNA fragments 
down to number of molecules and to determine the exact molecular weight of these 
fragments. Since 100% methylation will change the molecular weight by an amount that 
can be mathematically determined we speculated that it would be possible to produce 
DNA standards for the TR1 and TR2 regions either completely non-methylated or 100% 
methylated and run quality control if this indeed would be achieved.  
 
During DNA synthesis it is, at least in theory, relatively easy to produce a completely 
non-methylated or alternatively 100% methylated DNA fragment by choosing either 
non-methylated or methylated nucleotides for the elongation process during synthesis. 
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Initially two complementary strands are synthesised, and afterwards allowed to re-
nature into double-stranded DNA, a process confirmed by the commercial supplier. The 
non-methylated and 100% methylated synthetic double-stranded DNAs obtained for 
TR1 and TR2, referred to as TR1-unmethylated, TR1-methylated and TR2-
unmethylated, TR2-methylated, were then subjected to several quality control tests at 
the NMI.  
 
In order to confirm that the manufactured DNA fragments were of the correct quality, 
and that they were methylated correctly, mass spectrophotometry was used in order to 
determine what the DNA standard contained on a molecular level. This was done using 
several different methods. Firstly, in order to determine if the dilutions of the standard 
made were pure, a 10 ng/µL sample of the standard was made and analysed with an 
Agilent Bioanalyser. The results are shown in Figures 5.6a (TR1-unmethylated); 5.6b 
(TR1-methylated); 5.6c (TR2-unmethylated); and 5.6d (TR2-methylated). This shows 
that there is only one major peak for all the standards (the far left and far right peaks are 
markers with a known number of bp to give a basis for determining the size of the 
analysed DNA standard). In addition, the determined sizes of the amplicons analysed 
are fairly close to the difference established from the primer design (with 78 and 83 bp 
for TR1 and TR2 respectively compared to 94 and 98 bp) to the size of the standard of 
the target regions, although the methylated standards are measured as being larger than 
the unmethylated standards, which is expected as the addition of methyl groups makes 
the DNA heavier, and thus move through the gel matrix of the BioAnalyser chip more 
slowly. It should be noted that the BioAnalyser is not a perfect means of measuring base 
pair numbers. The single peaks for the products indicate that the standards available 
have a very high level of purity and are unlikely to have a level of contaminants that 
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might give false positives or interfere with the accurate quantification of the standard by 
ddPCR. 
Figure 5.6 Agilent BioAnalyser analysis of TR1 and TR2 standards 
 
Figure 5.6: The manufactured amplicons were analysed using an Agilent Bioanalyser to 
determine if they were pure, homogeneous samples. Output files from runs are shown for TR1-
unmethylated (5.6a); TR1-methylated (5.6b); TR2-unmethylated (5.6c); and TR2-methylated 
(5.6d). As can be seen, there is one primary peak between the markers for 15 and 1500 BP 
(which serve as the baseline for the samples). In addition, the methylated amplicons (being 
heavier due to attached methyl groups) are measured as having a larger size (expressed as 
increased base pair number due to standardisation in regards to base pairs) than the 
unmethylated ones. 
 
The second step was to use a High-Performance Liquid Chromatograph (HPLC) to 
determine, if the manufactured DNA material was composed of a homogenous material, 
or if there was variation in the number of base pairs or the composition of the 
amplicons, and to ensure that the DNA standard was indeed double-stranded. 
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As can be seen in Figure 5.7a, (an example HPLC trace for the TR1-methylated DNA 
standard), there is a second ‘peak’ detected which is indicative of an additional, 
differently-massed molecule in the DNA standard solution. Following HPLC 
purification, this secondary peak was reduced (see Figure 5.7b). Notably the primary 
DNA standard peak is clean with no evidence of other peaks to indicate the presence of 
contaminants. However, the primary peak is somewhat asymmetrical, forming a 
shoulder, which suggests the possibility that not all of the DNA was formed into a 
duplex, meaning that some of the sample is composed of lower-mass single-stranded 
DNA, which could potentially alter the reading from the HPLC. Other explanations are 
possible, but these were largely eliminated through experimental variation with the 
HPLC. 
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Figure 5.7 Representative HPLC analysis of TR1- unmethylated amplicon 
 
Figure 5.7: This figure shows High-performance Liquid Chromatograph (HPLC) figures for the 
TR1-methylated standards. Figure 5.7a shows the amplicon prior to HPLC separation, and 
Figure 5.7b shows the standard after HPLC separation. As can be seen, there is an obvious 
second peak shortly after the standard peak (marked ‘impurity peak’ in the figure). After 
purification using the HPLC output, the sample was analysed again, and as can be seen the 
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impurity peak is no longer there. However, as can also be seen, the primary peak is not even, 
possessing a shoulder. This suggests that there are impurities in the primary peak as well. 
 
 
5.3.7 Measurement of target region concentration via ddPCR 
ddPCR was used to determine if the standards could be amplified effectively. As can be 
seen from Figure 5.8a and 5.8b, amplification was successful, indicating that they were 
correctly manufactured and can be measured using ddPCR. Furthermore, as can be seen 
in Figures 5.9a through to 5.9h, the unmethylated standards are digested by the 
restriction enzymes. Interestingly, as can be seen in the representative Figures 5.9e and 
5.9f, for TR2 the manufactured, unmethylated standard is almost entirely digested (with 
an efficiency of approximately 96%). This suggests that the previously observed 
incomplete digestion (efficiency of 93%) in hgDNA is consistent with a baseline level 
of methylation in normal human DNA.  
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Figure 5.8 ddPCR results for unmethylated and methylated TR1 and TR2 
amplicons 
 
 
Figure 5.8: This figure shows the ddPCR analysis of manufactured, double-stranded DNA 
amplicons of TR1 (5.8a and 5.8b, unmethylated and methylated respectively) and TR2 (5.8c 
and 5.8d, unmethylated and methylated respectively).  
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Figure 5.9 ddPCR results for methylated and unmethylated TR1 and TR2 
amplicons, both before and after digestion 
 
Figure 5.9: This figure shows ddPCR data of one representative experiment for both 
methylated and unmethylated amplicons with and without digestion. 5.9a and 5.9b show the 
unmethylated amplicon of TR1 before and after digestion (with a 99% reduction of DNA); 5.9c 
and 5.9d shows the methylated TR1 amplicon before and after digestion (with a 10% reduction); 
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5.9e and 5.9f shows the unmethylated TR2 amplicon before and after digestion (with a 96% 
reduction); and 5.9g and 5.9h shows the methylated TR2 amplicon before and after digestion 
(with a 21% reduction). As can be seen, the unmethylated amplicons are almost completely 
digested, while the methylated amplicons remain largely undigested, confirming that the 
amplicons are methylated as expected. 
 
 
5.3.8 Digestion efficiency measurement 
Using the standards, the digestion efficiency of the restriction enzymes could be 
accurately measured. As seen in Figure 5.10, there is a relatively high proportion of 
DNA remaining following digestion in the hgDNA for TR2 (for a mean of 7.2%). This 
compares to the almost complete digestion of the TR2 unmethylated amplicon, which 
has 1% methylated DNA remaining according to the assay. The difference between the 
two is significant (p=0.007). By comparison, for TR1, the proportion of methylated 
DNA for hgDNA is 0.18%, while that of the amplicons is 0.12%; this difference is not 
significant (P=0.596). 
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Figure 5.10 Comparison of digestion efficiency for TR1 and TR2 in both hgDNA 
and manufactured amplicons 
 
Figure 5.10: The above figure compares the average percentage, for n=3, of undigested, 
nominally unmethylated DNA remaining in samples following their digestion. For TR1, in both 
hgDNA and the amplicons, almost all the DNA is digested. The digestion of TR2 is not as 
efficient as that of TR1 in either hgDNA (P=0.004) or the standards (P<0.001), however there is 
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a significant proportion of TR2 hgDNA remaining compared to the standard of TR2 (P=0.007), 
suggesting some baseline of methylated DNA in normal hgDNA. 
 
5.3.9 Detection of MGMT TR1 and TR2 methylation in tumour-tissue DNA 
Fresh-frozen tumour tissue samples from 20 brain cancer patients, nineteen with GBM 
and one with grade three anaplastic astrocytoma, were obtained from the CONCERT 
biobank at the Ingham Institute for Applied Medical Research and DNA was extracted. 
Importantly, for 15 of the patients, tumour samples had previously been tested for 
MGMT methylation using the diagnostic service at Liverpool Hospital pathology which 
uses the Qiagen Therascreen kit to detect MGMT promoter methylation. The same 
genomic region of the MGMT promoter that is tested in the diagnostic assay is covered 
by the TR2 region assay developed in this project.  
Extracted tumour tissue DNA was analysed using the above developed TR1 and TR2 
assays to validate their use. Results were compared to existing data from the diagnostic 
assay, as obtained from the patient records and by correlating findings of methylation 
with our assays with patient disease parameters. The outcomes we obtained suggested 
that the results for TR2 needed to be normalised, due to our fnding that there is a level 
of non-disease-related methylation. Our collaborators at the NMI had previously found 
that detection of methylation using methylation-sensitive restriction enzymes would 
find methylation roughly 10% higher, as a proportion of total DNA (Daniel Burke, 
personal communication), than bisulphite conversion. By using this information, as well 
as the known cut-off in the routine clinical test of 30% methylation for clinical 
relevance, and our findings of methylation in normal samples, cut-off of 50%, to some 
extent arbitrary, was set for TR2. Because normal brain tissue to measure the baseline 
level of MGMT promoter methylation was unavailable, there was no way to determine a 
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level of methylation in TR2 in healthy controls to inform our cut-off. Figure 5.11 shows 
the detection of methylated DNA with the ddPCR TR1 and the normalised TR2 assays 
(that is, only methylation above significance is shown) for the 15 of 20 patient tumour 
tissue samples where the methylation status is known, and for the patient samples where 
methylation status is unknown. For this figure the proportion of methylation detected 
using the TR1 assay (i.e. the proportion of positive events detected by ddPCR after 
methylation sensitive digestion versus without digestion) has not been further 
normalised. The non-normalised methylation data can be seen in Table 5.1, which 
presents the methylation data for all 20 patient samples. 
 
Interestingly, although the cohort of patients analysed remains small this results in 
detection of MGMT methylation for 5 out of 7 (71%) patients that had previously 
positive diagnostic tumour tissue testing. All those patients had detected methylation by 
both the TR1 and the normalised TR2 assay. For only one of eight patients with 
previous methylation negative diagnostic findings did both our assays detect 
methylation, while four of those patients tested positive with only either the TR1 or the 
TR2 assay and another four tested negative with both of our assays, as seen in Figure 
5.11. Of the five remaining patient tumour tissues not previously tested for MGMT 
methylation one tested positive with both the TR1 and the TR2 assay while three tested 
positive with one assay and one patient tumour tissue tested as non methylated. These 
data are shown in Figure 5.11. 
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Figure 5.11 DNA methylation in TR1 and TR2 in patient tissue DNA 
 
 
Figure 5.11: This figure compares the outcomes of methylation analysis in patient tissue DNA, 
both in TR1 and TR2. TR2 data is shown following normalisation (that is, the results given are 
calculated from the raw data and given in % with the value of 50 subtracted, based upon an 
assumed baseline level of methylation from prior experiments and knowledge of the outcomes 
from the histopathological clinical test for TR2 for these patients). Samples are sorted based 
upon the outcome of the clinical test. On the left, those patients with previous negative MGMT 
promoter region methylation from testing of tumour tissue are listed. In the centre, patients with 
previously confirmed positive MGMT methylation, and on the right are listed those patients upon 
whom no prior test has been run. 
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Table 5.1 Specific DNA concentrations for both TR1 and TR2 
Sample 
Number 
Clinical 
Methylation 
Status 
Concentration 
TR1 
Undigested 
(cp/μL) 
Methylation 
Percentage 
TR1 
Concentration 
TR2 
Undigested 
(cp/μL) 
Methylation 
Percentage 
TR2 
Pt 1 Unmethylated 93 1.08 107 44.13 
Pt 2 Methylated 536 45.15 542 59.58 
Pt 3 Unmethylated 342 0 415 33.21 
Pt 4 Methylated 2756 1.89 3285 38.47 
Pt 5 Unmethylated 7745 17.51 8690 76.92 
Pt 6 Unmethylated 6910 0.23 7642 51.34 
Pt 7 N/A 12077 20.53 13690 66.4 
Pt 8 Unmethylated 525 10.86 593 34.9 
Pt 9 Unmethylated 3900 0.13 3475 62.5 
Pt 10 N/A 13359 0.1 13288 65.75 
Pt 11 Unmethylated 12985 0.12 13206 50.71 
Pt 12 Methylated 63 74.6 117 92.12 
Pt 13 N/A 6906 0.48 7502 57.09 
Pt 14 Methylated 8155 21.28 8887 83.66 
Pt 15 Methylated 630 40.95 790 59.23 
Pt 16 Methylated 1126 0.18 1224 31.16 
Pt 17 N/A 1180 10 1289 44.01 
Pt 18 Methylated 23422 24.76 22801 88.49 
Pt 19 Unmethylated 666 0.15 671 47.86 
Pt 20 N/A 858 0.12 1007 23.71 
  142 
 
Figures 5.12a and 5.12b compare the average level of methylation detected for TR1 and 
TR2 respectively for patient samples with known methylation status. As can be seen in 
Figure 5.12a, our TR1 MGMT promoter methylation assay correlates well with the 
clinical test, as there is a clear difference in the average level of methylation between 
the samples known to be methylated and the samples known to be unmethylated 
(P=0.039). For TR2, as can be seen in Figure 5.12b, the gap between the two is less 
large, and not significant (P=0.098). 
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Figure 5.12 Comparison of methylation in confirmed methylated and 
unmethylated samples for TR1 and TR2 
 
Figure 5.12: This figure compares the average measured methylation in TR1 (Figure 5.12a) 
and TR2 (Figure 5.12b) for the samples that were confirmed to be methylated and 
unmethylated. As can be seen, there is a difference between the two populations in both of the 
samples. The average level of methylation in TR2 is higher than both the clinically accepted and 
the estimated baseline level of methylation (represented by the dotted lines). 
 
 
5.3.10 MGMT TR1 and TR2 methylation in tumour-tissue DNA and patient 
survival 
MGMT promoter methylation as detected by the current clinical prognostic test is 
sometimes an imperfect predictor of MGMT expression and patient outcomes25,205,206, 
therefore it is important to correlate our novel assay results to patient outcome. As can 
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be seen in Figures 5.13a and 5.13b, there is, for TR1, a clear differentiation between the 
PFS (P=0.004) and OS (P=0.036) for methylated and unmethylated patients. For TR2, 
as can be seen in Figures 5.13c and 5.13d, there is no clear differentiation between the 
two populations, either for PFS (P=0.173) or OS (P=0.772). 
In order to prevent differences in treatment from affecting the outcome of the analysis, 
Kaplan Meier survival curves were produced for the 12 patients who had received the 
same treatment (surgery, followed by chemotherapy and radiotherapy). For TR1, the 
difference in PFS of the patients who received this treatment based upon methylation of 
TR1 was significant (p=0.039) (see Figure 5.13e), while the difference in OS was not, 
albeit it was close to significance (p=0.053) (see Figure 5.13f). For TR2, the difference 
in PFS based upon methylation analysis was not significant, again barely (p=0.054) (see 
Figure 5.13g), nor was the OS, (p=0.701) (see Figure 5.13h).  
Given the differences in the methylation of TR1 and TR2, the survival of patients based 
upon the combination of these factors was also analysed. As can be seen in Figure 5.14a 
and 5.14d, patients with both TR1 and TR2 methylated had a greater PFS than patients 
who did not. In terms of OS, while methylation in both TR1 and TR2 suggested greater 
survival than patients unmethylated in both TR1 and TR2, survival of patients 
methylated in only TR1 matched methylation in both TR1 and TR2, although numbers 
for each of these specific subdivisions of the patient population are too low for a reliable 
outcome comparison. For TR2, patients who were only methylated in that region had a 
PFS roughly equal to that of the patients unmethylated in both TR1 and TR2 (P=0.872), 
although for OS there was no significant difference in outcomes between patients 
methylated in both TR1 and TR2 and those methylated in only TR2 (P=0.191).  
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Figure 5.13 Comparison of PFS and OS for TR1 and TR2 in patient tissue samples 
following methylation analysis 
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Figure 5.13: This figure shows the Progression Free Survival (PFS) (Figure 5.13a, n=20) and 
Overall Survival (OS, n=20) (Figure 5.13b) for the analysed patient tumour samples in TR1; and 
the PFS (Figure 5.13c n=20) and OS (Figure 5.13d, n=20) for the samples in TR2. As can be 
seen, there is a difference between the outcomes for methylated and unmethylated patients for 
TR1 (for PFS, P=0.004, for OS, P=0.004), but not for TR2 (for PFS, P=0.173, for OS, P=0.772).  
In addition, this figure also shows the PFS (5.13e, n=12) and OS (5.13f, n=12) for patients who 
received identical treatment in TR1, and the PFS (5.13g, n=12) and OS (5.13h, n=12) for 
patients who received identical treatment in TR2. In TR1, while PFS is still statistically significant 
(P=0.039), OS is not (P=0.053), albeit significance is approached. In TR2, neither PFS 
(P=0.054), nor OS (P=0.701) are statistically significant. However, PFS for TR2 approaches 
significance. 
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Figure 5.14 Patient outcomes based upon both combined and individual analysis of 
methylation in TR1 and TR2 
 
Figure 5.14: This figure shows the PFS (5.14a) and OS (5.14b) using the combined methylation 
results of both TR1 and TR2. As can be seen, there is a significant difference in survival 
between patients who have methylation in both TR1 and TR2 (n=7) and patients who are 
unmethylated in both TR1 and TR2 (n=5). In addition, patients methylated in TR2 only (n=5) 
have a similar survival to patients unmethylated in both, while patients methylated in only TR1 
have a similar survival to patients methylated in both TR1 and TR2 (n=3). A total of n=20 
samples was used for this cohort. 
 
 
5.3.11 cfDNA TR1 and TR2 methylation analysis: healthy control plasma donors 
To perform the first step of testing the novel methods developed in this chapter plasma 
taken from healthy control individuals was used to confirm that the cfDNA extraction 
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method and the DNA digestion method were compatible with the ddPCR assays. In our 
hands, the best method of cf/ctDNA extraction utilised the Qiagen QIAmp Circulating 
Nucleic Acid kit in comparison to a range of other kits as tested for NSCLC patients and 
healthy control individual plasma207. Therefore, this method was also the preferred 
method to test for compatibility with our ddPCR assays. When cfDNA from six healthy 
donors was used with our ddPCR TR1 and TR2 assays, comparison of DNA 
detectability with and without methylation sensitive restriction digests revealed that the 
digest effectively removes detectable DNA for TR1 (Figure 5.15). Accordingly, the 
TR1 genetic region can be assumed to be completely non-methylated in healthy 
individual’s cfDNA from plasma, confirming the data presented above for purified 
hgDNA and the synthetic DNA standards. Also in agreement with our previous data, 
TR2 DNA is not completely removed from plasma derived healthy donor cfDNA. In 
fact, the retained amount of DNA is quite variable, and is between 6.5-100% (Figure 
5.15). 100% methylation was detected with the TR2 assay for one healthy control 
individual (HC2) - one explanation is that this was an artefact of the assay - therefore 
we did not take it into account to determine the TR2 cut-off for cfDNA. Instead, given a 
range of 6.5-55.6%, we used the same cut-off (50%), previously used for the tissue 
DNA. Further discussion of the potential reasons for the 100% methylation result for 
TR2 and HC2 cfDNA follows below. 
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Figure 5.15 Methylation of cfDNA in healthy controls 
 
Figure 5.15: This Figure shows the level of methylated DNA in healthy control cell-free DNA 
(cfDNA). As can be seen, all DNA is digested in TR1, but not in TR2. Data for HC2, TR2, were 
quite unexpected and will be further discussed in the Discussion section, for the purpose of 
setting a threshold these data were ignored and a baseline level of disease associated 
methylation assumed to be at 50% as previously for the tumour samples. 
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Table 5.2 Calculated ddPCR concentration for healthy control cfDNA 
Sample 
Number 
Concentration 
TR1 
Undigested 
(cp/μL) 
Methylation 
Percentage 
TR1 
Concentration 
TR2 
Undigested 
(cp/μL) 
Methylation 
Percentage 
TR2 
HC1 33 0.0 90 55.6 
HC2 27 0.0 83 100.0 
HC3 40 0.0 344 16.3 
HC4 20 0.0 77 6.5 
HC5 18 0.0 27 29.6 
HC6 27 0.0 31 22.6 
 
 
5.3.12 TR1 and TR2 methylation analysis of patient cfDNA 
After establishing that there is no background methylation for the TR1 assay and using a 
cut-point of 50% for likely disease associated methylation for TR2 assay, cfDNA was 
extracted from 13 patient samples and assayed for TR1 and TR2 methylation. The 
outcome of TR1 and TR2 methylation analysis of the patient cfDNA samples is 
presented in Figure 5.16. The TR1 assay detected methylation in 6 of 13 (46%) of 
cfDNA samples which is nearly identical to TR1 detection of methylation found in 
tumour tissue DNA of 45% (9/20) as presented above.  
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After normalisation, methylation was detected with the TR2 assay for 69% (9/13) 
cfDNA patient samples. That value compares with 60% (12/20) of patient tumour tissue 
samples having TR2 methylation. Thirty-eight percent of cfDNA samples (5/13) 
showed methylation with both assays and that compares to 35% of tumour tissue 
samples (7/20). 
Interestingly, despite the near match of the proportion of samples found methylated for 
TR1 or TR2, when comparing the patient cohort analysed using cfDNA with the one 
analysed using tumour tissue DNA, in our small cfDNA patient cohort there appears to 
be no relation between PFS and OS of the patients tested methylation positive by 
cfDNA (see Figure 5.17), which appears to contrast with the tissue DNA data presented 
above. However, it should be noted that the same patient cohort was not used for the 
plasma samples as the tissue samples. While treatment did largely consist of surgery 
with adjuvant radiotherapy and TMZ, 10 of the 15 patients were being treated with 
experimental or additional treatments, meaning that statistical analysis of treatment-
limited patients was unfeasible. 
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Figure 5.16 Percentage of methylation in patient sample cfDNA for TR1 and TR2 
 
Figure 5.16: This figure shows data of patient cfDNA assays for TR1 and TR2. As can be seen, 
digestion is much more complete in TR1 than in TR2. Based upon the healthy controls, a cut-off 
of 50% methylation was as normalisation for the TR2 assay data. 
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Table 5.3 Calculated ddPCR concentration for patient sample cfDNA 
Patient 
Sample 
Concentration 
TR1 
Undigested 
(cp/μL) 
Methylation 
Percentage 
TR1 
Concentration 
TR2 
Undigested 
(cp/μL) 
Methylation 
Percentage 
TR2 
P1 21 0.0 74 93.2 
P2 76 0.0 156 54.5 
P3 11 9.1 90 64.4 
P4 107 0.0 221 72.4 
P5 29 3.4 81 100.0 
P6 17 5.9 99 61.6 
P7 14 7.1 69 78.3 
P8 15 0.0 94 12.8 
P9 159 0.6 258 18.6 
P10 42 0.0 59 33.9 
P11 18 0.0 2027 0.5 
P12 11 0.0 20 80 
P13 14 14.3 19 84.2 
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Figure 5.17 PFS and OS of patients based upon methylation in TR1 and TR2 
 
Figure 5.17: This figure shows data for the TR1 and TR2 analysis from cfDNA (n=13), 
respectively the PFS (5.17a and 5.17c) and OS (5.17b and 5.17d) of the cfDNA patient 
samples, with division into methylated and unmethylated samples based upon the outcomes 
from 5.16. As can be seen, there is no clear division between the methylated or unmethylated 
samples for either TR1 (for PFS p=0.481, for OS p=0.796) or TR2 (for PFS p=0.423, for OS 
p=0.271). For the methylated in TR1 samples, n=6; for the unmethylated samples, n=7. For 
TR2, for the methylated samples, n=9, for the unmethylated samples, n=4. 
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5.3.13 Comparison of Therascreen and Endonuclease Methylation Measurement 
The current diagnostic method to detect MGMT promoter methylation for Liverpool 
Hospital patients is the Therasceen. Data from this screen were available for some of the 
patients tested here using TR1 or TR2. To compare analysis of GBM tissue samples 
Figure 5.18a and Figure 5.18c show that patient PFS for both the Therascreen and TR1 
endonuclease digestion methods are similar. PFS for the methylated and unmethylated 
populations in both groups are significantly different (P=0.0053 and P=0.0020 
respectively). It should be noted that the P-value for the PFS for the TR1 endonuclease 
digestion is slightly lower than that for the Therascreen. 
For the OS of Therascreen and endonuclease methylation measurement methods, as can 
be seen in Figures 5.18b and Figure 5.18d, the calculated outcomes are again similar. 
However, in this case, the OS of the Therascreen method just fails to reach statistical 
significance (P=0.0709), while the OS for the TR1 methylation measurement is 
(P=0.0361). 
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Figure 5.18 PFS and OS of Therascreen and TR1 Restriction Endonuclease 
Digestion 
 
Figure 5.18: This compares the PFS and OS for patients segregated by MGMT methylation 
status as measured from tissue DNA (TR1) compared to available outcomes from the clinical 
test for the same patients. Figure 5.18a shows PFS using the clinical Therascreen test 
(P=0.0053). Figure 5.18b shows OS using the clinical Therascreen test (P=0.0709). Figure 
5.18c shows PFS using the TR1 digestion (P=0.0020). Figure 5.18d shows the OS using the 
TR1 digestion (P=0.0361) 
 
In addition, a similar comparison was made for the patient data using the clinical test 
and the cfDNA data described in section 5.3.12. Figure 5.19 shows the comparison 
despite only 5 patients from the patient cohort having clinical MGMT promoter 
methylation test data available. While the P values for the PFS analysis in the ctDNA 
test were slightly lower than with the clinical test, patient numbers are too small to draw 
conclusions. 
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Figure 5.19 Comparison of PFS and OS for the clinical tissue test and the ctDNA 
test 
 
Figure 5.19: This figure shows the comparison between the diagnostic MGMT methylation 
analysis (from tissue) compared to ctDNA-based analysis from the same patients. Figure 5.19a 
shows the PFS of the population divided by MGMT methylation positivity with the clinical test 
(P=0.7822) and Figure 5.19b shows the OS (P=0.0833). Figure 5.19c shows the PFS of the 
population divided according to MGMT methylation detected using the established ctDNA test 
(P=0.1937) and Figure 5.19d shows the OS (P=0.5637). 
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5.4 Discussion 
This chapter is focussed on the development of a highly sensitive, novel method for the 
analysis of DNA methylation in the MGMT promoter region, that can be used for liquid 
biopsy derived DNA, especially for patients where other sources of tumour DNA are 
not readily available. 
 
 
5.4.1 Method development 
Several regions in the MGMT promoter were identified with priority given to those that 
had previously been shown to be methylated when analysing tumour tissue or cell 
lines204,205. Additionally, since a methylation sensitive restriction digest and ddPCR-
based method was to be developed the regions to be analysed had to have relevant 
restriction sites. While that resulted in three candidate regions for assays to be 
developed, one region was not amplifiable by to PCR using our approaches, most likely 
explained by the extremely high GC content in that area (greater than 70%) compared to 
TR1. ddPCR assays were successfully developed for two regions, TR1 and TR2, and 
multiplexing for these assays was developed and used for most of the data presented 
here. The ability to multiplex is important as it saves cfDNA sample, which can then be 
used for other biomarker assays as presented in the next chapter. Importantly, TR2 
contains in its entirety, the genetic region currently analysed using the clinically 
approved assay that uses bisulphite conversion to detect methylation, TR2 extends 
upstream and downstream of that region204,208. 
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Overall ddPCR data for the TR1 assay are more robust. Firstly, it produces very good 
separation of positive and negative events during ddPCR (see Figure 5.3) and secondly, 
the efficiency of the involved digest is consistently very high, suggesting there is no or 
minimal background methylation in healthy human DNA in that MGMT promoter 
region. For the TR2 assay the ddPCR separation of positive and negative events is less 
convincing and the assay produces what is apparent in the dot blot images (see Figure 
5.3) as some amount of ‘rain’ of the positive droplet population indicated as green dots 
towards the negative population shown as black dots. The explanation is that the 
positive droplet population has a wide distribution of amplitude. Usually, highly 
efficient ddPCR assays do not have this ‘rain’ issue, which is in general interpreted as 
being a result of PCR inhibitors in the reaction mixture, or a need for further 
optimisation of the annealing temperatures. Any attempts to ameliorate this problem, 
including the annealing temperature optimisation, had little effect on the overall 
outcomes. Therefore, the best working TR2 PCR conditions were used for the 
multiplexed assay as the more robust TR1 worked well with those. The exact reason for 
the TR2 assay working somewhat less efficiently is hard to pinpoint. It may involve 
poor denaturing of GC rich DNA in the PCR reaction, while general presence of PCR 
inhibitors or limiting availability of components such as nucleotides are unlikely 
explanations because the TR1 assay in the same multiplex reaction mix consistently 
worked robustly. 
In addition, as seen in Figures 5.4d and 5.5b, there is a significant remainder of TR2 
DNA following digestion of hgDNA. This most likely indicates presence of a baseline 
level of methylation in normal human DNA in this MGMT promoter region. This is not 
surprising since promoter methylation is a mechanism for gene expression regulation in 
normal cells even if commonly used by cancer cells for their advantage. It also parallels 
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data from the commercial diagnostic assay, which assumes methylation of up to 30% of 
the TR2 genetic region is normal and not disease related23. Regardless, there may also 
be other reasons for inefficiency of the restriction enzyme digestion in the TR2 region. 
For example restriction digests, although targeted to highly sequence specific restriction 
sites can be affected by the sequences adjacent to these minimal restriction sites155,156. 
Differences in sequences around the restriction sites might help explain why the 
digestion of TR2 consistently was incomplete while TR1 with the same enzymes, in the 
same reaction mix consistently worked well, although this would likely not explain all 
the difference as seen by the largely complete digestion of the TR2 standard amplicon, 
though interestingly, even the TR2 standards had some (1%) DNA remaining post 
digest, suggesting low-level methylation. This finding is puzzling, since that DNA was 
synthesised without any methylated nucleotides and should be totally methylation free. 
hgDNA showed a higher proportion of DNA remaining post digest (8%), suggesting 
some real background methylation in hgDNA, above that seen in the standard. 
To confirm our observations, healthy brain tissue genomic DNA should be tested to 
clarify what background methylation TR1 and TR2 assays detect in the MGMT 
promoter. However, we did not have access to normal brain tissue for such a test, and 
DNA from other human tissues may not reflect the normal level of MGMT promoter 
methylation of brain tissue. 
  
While the TR1 assay is very robust, the TR2 assay ddPCR is less efficient and the lack 
of clear differentiation between the positive and negative event populations affects 
accurate measurement of the concentration of DNA in the sample. Furthermore, and 
independent of that, the restriction digest consistently leads to incomplete cleavage of 
human TR2 DNA, which we interpret at least in part as real background methylation in 
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healthy tissue DNA. Nevertheless, this assay may still be useful as long as a careful 
threshold can be determined to test for cancer specific methylation. It also is relevant to 
compare this potentially less useful assay with the currently used diagnostic assay that 
analyses the same genetic region with a different method. 
 
As mentioned in the introduction (chapter 1, Circulating tumour DNA, page 20) there is 
a limited amount of DNA available from ctDNA, one study finding less than 10 mutant 
fragments of brain cancer DNA per 5 mL of blood, significantly lower than most other 
types of cancer122. Due to this low level of cfDNA available, any method of detecting 
and measuring GBM ctDNA must be both sensitive and accurate. 
For these reasons, a better form of control was necessary. Manufactured standards were 
determined to be useful as the methylation of the standards could be controlled, unlike 
in the commercial hgDNA used initially for control purposes. Synthesis results in 
double stranded DNA sequences encompassing the exact genetic region amplified as 
TR1 or TR2 from human DNA with either complete methylation of all methylation sites 
or complete lack of methylation. To be able to judge whether these strict requirements 
are indeed fulfilled, several tests were performed. 
The Agilent BioAnalyser was used to determine components of the standard solution 
and all samples gave a signal that indicated that there was DNA present of the expected 
size for both regions, seen as one strong peak. Also as expected, methylated TR1 and 
TR2 standards appeared to be longer; this is because the BioAnalyser is calibrated 
according to number of base pairs and the same molecule will “appear” to be longer if 
methylated versus non-methylated (see Figure 5.6). 
Final confirmation of the size and purity of the standards was performed using a 
Shimadzu HPLC. There were small impurities in the standards, which could potentially 
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explain the large range of fluorescence that was present in the ddPCR results for the 
standards (see Figure 5.8). Even following HPLC purification, there was still an obvious 
shoulder to the left of the main peak of the standard (that is, the main peak was clearly 
asymmetrical), (see Figure 5.7b). Given the manufacturing method used for the 
standards, it is likely that a small fraction of single-stranded DNA standards have not 
annealed correctly. 
Nevertheless, the standards were then analysed in the same manner as the hgDNA 
controls by ddPCR and the small potential presence of non-renatured DNA did not seem 
to interfere. Figure 5.8 shows the standards were successfully measured using ddPCR. 
This gives an indication that the target regions can be correctly analysed by the methods 
used, and successful ddPCR detection also confirms the sequence identify the 
manufactured standards being identical to the TR1 and TR2 regions in hgDNA. 
Following this, the digestion of the target regions had to be examined to determine if 
any of the unmethylated TR2 DNA would remain undigested. As can be seen in Figure 
5.9f, the digestion of the unmethylated TR2 DNA standard was almost complete, 
suggesting that the previously observed lack of digestion seen in human DNA (see 
Figures 5.4d and 5.5b) is due to a baseline level of methylation. For comparison, Figure 
5.9 shows the total undigested DNA for both the standards and hgDNA. As can be seen, 
in both the amplicon and hgDNA, approximately 99.9% of the DNA is digested in TR1. 
By comparison, for TR2, approximately 1% of the DNA remains. In contrast, between 
6% to 8% of the DNA remains following digestion of hgDNA. This would suggest that, 
irrespective of the inefficiency of the digest in this region even for highly controlled 
non-methylated DNA, that there is indeed a requirement in our study for a threshold 
above which we can consider patient samples to be positive in TR2, although this risks 
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some false negatives if a patient sample contains MGMT promoter methylation 
sufficient for regulation of gene expression, but not enough to register in this assay. 
While this has not been examined specifically in healthy controls for brain cancer 
previously, other research performed in colon cancer does suggest that there is a 
baseline level of methylation, even in the DNA of cells that still have MGMT 
expression209. In addition, another study examining the levels of MGMT promoter 
methylation in PBMCs found that there is a relatively high level of methylated DNA, 
consistent with the results that are shown in Figures 5.4d and 5.5b210. 
We conclude that the amplicons, even if the digestion of TR2 was slightly inefficient, 
could serve as confirmation of the accuracy of the digestion process to measure 
methylation. 
This contributed to the final interpretation of the TR2 results from the hgDNA in that it 
was clear that a reliable limit of detection, or digestion efficiency, would be impossible 
to calculate, since the methylated remainder would obfuscate the results. Our choice of 
50% methylation as a cut-off to discriminate likely disease related from healthy TR2 
methylation detection was somewhat arbitrary, based upon the 30% threshold of the 
current diagnostic test combined with the understanding of the higher detected level of 
methylation using restriction enzymes versus bisulphite conversion, and based upon our 
knowledge of patient methylation from the clinical assay. 
In a comparison of the two assays, it was clear that the assay for TR1 was more efficient 
for digestion and detection (see Figure 5.4a and 5.4b). However, TR1 is not directly 
comparable with the currently used and validated clinical assay as it targets a different 
genetic locus. 
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5.4.2 Testing the TR1 and TR2 methylation assays in human tumour tissue 
samples  
Following the development of the methylation assays, we wished to validate them using 
DNA extracted from patient brain tumour tissue. DNA from 20 patients (largely 
comprising GBM, but one patient had grade 3 astrocytoma) was tested for methylation 
at MGMT promoter region TR1 and TR2 using the ddPCR assays.  
For 15 patients, the methylation status of their tumour was known. Concordance 
between the two novel tests and previously provided results was 80% (12/15) for TR1 
alone and 47% (7/15) for TR2 alone, whereas combined detection at TR1 and TR2 
matched for 40% (6/15) of patients. Overall, we consider this as high concordance for 
several reasons: the different methylation detection prinicipals, the inclusion and 
distinction between genetic region TR1 and TR2 in our novel assay, and the different 
tumours or different parts of the same tumours (since heterogeneity is highly likely 
within the tumour and due to varying ratios of included normal tissue) assayed. While 
test outcomes can vary when performed on biopsies from different time points, brain 
surgery is rarely undertaken repeatedly, and our samples were taken, almost entirely, 
from patients undergoing a first-time surgery for GBM, which would be the samples 
that tests were performed on. Similar discrepancies have been reported in other 
examinations of patterns of MGMT promoter methylation211,212.  
For the TR1 assay, as can be seen in Figure 5.18, the P-value calculated for the PFS and 
OS are very similar to that of the clinical assay, if not a little lower. This means that, 
based upon the samples shown here, that the TR1 assay is at least equal to the clinical 
assay. 
 
  165 
Interestingly, in a prior study that correlated patient outcomes and concordance between 
methylation at different MGMT promoter regions including regions overlapping with 
TR1 and TR2 showed that both sites may be differentially methylated 204, which we also 
observed in our samples. In the previous study, regardless of whether methylation 
occurred at TR1 or TR2, both seem to affect MGMT expression in a similar way 204. If 
these findings can be replicated, the implication would be that distinguishing between 
TR1 and TR2 may not provide additional information, since both would have similar 
prognostic value. 
 
Nevertheless, the importance of TR1 versus TR2 is best assessed by correlation with 
disease outcome in patient samples. Nearly all advanced brain cancer patients are 
treated with TMZ as discussed in chapter 1, Biomarkers in Glioblastoma, therefore it is 
a valid assumption that the improved OS and PFS seen for patients with tumour tissue 
DNA determined to be methylated by the TR1 assay may be at least in part be due to 
repression of the MGMT promoter. This cannot be assumed for patients with TR2 
methylation in our dataset, given its lack of correlation with better survival outcomes. 
However, no firm conclusions can be drawn, as only 15 patients had MGMT promoter 
methylation status previously available from traditional methods, which we take to be 
the gold standard. 
As patient treatment may have also skewed the results for the patient population, 
survival curves, for both OS and PFS, were also analysed via the Kaplan Meier method 
to determine if the assays were truly indicative of the patient outcomes. As can be seen 
from Figures 5.13e, PFS is still predicted by methylation of TR1 (P=0.039). For OS, 
TR1 methylation still demonstrates a trend towards significance, but does not achieve it 
(P=0.053). However, through modelling, it can be determined that this is likely an effect 
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of the small number of unmethylated patients within the cohort (n=4). One of the 
unmethylated patients had a much higher OS than the mean for the unmethylated patient 
population. The addition of a single patient with the mean OS to the unmethylated 
patient population would mean that there is a significant difference between the 
methylated and unmethylated populations in terms of OS. 
For TR2, however, neither OS (P=0.701) nor PFS (P=0.054) was statistically 
significant. In addition, modelling does not indicate that a trend might be formed with 
the addition of more patients to the cohort (though it must be stressed this does not 
preclude the possibility). Due to the small number of patients in the cohort, this 
analsysis in particular will need to be repeated with a larger cohort of patients.  
 
Part of the reason that a positive TR2 assay showed little correlation with disease 
outcome may be that this assay is less robust than the TR1 assay; another explanation 
may be the arbitrary threshold definition of 50%. We originally chose 50% cut-off as a 
conservative assumption of disease correlation for any methylation detected with the 
TR2 assay, but this may not have been conservative enough. Since methylation is a 
physiological way of regulating gene expression (see chapter 1, Methylation and 
Methylation Detection Methods, page 29) and since our data suggest at least some 
normal background methylation of the TR2 MGMT promoter region, the only way to be 
able to set a well-defined threshold for this assay would be to test DNA methylation 
with our TR2 assay from normal brain tissue from a reasonable size cohort of 
individuals. It would however be extremely difficult to access such samples, since brain 
surgery is normally only indicated for diseases of the brain, and the diseased brain, even 
if “normal” by histology, may have very different background methylation for the 
analysed DNA region. 
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Further, although our TR2 assay represents the same region as the currently used 
diagnostic test in fixed paraffin tissues by pathologists, in our small patient cohort, 
methylation in the TR1 region alone is highly associated with disease outcome, while 
methylation found in the TR2 region alone is not informative. Further, we found that 
detection of methylation with both assays adds little in regard to survival prediction, in 
comparison to methylation detection with the TR1 assay alone. Clearly, these findings 
need to be confirmed in a much larger patient cohort, but if it were confirmed, the TR2 
assay may be redundant, which would question the validity of the current tissue 
methylation detection methodology used by pathologists. Our data indicate that, for the 
TR1 assay, no threshold level is necessary. However, this needs confirmation using 
healthy brain tissue DNA, with the caveats on “normal” brain tissue testing as 
previously discussed above. 
 
 
5.4.3 Testing the TR1 and TR2 methylation assays in human cfDNA samples  
Using our TR1 and TR2 assays to assess methylation in plasma derived cfDNA was 
challenging. As outlined in chapter 1, Circulating Tumour DNA, page 20 ctDNA only 
makes up a very small amount of total cfDNA, and due to the blood brain barrier, the 
expected amount of ctDNA for brain cancer patients is even lower122. Therefore, our 
initial question was whether we could detect any TR1 or TR2 methylation in cfDNA in 
patients, along with any background methylation in healthy control cfDNA. Again, the 
TR1 assay proved more reliable, as matching our data from hgDNA and TR1 standard 
DNA showed that no methylation was detected in cfDNA samples from six different 
healthy donors. On the other hand, the TR2 assay detected some degree of methylation 
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in all samples. What was more surprising was that background DNA methylation, as 
defined by the TR2 assay, was extremely variable in the control cfDNAs from the six 
healthy donors, varying, in absolute terms, between 10-100%. Most samples (5/6) had 
around or less than 50% DNA methylation compared to total DNA detected by the TR2 
assay. However, one control sample had 100% background methylation detected by the 
TR2 assay. We assumed this to be an artefact, as the alternative would have been to 
judge the TR2 assay as unreliable due this one healthy control sample. Consequnetly, 
we set 50% methylation as the threshold (as can be seen in Figure 5.16, where the 
methylation values given for the TR2 cfDNA represent the percentage of methylation 
over 50%). 
 
We are unable to explain the 100% methylation reading of sample HC2, since it is 
difficult to argue that the DNA digest simply did not work for that sample, because the 
TR1 assay digest worked in the same reaction mix with the same enzymes at the same 
time. Restriction digests are sensitive to some reaction conditions such as ionic strength 
and pH and it was already highlighted that possibly the DNA sequences adjacent to the 
restriction site make the digest functioning less optimal for TR2 than TR1. Maybe some 
of these factors together combined in providing poor digest conditions for TR2 while 
still allowing TR1 digest, but this is not really a convincing explanation. Unfortunately, 
the amount of cfDNA was limited (some cfDNA of that sample had already been used 
for other assays) and therefore a repeat experiment could not be done with that sample. 
We must also consider the possibility that the result is real and that this healthy donor 
had, at least at the time of blood draw, completely methylated TR2 cfDNA in their 
plasma. That would raise the question whether TR2 methylation presents a pathogenic 
result in this case and it would be interesting to evaluate whether methylation of TR2 in 
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cfDNA was a temporary event for this healthy control individual. If methylation of TR2 
was really 100% for this individual it would likely exclude the utility of the TR2 assay 
for MGMT methylation testing of cfDNA unless the individual had an undetected 
malignancy at the time (which is considered unlikely). Testing of a larger cohort of 
healthy control blood donors could clarify the range of TR2 methylation in cfDNA. 
 
The question of background DNA methylation found in liquid biopsies is worth 
considering. Most studies of methylation have not compared normal tissue matched 
DNA, while one study actively avoided them because healthy controls in prior studies 
had not demonstrated any background methylation116. A study that examined the 
methylation of MGMT in both patient tissue and plasma did manage to successfully 
find methylated MGMT promoter markers in 41.4% in the patients’ ctDNA. They found 
methylation in 60.4% of their tissue DNA, with a concordance ratio of 0.75 between the 
ctDNA and the tissue DNA. It is important to note, however, that they likewise made no 
mention of healthy controls, although their project involved samples being taken before 
treatment began, which might have increased the amount of ctDNA available, based 
upon previous reporting of reductions in ctDNA as treatment progresses88,116.  
Notably, our analysis found promoter methylation of MGMT for TR1 in roughly the 
same proportion as the above study (38% of samples, compared to 41.4% for the 
above). However, the above study still found a correlation between patient outcomes 
and the methylation status in the plasma. 
TR2 demonstrated a very high level of methylation, such that the proportion of samples 
that were found to be methylated, even after normalisation, was 69.2%. 
This emphasises the need for a baseline level of methylation in our study, as if we had 
set the level of DNA methylation for the TR2 assay to be an indicator of clinical 
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outcome in GBM at 30% (as is the case for the current diagnostic assay of that genetic 
region), then several of the healthy controls would have nearly, or actually, exceeded 
the threshold. It is possible, given the difference in methylation amount between this 
and the previous work, that the threshold needs to be set even higher. This would 
require more healthy controls to validate. 
 
There have been no studies of baseline DNA methylation in brain cancer. However, a 
study in renal cancer patients did find that MGMT promoter methylation in the serum 
increased in cancer patients compared to healthy controls, based upon the ratio of 
methylated MGMT promoter compared to methylated β-actin213. Our own discrepancies 
in the detection of DNA methylation between the TR1 and TR2 assays, and the 
differences between methylation found in previous examinations of the various CpG 
islands in the MGMT promoter region, is consistent with the literature204. 
 
Methylation with the TR1 assay was detected in 46% of patients cfDNA. The 
proportion of TR1 methylated cfDNA was always relatively small. This is expected as 
ctDNA especially in brain cancer patients makes only up a very small proportion of 
cfDNA. Also, given that no methylation was found in healthy donor cfDNA with the 
same assay, we are confident this represents a real result. However, although data from 
our work implies very good efficiency of the digestion process for TR1 and it always 
worked to completion for all unmethylated DNAs in our hands it raises the question 
how confidently methylation positivity can be reported when only measuring effectively 
1 -5 positive events using ddPCR. There remains a small theoretical chance that 
inefficiency of even the TR1 digestion process could occur due to sample specifics and 
may play a role in detecting false positive DNA methylation. 
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To better control for digestion efficiency, it may be possible to design a control DNA 
molecule that could be spiked into each reaction and then be detected with its own 
primers and probe. If that molecule had identical restriction sites and adjacent 
sequences, it should be just as well digested as the TR1 region. Further, if future testing 
indicates multiplexing the TR1 assay with the TR2 assay is not diagnostically relevant, 
such a spiked-in molecule could function as internal control by being instead of TR2 
multiplexed with TR1. 
For our small patient cohort, we did not find any overall survival correlation with 
cfDNA methylation detection by TR1, TR2 or both assays, while there may be a slight 
trend towards better PFS for patients with cfDNA detected methylation, especially with 
the TR2 assay. No statistical significance was found however, and unlike for the tissue 
samples, limited modelling did not indicate that further samples would make the 
outcomes significant. Future work needs to examine larger patient cohorts to clarify if 
these highly sensitive assays are able to predict survival differences for patients from 
liquid biopsies. 
A further limitation of our patient cohort was that there is insufficient information on 
the MGMT promoter methylation status using the clinical test to truly compare the two 
methods. While, as can be seen in Figures 5.19a and 5.19c, the P value for the PFS is 
lower in the ctDNA data, there is likely due to the extremely small sample size, and this 
trend is reversed in the OS P values, as seen in Figures 5.19b and 5.19d. Future 
validation of this method would benefit from a greater number of patient samples taken 
from patients whose MGMT promoter methylation status has already been determined 
through the clinical test. 
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5.5 Conclusion  
In this chapter, two highly sensitive assays were established to detect methylation of the 
MGMT promoter at two distinct genetic regions. Both methylation sensitive restriction 
enzyme-based assays have been multiplexed in a single ddPCR reaction and thus rely 
on very small amounts of input DNA. Methylation was successfully detected in brain 
cancer tumour tissue, and we found that TR1 and TR1/TR2 methylation detection 
correlated clearly with better OS and PFS, despite the small cohort. For the subset of 
patients that had previously available MGMT methylation data from the currently used 
diagnostic assay, the data indicate that our novel assay may indeed be better in 
predicting survival. This however needs to be confirmed in larger patient cohorts. The 
assays were also used successfully to detect MGMT methylation in cfDNA samples 
from brain cancer patients and the frequency of positive findings correlated well with 
patient tissue DNA. However, in our small patient cohort, no correlation with survival 
was found for the methylation detected in patient cfDNA. Larger studies are needed to 
better evaluate these assays in cfDNA and clarify whether there is a correlation of liquid 
biopsy MGMT promoter methylation detection and GBM patient survival. 
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6  Detection of IDH1 mutations in cfDNA 
6.1 Introduction 
An important marker for outcomes in GBM is isocitrate dehydrogenase 1 (IDH1). This 
is an enzyme that is involved in the reversal of oxidative damage40. Mutations of IDH1 
are associated with increased OS and PFS in GBM. They are also predominantly 
associated with secondary GBM, which has a longer PFS and OS41. In GBM 
approximately 85% of the mutations in IDH1 is a guanine to adenine change at codon 
132 of the IDH1 gene, causing an argenine to histidine change (IDH1-R132H)31. 
Testing for this common mutation can easily segregate patient populations based upon 
prognosis, making it one of the more important tests that can be run in order to inform 
the patient’s care214. 
However, the difficulties in obtaining this information are identical to that of other 
biomarkers in GBM, namely remoteness of tumour tissue to the current clinical scenario 
and the inaccessibility of the tumour in some patients, as outlined in chapter 1, Novel 
Biomarkers, page 11. This chapter describes a method for the analysis of DNA for the 
presence of the IDH1-R132H, and subsequently use of this method in order to analyse 
DNA that has undergone whole genome amplification (WGA) from a single CTC, and 
to analyse cfDNA from patients. 
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6.2 Methods 
6.2.1 Cell line culture and harvesting 
The cell lines A172 (IDH1 wild type) and BT142 (hemizygous IDH1-R132H) were 
chosen for use in the experiments, as BT142 is the only cell line to express the IDH1-
R132H mutation naturally, and A172 was an easily available cell line from other 
experiments that was known to have the wild-type IDH1 gene (see Table 6.1). Adherent 
A172 cells were cultured for 72 h in DMEM media with 10% FBS and 1mM glutamine 
after routine passaging to obtain a confluence of roughly 80% in the cells lines. A172 
cells were harvested for use in experiments with incubation in 0.2 mM EDTA in PBS 
for five min, followed by repeated pipetting to detach the cells. Semi-suspension sphere 
BT142 cells were cultured for 72 h in Neurocult media after routine passaging with 20 
ng/mL human Epidermal Growth Factor; 100 ng/mL platelet-derived growth factor; 20 
ng/mL Fibroblast growth factor; and 2 µg/mL heparin sulphate. Semi-attached cells 
were harvested by pipetting with growth media which provided sufficient force to 
remove them from the tissue culture dish.  
After harvest cells were centrifuged at 300 xg for 5 min and the supernatant was 
discarded. 
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Table 6.1 Cell line data for chapter 6 
Cell Line Mutations Origin 
A172 EGFR (Substitution, 
position 3159 T->C) 
Primary glioma, 53-year 
old male. 
BT142 IDH1-R132H Oligoastrocytoma, Grade 
III, 38-year old male. 
Data for the A172 cell line was taken from the COSMIC somatic cancer cell database166. 
Data for the BT142 cell line was taken from the ATCC website215. 
 
 
6.2.2 Cell line DNA extraction 
Cell line DNA was extracted using the Isolate II Genomic DNA kit [Bioline]. 107 cells 
were resuspended in 200 µL of the included lysis buffer GL, 25 µL proteinase K and 
200 µL lysis buffer G3. Cells were incubated at 70° C for 15 min. Cells were then 
vortexed for 15 s, and 210 µL of ethanol (96-100%) was added, followed by further 
vortexing for 15 s. A spin column [Bioline] was placed in a 2 mL collection tube 
[Bioline]. The sample was pipetted into the spin column and centrifuged at 11 000 x g 
for 1 min. 500 µL of buffer GW1 was added to the column. Then the column was 
centrifuged for 1 min at 11 000 x g. 600 µL of buffer GW2 was added and centrifuged 
at 11 000 x g. After discarding flow-through, the spin column and collection tube were 
centrifuged at 11 000 x g for 1 min. The spin column was then transferred to a 1.5 mL 
tube. 100 µL of elution buffer was heated to 70° C and added to the spin column. The 
column was then incubated at room temperature for 1 min, then centrifuged for 1 min at 
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11 000 x g. DNA concentrations were determined by NanoDrop [Thermofisher 
Scientific]. 
 
 
6.2.3 IDH1 ddPCR  
Primers and probes for the IDH1 wild type and R132H mutation were designed using 
the NIH primer blast online software (see Table 6.2 for sequences). The IDH1 wild type 
probe used a HEX dye. The IDH1-R132H probe used a FAM dye. Both used a BHQ1 
quencher. The optimum annealing temperature was determined using a gradient 
temperature ddPCR, otherwise employing the standard protocol for the BioRad QX200 
instruments (see Chapter 2, ddPCR). Optimised PCR conditions were as follows:  
1. Initial denaturation: 95° C 10 min. 
2. Denaturation: 94 C 30 s. 
3. Annealing: 53° C 1 min. 
4. Repeat steps 2 and 3 40 times. 
5. Final extension: 98° C 10 min. 
Data were analysed with the Quantasoft software. 
 
Table 6.2 IDH1 primers and probes 
DNA Product Sequence (5'->3') Length bp 
Forward Primer CTTGTGAGTGGATGGGTAAAACCTA 25 
Reverse Primer CCAACATGACTTACTTGATCCCCATA 26 
Wild-Type Probe CATCATAGGTCGTCATGC 18 
Mutant Probe CATCATAGGTCATCATGC 18 
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6.2.4 Whole genome amplification 
CTCs were isolated as described in chapter 3 of this thesis and single CTCs picked 
using the ALS CellCelector (see Chapter 2 for technical details). Single CTCs were 
WGA amplified using initially the GenomePlex Whole Genome Amplification Kit 
[Sigma Aldrich] and later the Ampli1 kit [Silicone Biosystems, Bologna, Italy]. 
 
 
6.2.5 Patient data 
Patient data regarding type and stage of brain cancer and previous diagnostic IDH1-
R132H test results were obtained from our collaborators (see Table 6.3). 
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Table 6.3 Patient Characteristics 
Patient 
Number 
IDH1 status Treatment 
begun at time of 
collection 
P1 Mutant No 
P2 Unknown Yes 
P3 Unknown Unknown 
P4 Wild type Yes 
P5 Wild type Yes 
P6 Unknown Yes 
P7 Wild type No 
P8 Wild type No 
P9 Unknown No 
P10 Wild type Yes 
P11 Wild type No 
P12 Mutant Yes 
P13 Wild type No 
P14 Wild type Yes 
P15 Wild type Yes 
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6.3 Results 
6.3.1 IDH1-R132H ddPCR assay 
The assay to detect IDH1-R132H has been previously established in our laboratory. In 
brief, primers and an IDH1-R132H mutant specific Taqman probe conjugated to 6-FAM 
as well as an IDH1 wild type Taqman probe conjugated to HEX were developed and the 
assay was optimised using gDNA from the cell line BT142 (hemizygous for IDH1-
R132H) as well as wild type gDNA. (see Figure 6.1216). 
The limit of detection for mutant DNA in a background of wild type DNA was 
determined by spiking BT142 gDNA (IDH1-R132H) into an equal amount of IDH1 
wild type PBMC gDNA (see Figure 6.1a). When spiking 6 pg of BT142 gDNA (the 
amount theoretically attributed to 2 cells) into the equivalent of wild type gDNA 
representing 4000 cells the expected small amounts of mutated DNA can be readily 
detected in a large background of control DNA (see Figure 6.1b).  
To confirm whether the IDH1-R132H mutation can be detected in single cells as 
planned for the analysis of CTCs, single BT142 cells or PBMC were picked into PCR 
tubes using the ALS CellCelector and DNA was amplified using WGA. WGA samples 
were analysed with the ddPCR assay. One, five or ten single BT142 cells allowed 
successful detection of the IDH1-R132H mutation using this strategy. Importantly, even 
if the cancer cells are combined with 10 normal PBMCs the mutation plus the wild type 
DNA originating from the PBMCs can be detected (see Figure 6.2). This suggests that 
there is a high sensitivity when using the BT-142 cell model, as the mutant DNA is 
detected at the same rate with and without the PBMCs.This is important, since when 
using real samples under non-optimal conditions, it may not always be possible to pick 
single CTCs without picking up one or two neighbouring lymphocytes in the process, 
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which would give a background signal against which the mutated DNA would need to 
be detected. As IDH1-R132H can be detected against the background of 4000 cells’ 
worth of DNA, the presence of two or three lymphocytes should not hinder detection 
unduly. BT142 cells contain one allele with the IDH1-R132H mutation, and the other 
allele is deleted (ergo no wild type DNA can be detected from the cells).  
 
Figure 6.1 IDH1 wild type and R132H ddPCR analysis 
 
Figure 6.1: Droplet digital PCR analysis of the IDH1 gene for both the wild type (green) and the 
IDH1-R132H mutation (blue, outlined in red). Figure 6.1a shows the detection of DNA when the 
input of both wild type and mutant DNA is equal. Figure 6.1b shows the detection of 1 cell’s 
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worth of mutant DNA in a background of 4000 cells worth of DNA of wild type. Limited crossover 
between the two assays (orange dots in the top right quadrant) was detected. Adapted from216  
 
Figure 6.2 Comparison of detection of IDH1 wild type and IDH1-R132H in WGA 
 
Figure 6.2: This figure shows the detection of IDH1-R132H from single cells using whole 
genome amplification (WGA) and ddPCR. As can be seen, IDH1-R132H can be detected from a 
single BT142 cell against a background of 10 PBMCs. Note BT142 cells are IDH1-R132H 
hemizygote, thus no wild type is detected in BT142 only samples. Taken from216 
 
 
6.3.2 IDH1-R132H in GBM: analysis of CTCs 
Single CTCs were detected and picked from 3 patient samples (with known IDH1-
R132H positivity) and DNA from CTCs was amplified using WGA in order to analyse 
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the DNA for the IDH1-R132H mutation. However, some inconsistencies with WGA 
reactions using initially the Sigma GenomePlex kit meant that there was no analysable 
DNA amplified from these reactions. Experiments that were run with the original Sigma 
GenomePlex kit would often fail to produce DNA. While failures in a procedure as 
delicate as amplifying DNA from a single cell are to be expected, this kit would allow 
perhaps 30% of experiments to succeed. After eliminating the possibility that the 
current kit was the cause of the effects, it was decided to trial a WGA kit from an 
entirely different company, to determine if it had better results. After confirming a 
significantly improved success rate (80% of experiments would now produce usable 
quantities of DNA at the end), the new WGA kit was used in place of the Sigma kit for 
all future experiments. 
Using the new Ampli1 WGA kit, DNA from a CTC of a patient with an IDH1 wild type 
GBM underwent WGA. As shown in Figure 6.3, while DNA was amplified successfully 
from this CTC, as expected, no IDH1-R132H DNA could be detected. Only wild type 
DNA was amplified. 
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Figure 6.3 Whole genome amplification of GBM CTC 
 
Figure 6.3: DNA was amplified from a single GBM CTC and analysed by ddPCR. As can be 
seen, only wild-type DNA (green) was detected. The patient was confirmed by histopathology to 
not be IDH1-R132H positive. 
 
 
6.3.3 Analysis of cfDNA for IDH1-R132H 
Extracted cfDNA (as described in Chapter 5) from six healthy control individuals and 
15 brain cancer patients was used for IDH1-R132H testing by ddPCR. ddPCR of 
cfDNA from the 6 healthy control individuals did not detect any IDH1 mutant events. 
When extracted cfDNA from patients was used for IDH1-R132H analysis, 14/15 
(93.3%) of patients were IDH1-R132H mutation negative by ddPCR, despite the fact 
that two of those patients were considered IDH1 positive according to diagnostic 
immunohistopathology. Two of the patients had yet to start treatment (which is when 
the tumour tissue used for the test would have been taken), which means that the state of 
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any cfDNA found would likely be similar to that found in the tumour tissue. It cannot 
be confirmed that there is tumour DNA in the cfDNA samples taken, owing to the lack 
of positive events. One of 15 patients had one positive IDH-R132H event detected 
during ddPCR of their cfDNA sample (shown in Figure 6.4c). However, this patient did 
not have IDH1 testing run at the time of analysis, though later tests confirmed that the 
patient was IDH1 negative. However, the detection of a single positive event, when 
none of the healthy controls displayed any, means that it should be regarded as a true 
positive. However, assuming that the known IDH1 mutation statuses are not affected by 
sensitivity or specificity issues of the clinical tests used to identify them, meaning they 
are indeed correct, it must be concluded that the specificity and sensitivity of our 
ddPCR test is 0% in this specific case, as it has not detected any mutant cfDNA in 
patients with known mutation positive GBM tissue, and detected a positive event in a 
patient’s cfDNA sample with a previous tissue IDH1 negative test. 
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Figure 6.4 Healthy controls and positive IDH1-R132H cfDNA detection 
 
Figure 6.4: The above figure shows the mutant (6.4a) and wild type IDH1 (6.4b) results for the 
IDH1-R132H ddPCR assay in 6 healthy controls. As can be seen, no mutant events are 
detected in the healthy controls, suggesting that any positive events are true positives for IDH1-
R132H. In 6.4c and 6.4d, there is a single representative patient sample with a positive IDH1-
R132H event, along with the results of IDH1 wild type analysis. As can be seen, there is a single 
IDH1-R132H event, and multiple wild type events. 
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6.4 Discussion 
6.4.1 CTC analysis for IDH1-R132H 
Currently, this is the first study isolating of GBM CTCs and performing DNA analysis 
for IDH1-R132H, although one study has examined cellular RNA expression by in-situ 
hybridisation, but that study did not investigate IDH1 expression or mutations108.  
In our laboratory, we developed a ddPCR based test that clearly detects the IDH1-
R132H mutation in single cells even in a background of 10 normal cells. This highlights 
that our ddPCR test is capable of detecting IDH1-R132H in single CTCs in light of our 
ability to amplify DNA from individual CTCs, even if the specific one shown in Figure 
6.3 only had wild-type DNA. 
In this work, detection of IDH1-R132H in patient derived CTCs was hampered by 
technical problems, specifically reproducibility and reliability of WGA reactions. This 
is consistent with a report that single cell WGA has a tendency towards errors, 
particularly in GC rich regions of the DNA, including allelic dropouts that can mask 
certain mutations and features of the DNA, errors that are compounded if only a single 
cell is available for amplification217. Further, only a limited number of patients known 
to be positive for IDH1-R132H by standard histopathogical methodologies were 
available. Therefore, although the ddPCR IDH1 mutation assay worked for one 
patient’s CTC, reliable, high quality CTC WGA samples could not be analysed from 
confirmed IDH1-R132H positive patients in the duration of this study. Future work with 
better quality CTC WGA samples is needed in our laboratory to detect the IDH1-
R132H mutation in patient CTCs using our assay. 
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6.4.2 Analysis of patient cfDNA for IDH1-R132H 
Testing our assay using cfDNA extracted from healthy controls was very encouraging 
as no false positive IDH1-R132H mutation ddPCR events were detected in healthy 
control samples. However, only 6.6% (1/15) patient derived cfDNA samples 
demonstrated the presence of IDH1-R132H. Moreover, detection was limited to only a 
single ddPCR mutant event. Despite the heterogeneity of GBM, the literature suggests 
that IDH1 mutations arise early in the disease, and thus tend to be expressed quite 
thoroughly throughout its course218. While the healthy control data indicate that the 
IDH1-R132H assay does not detect false positive events in cfDNA from six individuals, 
detecting more than one event in patient cfDNA would have provided more confidence 
to the result. Furthermore, two of the 15 patients tested for IDH1 mutation by ddPCR 
from cfDNA had previously been tested as IDH1-R132H positive, but this was not 
confirmed in any of the patient’s cfDNA samples. 
The samples could have been discordant due to a bias in the selected area of tumour 
tissue analysed (that is, tissue DNA analysis would have taken place on DNA from part 
of the tumour that was IDH1-132H positive, while any ctDNA detected could have 
come from IDH1 wild type tissue, or vice versa). In addition, the blood collection could 
have occurred at such a time as it was not possible to detect ctDNA, as ctDNA 
concentrations have been reported to change after treatment such as surgical 
resection219. 
As IDH1-R132H arises early in the development of the tumour220, it is likely that the 
presence of IDH1-R132H mutations would be consistent throughout the development of 
the disease. Alternatively, the data could mean that the mutant DNA detected was from 
a part of the tumour that was IDH1-R32H positive, while the tissue was IDH1 wild 
type. This is, of course, speculation, but is at least consistent with the notion of tumour 
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heterogeneity, which has been reported in some cases in regards to IDH1-R132H 
mutations221, suggesting the possibility of bias in the selection of tumour tissue. 
However, the most likely explanation for our lack of detection of the IDH1-R132H 
mutations in patients known to be positive is the lack of sensitivity of ctDNA detection 
from brain cancer patients (that is, the detection of DNA of a definite tumour origin), 
with the blood-brain-barrier lessening the amount of ctDNA in circulation. As shown in 
Figure 6.1, the IDH1-R132H assay that we have developed is able to identify small 
volumes of mutant DNA in large volumes of background DNA. Given that ctDNA is 
less detectable in GBM patients due to the blood brain barrier, the most likely 
explanation for not detecting the IDH1-R132H mutation is it not being present in 
plasma in high enough quantities to be detectable with our assay.  
An improvement that could be made to our methods would be to increase the 
concentration of DNA in the solution. This could be achieved by attempting to increase 
the volume of patient plasma used in the extraction process. The protocol for the 
extraction method used limits plasma volume to 3 mL; if this could be increased, then a 
larger amount of DNA could be extracted. 
In addition, this protocol could be expanded to include more patients with grade II and 
III gliomas. In these tumours, IDH1-R132H mutations are very common, occurring in 
64.0% to 72.7% of WHO grade II and III gliomas222, while in GBM (which 
compromised almost the totality of our patient cohort) IDH1 mutations occur in only 
6% of tumours41. 
In prior studies, ctDNA has been detected in the plasma of brain cancer patients. For 
example, one study confirmed detection of IDH1-R132H from cfDNA of 60% of 
patients and mutation detection appeared to be associated with larger tumour size 117. 
However, the concentration of ctDNA in the blood of glioma patients has been 
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previously reported to be low, approximately 10% that of other cancers, on average (for 
example, finding less than 10 mutant fragments in glioma per 5 mL of plasma, 
compared to more than one hundred for gastroesophogeal cancer)122. Further work is 
needed to yield better results. For instance, our study used only 3 mL of plasma to 
extract cfDNA. The above mentioned study that found IDH1-R132H used 4 mL of 
plasma117. The kit proven best in our laboratory to extract cfDNA207 can extract DNA 
from up to 3 mL plasma and theoretically could process more with reloading of 
columns. Currently we elute DNA in 60 µl and that could potentially be reduced to 
further concentrate DNA being put into the ddPCR assays. The maximum template 
input volume per ddPCR reaction is 7 µl and cannot be further increased, but there is the 
possibility to run several samples per cfDNA to effectively multiply the number of the 
ddPCR droplets analysed. These measures need to be tested in larger patient cohorts to 
better validate the IDH1 ddPCR assay, to obtain statistically reliable data. 
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6.5 Conclusion 
This chapter has presented a method that can detect low levels of IDH1-R132H mutant 
DNA. However, based upon the results in patient cfDNA, the method is less sensitive 
than those reported previously by others. Given the overall smaller amount of cfDNA 
expected from brain cancer patients, the best way forward would likely be to increase 
the amount of plasma used for cfDNA extraction and run several ddPCR reactions per 
cfDNA to effectively increase the potential of IDH1-R132H detection in cfDNA which 
only contains a low proportion of ctDNA.  Most importantly, larger patient cohorts are 
needed to validate the assay in cfDNA and CTCs. 
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7 Discussion 
7.1 Summary of findings and outcomes 
The overarching hypothesis of this thesis was that CTCs and ctDNA directly correlate 
to tissue biomarkers and so can be used as a tissue substitute for detecting these 
biomarkers. 
The specific aims of this thesis, as outlined in Chapter 1, Aims, were: 
1. To establish a method of directed immunomagnetic isolation of CTCs from the 
blood of brain cancer patients and improve on current GBM CTC identification 
(Chapter 3).  
This aim was successful. We established the world’s first immunomagnetic isolation 
method for GBM CTCs. It further identified a novel GBM CTC marker, GLAST, 
which was proven to better detect CTCs after immunomagnetic enrichment and 
distinguish them from residual lymphocytes by immunocytostaining.  
2. To determine the utility of cryopreservation of PBMCs for delayed GBM CTC 
isolation and to screen GBM CTCs for PD-L1 expression (Chapter 4).  
The method for cryopreservation of GBM CTCs pioneered in this study has been 
shown to be a poor preserver of CTCs. However, on the few GBM CTCs detected 
after cryopreservation (as well as on freshly isolated GBM CTCs) it was clearly 
demonstrated that PD-L1 could be detected. Probing CTCs for additional, clinically 
relevant biomarkers is an essential part of their analysis and the PD-L1 detection on 
CTCs is used in other projects in the Centre for Circulating Tumour Cell 
Diagnostics and Research (CCDR). Additional work has been completed since the 
study described in chapter 4 as a collaboration with Dr Daniel Brungs, which 
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produced a much improved cryopreservation protocol for PBMCs allowing highly 
successful CTC recovery194. 
3. To establish a novel, highly sensitive assay to determine MGMT promoter 
methylation, validate it using patient derived tumour tissue DNA and cfDNA 
and correlate the resulting data with patient disease outcome (Chapter 5).  
A novel, extremely sensitive MGMT promoter methylation assay was developed. 
This study confirmed that this assay, in tissue samples, is capable of distinguishing 
patients with poor PFS from those with an improved PFS (with confirmation of an 
improved OS likely not being possible due to the limited number of patient 
samples). However, when analysing cfDNA from a small cohort of patients with the 
new assays, no correlation of MGMT promoter methylation and survival was found, 
though this may, again, be due to the small sample size. Nevertheless, given that a 
similar proportion of patients were found to have MGMT promoter methylation 
when tumour tissue DNA of cfDNA was analysed, investigating cfDNA from a 
larger patient cohort may reveal a correlation. This new cohort will also need to 
compensate for the presence of other confounding factors such as treatment methods 
and delivery; compliance to treatment plans; and co-morbidities. 
4. To screen GBM CTCs and patient cfDNA for IDH1-R132H using a ddPCR 
assay (Chapter 6).  
Technical issues and access to only a small number of brain cancer patients that had 
previously been diagnosed as IDH1 mutant is likely to have prevented detection of 
IDH1-R132H in CTCs, as we have produced evidence that the assay works for 
single cells. Detection of IDH1 from patient’s cfDNA also failed in our hands but 
we suggest sensitivity of the assay might be improved by maximising the input of 
plasma for cfDNA extraction. 
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7.2 Clinical implications of liquid biopsies in GBM 
As outlined in Chapter 1, there is an urgent need to find alternative sources of cancer 
biomarker information from GBM patients. In this PhD thesis, I developed and present 
several techniques in order to identify clinically relevant biomarkers from simple blood 
biopsies. While part of the CTC isolation is dependent on specialised expertise and 
equipment, the results of this project have sparked the development of an improved 
cryopreservation of semi-processed blood and thus this method could be easily adopted 
to accompany clinical trials as a first proof of clinical utility. Moreover, testing for 
biomarkers of response in CTCs, of which PD-L1 may be one, is an important way of 
stratifying patients for specific clinical trials. 
Another technique central to our assays is ddPCR and that is becoming more widely 
available in diagnostic laboratories and the first ddPCR based assays are now approved 
for clinical use. Thus our assays to detect MGMT promoter methylation and point 
mutations have the potential to be used in clinical diagnostic settings in the future. In 
particular the TR1 MGMT promoter assay has shown great promise when used with 
GBM tissue DNA and larger studies are needed to further confirm its use not only from 
tumour tissue but also from liquid biopsies. 
 
 
7.2.1 Limitations and future direction 
The limitations of this study are mainly attributable to small patient cohorts, with 
generally low numbers of GBM CTCs or low concentrations of cfDNA being isolated 
from those patient’s blood samples. This limitation on material is possibly due to the 
nature of the disease, and because the blood brain barrier prevents free release of cells 
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and tumour material into the circulation. However, the primary aim of this thesis was to 
develop and establish the feasibility of the novel methods used. For this reason, the 
treatment and patient status were not considered during recruitment. 
Currently, we consider it very encouraging that this project was able to isolate CTCs 
from 60% of GBM patients. From these rare CTCs, we were able to detect the 
biomarker PD-L1. Further, we show that detection of biomarkers from cfDNA of brain 
cancer patients is promising (MGMT, TR1 assay) and less so for IDH1, but this may 
improve with increased plasma input for cfDNA extraction. 
 
We also raise the possibility that current methods to detect MGMT methylation, based 
on the TR2 region, may be less reliable than our novel TR1 test. Future work in this 
field will need to focus on determining the methylation regions most consistently 
expressed in the cfDNA in patients, as this would give the greatest chance of detecting 
useful information in an assay. The development and validation of a cheap, sensitive 
and accurate liquid biopsy method to determine MGMT methylation would be expected 
to have immediate impact on clinical practice, since decisions are already based on the 
presence or absence of MGMT methylation in GBM. 
Clearly, utility of our assays developed in this PhD would need to be more thoroughly 
validated in larger patient cohorts and then there would need to be a large-scale health 
economic study taking into account quality of life decisions for the patient to evaluate 
how liquid biopsy testing for biomarkers in brain cancer might be progressed into the 
clinic. 
Once validated, the assays would permit longitudinal studies of GBM, which would be 
important for increasing understanding of the progression of the disease, as well as the 
effects of treatment. The further validation of our assays will therefore not only be an 
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important addition to clinical practice, but will also serve as a part of the future research 
into treatment for GBM, which currently has dismal prospects. 
 
 
7.2.2 Final conclusions 
The outcome of this thesis has been to establish several assays that could be of future 
clinical relevance. The initial overall hypothesis, that liquid biopsies may be useful to 
detect clinical biomarkers has been explored and CTCs and ctDNA have been extracted 
and analysed. Important milestones have been reached, but future work will need to be 
undertaken to validate findings.  
Key findings of this PhD project are: 
1. Establishing a novel method of GBM CTC isolation and identification. 
2. Detection of additional biomarkers (such as PD-L1) on GBM CTCs. 
3. Establishment of a novel, highly sensitive ddPCR-based assay to screen MGMT 
promoter methylation, which correlates with survival for tumour tissue DNA, 
while correlation with disease parameters needs to be tested in larger patient 
cohorts for cfDNA. 
4. Establishment that extraction of cfDNA from only 3ml is not sufficient to detect 
biomarkers for GBM patients. 
The work performed in this PhD has aided successful grant applications and formed the 
basis of a follow-on PhD project as well as an Honours project. 
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